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ABSTRACT 
Among the factors that regulate transmission of malaria are host-derived immune factors 
which can inhibit the progression of Plasmodium through the mosquito. This thesis 
addresses whether members of a family of LCCL/lectin Adhesive–like Proteins (LAPs) 
could act as feasible targets to elicit an antibody-mediated blockade in parasite 
transmission. The LAP family comprises six putatively secreted multidomain proteins 
which appear conserved among Plasmodium species and other apicomplexan parasites. 
Studies utilise the Plasmodium berghei rodent malaria parasite as an experimental system 
to evaluate the potential transmission-blocking activity of antibodies raised against LAPs. 
Regions of the proteins were selected for heterologous expression in Escherichia coli. 
Eight recombinant proteins were successfully expressed and were used as antigens to 
generate antisera in mice. Following immunogenicity tests, antisera against regions of 
LAP1, LAP3, LAP4 and LAP6 were selected for further characterisation and tested for 
antimalarial transmission-blocking activity. A combination of in vitro and in vivo assays 
revealed that the presence of anti-LAP antibodies did not inhibit parasite development. 
Whilst not conclusively excluding their potential, this work provided no further evidence 
to support the inclusion of LAPs as candidates for transmission-blocking vaccines. 
Immunolocalisation studies using anti-LAP1 antibodies revealed that the protein is 
expressed in cytoplasmic regions of female gametocytes and to a lesser extent in female 
gametes. Although it has been proposed that LAP expression may cease following 
fertilisation, PbLAP1 was detected in the cytoplasm of developing zygotes and 
intriguingly was subsequently found to concentrate in compartments of the P. berghei 
ookinete corresponding to the crystalloids. Antisera against regions of LAP1, LAP3, 
LAP4 and LAP6 were all found to similarly label the distinct electron dense cellular 
compartments. Furthermore, observation of Pblap mutant ookinetes by light microscopy 
indicated deficiencies in the formation of crystalloids. A transient cellular compartment, 
formed in the ookinete and subsequently fragmenting during early stages of oocyst 
development, roles of the crystalloid remain unknown. The association between LAPs 
and the crystalloids however leads to potential insights into the biological roles of the 
LAP family, the crystalloids, and the cellular processes of Plasmodium sporogony. 
Through microarray analysis, a comparison of the transcriptional profiles of P. berghei 
∆lap1 and wild-type ookinetes was made, detecting 274 differentially expressed genes 
and thereby indicating that the absence of PbLAP1 and resulting deficiency in crystalloid 
formation may have several knock-on effects on cellular processes important to 
Plasmodium development in the mosquito.    
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1 GENERAL INTRODUCTION 
The post-genomic era of malaria research is yielding an ever increasing number of 
genetic, transcriptomic and proteomic datasets for both malaria parasites (Plasmodium 
spp.) and their mosquito vectors (Anopheles spp.). Mining this information provides 
exceptional prospects for malaria control — facilitating the discovery of genes, proteins 
and mechanisms critical to the development of Plasmodium, and presenting extensive 
opportunities for the identification of targets for drugs, vaccines, insecticides and novel 
vector control strategies.  
 
With recent estimates of the annual malaria burden in the region of 247 million malaria 
cases, around 1 million deaths (WHO World Malaria Report 2008) and a direct cost of at 
least $12 billion in Africa alone (Gallup and Sachs, 2001), the potential health and 
economic benefits of effective malaria control and elimination programmes are obvious. 
A worldwide effort to control malaria — driven by the Roll Back Malaria (RBM) 
consortium (Nabarro & Taylor, 1998) and backed by improved economic and political 
support — has enabled increased implementation of three chief malaria control measures: 
antimalarial drugs, insecticide-treated nets and indoor residual spraying with insecticides. 
Although these interventions can be remarkably effective (see for example review by 
Wakabi, 2007), the long-term success of malaria control and elimination programmes 
crucially depends on the effective deliverance of interventions to target reservoirs of 
transmission and counteract the extensive capacities of the Plasmodium parasite and its 
mosquito vector to adapt and resist control. Given the complex nature of the parasite’s 
life cycle, there are numerous possibilities for expanding the available repertoire of 
malaria control measures. Transmission-blocking strategies, which aim to disrupt 
transmission by preventing the establishment or progression of Plasmodium through the 
mosquito, offer a promising approach for improving prospects for long-term malaria 
control and elimination programmes. 
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1.1. Basis of malaria transmission and considerations for control 
1.1.1. Life cycle features of malaria parasites  
Malaria parasites (Plasmodium) belong to a large, diverse protozoan phylum of obligate 
intracellular parasites, the Apicomplexa, which includes pathogens responsible for a 
variety of diseases of medical and veterinary importance, such as Babesia, 
Cryptosporidium, Eimeria, Theileria and Toxoplasma. The apicomplexan life cycle 
typically involves transformation through phases of invasion (mediated by motile stages 
with a specialised apical complex), asexual replication (the production of daughter cells 
by division of sessile replicative stages) and sexual reproduction (the formation of 
gametes and subsequent fertilisation to form a zygote). Plasmodium and other genera of 
haemosporidian parasites have a complex (two–host) life cycle in which phases of 
development occur in the tissues and blood of a vertebrate host and transmission is 
mediated by haematophagous dipteran such as mosquitoes, hippoboscid flies or 
culicoides species (Valkiunas, 2005). The general life cycle of the Haemosporidia 
comprises three major phases: i) pre-erythrocytic development, initiated by the injection 
of sporozoites into the skin and culminating in the release of thousands of merozoites 
following asexual replication (schizogony) in vertebrate host tissues, ii) intraerythrocytic 
development in the blood of the vertebrate host, and iii) sexual reproduction and 
sporogony in a haematophagous vector (Valkiunas, 2005). The occurrence of a phase of 
intraerythrocytic schizogony in blood stages and the presence of malaria pigment 
(haemozoin), formed as a result of haemoglobin digestion, distinguish Plasmodium 
species from other haemosporidian parasites (Valkiunas, 2005). It is the repeated cycle of 
red blood cell invasion, asexual replication, and subsequent release of progeny 
(merozoites), which is associated with all pathological symptoms of malaria (reviewed by 
Miller, 2002).   
 
So far around 200 species of Plasmodium have been described, each infecting specific 
mammals, birds or reptiles. Those that infect humans: Plasmodium falciparum, 
Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and (by zoonotic 
transmission) the simian malaria parasite Plasmodium knowlesi, are transmitted 
exclusively by female Anopheles mosquitoes. Of more than 400 known anopheline 
species, around 35 are considered potentially important malaria vectors (Kiszewski et al., 
2004). The role of mosquitoes as hosts for Plasmodium became established by Ronald 
Ross towards the end of the 19th century. Inspired and guided by Patrick Manson (Bynum 
and Overy, 1998; Ross, 1902), Ross achieved two critical breakthroughs: in August 1897, 
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he discovered that parasites from the blood of a malaria patient could establish 
development in certain (Anopheles) mosquitoes to undergo growth on the outer wall of 
the mosquito gut (Ross, 1897) and in July 1898 — through further studies with an avian 
malaria species — he discovered that development of Plasmodium in the mosquito 
culminates in the invasion of mosquito salivary glands, and subsequently demonstrated 
transmission to a new host via infective mosquito bites (Manson, 1898).  
 
An overview of the life cycle of Plasmodium falciparum — the most virulent of the 
human malaria parasites, and the species responsible for the majority of malaria-related 
mortality — is shown in Figure 1.1. Species-specific features exist, but all malaria 
parasites follow the same general life cycle. Whilst repeated rounds of asexual replication 
in the vertebrate red blood cells maintains infection and causes pathology, a proportion of 
intraerythrocytic parasites differentiate into gametocytes: these are sexual stages that 
provide the essential link for transmission to mosquitoes upon their uptake in a blood 
meal. Developmental progression within the mosquito can be envisaged as four phases:   
i) sexual replication leading to formation of an ookinete, ii) ookinete invasion of the 
mosquito gut epithelium resulting in oocyst formation, iii) oocyst maturation and release 
of sporozoites into the mosquito haemocoel, and iv) sporozoite invasion of salivary 
glands. The phase of parasite development in the mosquito is known as the extrinsic 
period and takes approximately 10‒28 days, depending on species and temperature. 
Sporozoites residing in salivary glands are injected alongside saliva into the skin of a host 
when the infected mosquito takes a blood meal. In all mammalian species, sporozoites 
progress via the bloodstream to the liver where they invade hepatocytes. Intrahepatic 
parasites grow and replicate asexually by schizogony, resulting in a massive amplification 
in parasite numbers over a period of around a week. Each mature schizont contains 
around 10,000-40,000 uninucleate merozoites, which exit in packages termed merosomes 
and are released into the bloodstream where they invade red blood cells. P. vivax and 
species of P. ovale are known to produce hypnozoites, a life cycle stage referring to 
dormant stages of apicomplexan parasites (as coined by Markus in 1978; see Markus 
2010). A subset of invading P. vivax and P. ovale sporozoites may develop into 
hypnozoites, enabling the parasite to survive in the liver indefinitely and periodically 
initiate erythrocytic infections (known as relapse).  
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Figure 1.1 Life cycle of Plasmodium 
Transmission to mosquitoes is mediated by uptake of male and female gametocytes in a blood meal (1). Male 
microgametes and female macrogametes form in the gut of the mosquito and subsequent fertilisation results 
in the development of a zygote (2). The zygote differentiates into a motile ookinete, which leaves the blood 
meal, migrates through the midgut epithelium and comes to lie just beneath the basal lamina (3). The ookinete 
forms an oocyst which grows for several days and undergoes multiple rounds of asexual replication to form 
sporozoites (4). Upon oocyst rupture, sporozoites spill into the haemocoel of the mosquito, a proportion of 
which enter the mosquito’s salivary glands (5). Mosquito blood feeding induces a proportion of salivary 
glands sporozoites to enter the salivary duct, from where they are inoculated with saliva into the skin of a new 
host each time the mosquito takes a blood meal (6). Sporozoites migrate through skin cells to reach the 
bloodstream where they circulate until reaching the liver sinusoids (7). Invasion of hepatocytes is mediated 
via traversal through Kupffer cells (8). Parasites grow and replicate asexually (hepatocytic schizogony), 
reaching maturity in around a week (9). Merozoites are released into the bloodstream and invade red blood 
cells (10). Intraerythrocytic parasites grow and replicate asexually (erythrocytic schizogony) to give rise to 
blood-stage schizonts (11). Mature schizonts rupture, releasing a new progeny of merozoites into the 
bloodstream and the asexual cycle continues. A proportion of intraerythrocytic parasites differentiate into 
gametocytes (12). 
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1.1.2. Malaria transmission potential 
The basic determinants of malaria transmission are expressed in the Ross-MacDonald 
equation for the basic reproductive number (Ro), a term which denotes the theoretical 
number of new infections that will arise from a single infection in the absence of pressure 
from control or immunity.  
 
 
 
The expression comprises three components: 
i) Infectivity of the human reservoir (1/r); the inverse of the recovery rate from 
infection.  
ii) Vectorial capacity (ma²pⁿ/-logep); the number of infective bites that can arise from a 
vector after feeding on an infectious host. This depends on multiple parameters:  
m, the number of vectors per human; 
a, the average number of blood meals a vector takes from humans in one day; 
p, the expected daily survival probability of a vector (lifespan expectancy = 1/-logep); 
n; the number of days required for the parasite to complete sporogony. 
iii) Vector competence (b); the physiological capability of a mosquito species as a 
vector (may be included as an additional component of vectorial capacity). 
 
This basic model for Ro, and derivatives of it, are fundamental to the design of malaria 
control programmes, indicating the prospective impact on transmission of applying 
different interventions and the reduction in transmission necessary for eventual 
elimination of the disease. Crucially, for the number of infections in a given population to 
decrease and for disease to be eliminated, the reproductive rate (which under the pressure 
of control is termed Rc) must be sustained at a value of <1.  
 
The application of environmental, chemical and biological vector control interventions to 
reduce vector density (m), the number of blood meals taken from humans (a), and most 
influentially, vector longevity (p), have formed the basis of malaria control since the early 
1900s. Initial efforts focused on the practices of draining mosquito breeding sites, filling 
in stagnant pools of water or applying oils to destroy larvae populations, as advocated by 
Ronald Ross (Ross, 1902). Following their development and introduction in the 1940s, 
insecticide-based interventions have had the most dramatic effect on reducing 
transmission. Use of the long-lasting insecticide dichloro-diphenyl-trichloroethane (DDT) 
Ro   =   
ma²bpⁿ 
r -(logep) (MacDonald, 1956) 
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together with the antimalarial drug chloroquine formed the basis of the Global Malaria 
Eradication Programme (1955-1969), which contributed to the successful elimination of 
malaria from much of the temperate world. Chemical attack of adult mosquitoes with 
insecticides reduces vector longevity (p), which since it is raised to the power n is 
considered as the most important parameter contributing to transmission. Indoor residual 
spraying (IRS) with insecticides and the use of insecticide-treated nets (ITNs) have 
accordingly become central to control.  
 
More than a century after the introduction of targeted vector control, around half of the 
world’s population remains exposed to malaria (Hay et al., 2004); prevailing in tropical 
and subtropical regions of the world, where higher magnitudes of Ro and logistical 
problems associated with implementing and sustaining control sustained interruption of 
transmission make elimination of the disease far more challenging. In regions of sub-
Saharan Africa — where the overwhelming burden of malaria falls most heavily — 
estimates of Ro often reach >100 (Smith et al. 2007). Elimination is therefore far more 
difficult to achieve and the capacity for resurgence of transmission much greater in 
regions of sub-Saharan Africa than anywhere else in the world. High transmission 
potential can be largely attributable to ecological factors; most notably the existence of 
highly efficient malaria vectors in environments where conditions are ideal for the 
survival of both parasite and vector. The world’s most efficient malarial vectors are 
endemic to sub-Saharan Africa: Anopheles gambiae sensu stricto (hereafter referred to as 
An. gambiae) and Anopheles funestus almost exclusively take blood meals from humans, 
are characterised by a short gonotrophic cycle of around 48 hours (therefore require 
frequent blood meals) and have a high probability of daily survival (Coetzee, 2004). 
Combined with environmental conditions, these properties confer a high potential 
stability of transmission (see Figure 1.2.). 
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Figure 1.2. Global representation of the potential stability of malaria transmission 
The stability index depicted is calculated based on components of vectorial capacity, taking into account rate 
of blood feeding on humans, vector longevity and the extrinsic incubation period. Malaria has been 
eliminated from North America, Europe and Northern Asia where indices of stability were low, but remains 
prevalent across sub-Saharan Africa, Asia, Latin America and the Pacific Islands. Taken from Kiszewski et 
al. (2004). 
 
1.1.3. Capacities for parasite and vector adaptations 
The dynamic nature of malaria transmission, the large extent of vector biodiversity and 
parasite genetic variability, and the notorious abilities of both parasite and vector to adapt 
to selective pressures, leading for instance to mosquito resistance to vector control, 
parasite resistance to antimalarial drugs, parasite immune evasion strategies, and changes 
in host-parasite relationships pose fundamental limitations on malaria control 
interventions.  
1.1.3.1. Mosquito susceptibility/resistance to vector control 
The success of vector control, which depends foremost on the ability to effectively target 
susceptible mosquito populations, is considerably limited by the large extent of vector 
biodiversity and adaptive abilities. Firstly, a range of physiological and behavioural 
factors may render certain species and strains less susceptible to intervention by. For 
example, the two main transmission control measures, insecticide-treated nets (ITNs) and 
indoor residual spraying (IRS), inherently rely on endophilic mosquito feeding behaviour: 
whilst effective against mosquitoes that feed and rest indoors, mosquitoes which exhibit 
outdoor feeding and resting behaviours are not well targeted. Similarly, although targeting 
mosquito larvae can be a successful vector control approach where breeding sites are easy 
to identify and low in abundance, its application is limited where vectors are opportunistic 
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breeders and use diverse and abundant small temporary pools of water for oviposition. 
Furthermore, genetic-based resistance to insecticides, for example by mutations that 
confer amino acid changes on the insecticide target site, can enable the mosquito to 
survive a dose of insecticides that would normally be lethal. Knockdown resistance (kdr) 
conferred by mutation in the Anopheles voltage-gated sodium channel gene is of 
particular concern since it elicits cross resistance to both DDT and pyrethroids. ITNs are 
particularly vulnerable to the impact of resistance since they depend on pyrethroids, 
which, due to their low mammalian toxicity, are the only suitable choice of insecticide for 
treatment of bednets. The limitations of existing vector control interventions are discussed 
by Ferguson et al. (2010) who highlight that constraints imposed by vector ecology limit 
vector sontrol strategies to such an extent that current measures are insufficient to 
interrupt the transmission of P. falciparum in areas where transmission is most intense.   
1.1.3.2. Parasite resistance to antimalarial drugs 
A number of antimalarial drugs have been developed for treatment of the disease and/or 
for prophylaxis (reviewed by Greenwood, 2010). Yet with large intra–host population 
sizes and extensive genetic diversity, the strong selective pressure exerted by the use of 
antimalarial drugs inevitably leads to the emergence and selection for resistant mutants. 
This has been well documented in the case of the global spread of P. falciparum strains 
resistant to the antimalarial drug chloroquine: used widely over the final half of the 20th 
century, the spread of chloroquine resistant P. falciparum strains was a leading factor in 
the collapse of the Global Malaria Eradication Programme (1955-1969) and the 
subsequent resurgence in malaria. Chloroquine-resistant P. falciparum strains have been 
associated with not only a survival advantage under drug pressure, but also increased 
infectivity to mosquitoes compared with non-resistant strains (Sutherland et al., 2002).  
 
The use of combination drug therapy has become essential in order to stem the 
development of drug resistant parasite strains. Several drug combinations are possible, 
but constraints imposed by resistance, costs and side-effects pose considerable limitations 
on availability and use. Artemisinin combination therapy (ACT), in which an artemisinin 
derivative is used in combination with a longer acting drug, e.g. artesunate-mefloquine, 
and artemether-lumefantrine, is the prime option for treatment, yet due to expense and 
availability only reaches a small proportion of the African population (Marsh and Snow, 
2010). The anti-folate combination sulphadoxine-pyrimethamine (SP) is currently 
recommended for use in intermittent preventive treatment (IPT): for prevention of disease 
during pregnancy (IPTp) or for prevention of disease in infants (IPTi), and also remains 
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important for treatment. Resistance to SP — conferred by mutations in the genes 
encoding dihyrofolate reductase (DHFR) and dihyropterate synthase (DHPS) enzymes of 
the parasite’s folate synthesis pathway (Plowe et al., 1997) — and growing resistance to 
artemisinins (Dondorp et al., 2009; Noedl et al., 2009) pose critical threats to the success 
of current malaria control programmes. 
1.1.3.3. Parasite virulence and immune evasion strategies 
Host immune responses are counteracted by numerous parasite immune evasion 
strategies, enabling the parasite to maintain chronic infections in the vertebrate host and 
continue to contribute to transmission. Key evasive mechanisms are mediated by the 
expression of parasite adhesive proteins on the surface of infected RBC (iRBCs). The 
best characterised parasite iRBC surface protein is P. falciparum erythrocyte membrane 
protein 1 (PfEMP1), which mediates adherence to a range of different host tissue 
receptors (reviewed by Rowe et al., 2009). Resulting adherence to the endothelial lining 
of the microvasculature (cytoadhesion), to uninfected erythrocytes (rosetting) and to other 
parasitised erythrocytes (autoagglutination); reviewed by Rowe et al. (2009), initiates 
sequestration of iRBCs. This acts to enhance parasite survival and replication since 
sequestered intraerythrocytic parasites escape from the circulating bloodstream and 
thereby circumvent passage through the spleen. In addition to facilitating enhanced 
parasitemias, a combination of obstructed blood flow caused by sequestered cells and the 
induction of inflammatory processes due to the interaction of parasites with leukocytes or 
vessel endothelium sequestration, contributes to severe complications for the host, such as 
cerebral malaria, respiratory distress, and fatal multi-organ failure due to (Miller et al., 
2002). Immune recognition of parasite adhesive proteins exposed on the surface of iRBCs 
is counteracted by antigenic variation: the expression of antigenically distinct variants of 
parasite iRBC surface proteins, encoded by multigene families, enables evasion of the 
host immune response (reviewed by Kyes et al., 2001). For example, approximately 60 
different PfEMP1 variants are encoded by the multigene family var. The existence of 
antigenic variation is linked to the slow and incomplete acquisition of immunity against 
malaria. With repeated exposure to parasite antigens, a state of semi-immunity develops 
that can suppress parasitemia and disease but is insufficient to clear infections (Butcher, 
1989; Molineaux et al., 2002; Snow and Marsh 2002). 
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1.1.3.4. Changes in host-parasite population interactions 
Changes in the dynamics of host-parasite population interactions — caused for example 
by environmental change  — can enhance transmission and/or disease severity. Recently 
identified changes in transmission dynamics include increased zoonotic transmission of 
the simian malaria parasite P. knowlesi. Most commonly found in macaques, the 
transmission of P. knowlesi to humans is thought to be enforced by alterations in the 
behaviour of the vector, Anopheles leucosphyrus. This species is increasingly found in 
close association with humans as a consequence of deforestation, thereby contributing to 
the growing public health importance of P. knowlesi (Cox-Singh and Singh, 2008).  
 
It has recently been recognised that P. vivax infections, long established as being limited 
to individuals positive for the RBC Duffy glycoprotein due to the dependence of P. vivax 
merozoite invasion on the Duffy antigen (Miller et al., 1976), may be capable of infecting 
Duffy-negative individuals. Where Duffy-negative and Duffy-positive ancestry co-exists, 
it is thought that frequent opportunities to attempt infection of Duffy-negative blood cells 
may select for strains capable of causing blood stage infections in Duffy negative 
individuals, as has been demonstrated in Madagascar (Menard et al., 2010). Therefore, 
whilst the proportion of populations infected by P. vivax has previously been limited, 
there are indications that Duffy-negative individuals may no longer be refractory to 
infection.  
 
These examples of the extensive capacities for adaptation highlight how each individual 
malaria control intervention has fundamental limitations. The use of multiple 
interventions and a continuous pipeline of new control measures, including transmission-
blocking strategies, are therefore crucial to the prospects of malaria eradication (discussed 
by Mendis et al., 2009). 
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1.2. Antimalarial transmission-blocking strategies 
Malaria transmission can be reduced by both targeting the mosquito (vector-targeted 
strategies) and by targeting the parasite (antimalarial strategies). Vector control has 
provided the most effective means of reducing transmission to date and the development 
of vector-targeted interventions (e.g. insecticides, biological control and novel vector 
control strategies) continues to be a key area of research. The application of antimalarial 
strategies have so far focussed on reducing disease rather than transmission, but there 
exists considerable potential for antimalarial transmission-blocking strategies. The 
malaria life cycle comprises three phases of asexual replication, resulting in massive 
amplification in parasite numbers, and two population bottlenecks: upon transition from 
sporozoite-to-liver stage and gametocyte-to-oocyst (Figure 1.3). These bottlenecks 
represent key targets for interrupting the parasite’s life cycle.  
 
 
 
 
 
Figure 1.3.  Schematic representation of the Plasmodium life cycle depicting targets for interruption of 
transmission  
The malaria parasite life cycle comprises three phases of asexual replication: intrahepatic schizogony (liver 
stages), erythrocytic schizogony (asexual blood stages) and sporogony (oocysts). Each results in massive 
amplification in parasite numbers (represented as black arrows, as by Gandon et al., 2001). Since natural 
bottle-necks occur upon transition from sporozoite-to-liver stage and gametocyte-to-oocyst, these stages 
represent ideal targets for a complete blockade in parasite development, whilst targeting the asexual blood 
stages can reduce disease. 
 
Sporozoites are prime targets since blocking their progression has the advantage of 
directly preventing disease, yet transmission-blocking strategies — which intend to 
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reduce parasite infectivity to mosquitoes, or attack parasite development in the mosquito 
— represent an attractive approach for interrupting the parasite’s life cycle, particularly in 
the absence of a 100% effective preventative intervention.  
 
An effective transmission-blocking approach may not only prevent infections, but also 
have the potential to prevent the spread of drug and vaccine resistance by inhibiting 
transmission of resistant parasite populations (Carter, 2001). In addition, it is predicted 
that transmission-blocking interventions would not impose a selective pressure on 
increased virulence, and may actually select for reduced virulence (Gandon et al., 2001; 
Mackinnon et al., 2008). Three main antimalarial transmission-blocking approaches are 
under development: transmission-blocking drugs, genetic control of vector competence, 
and transmission-blocking vaccines. 
 
1.2.1. Transmission-blocking drugs 
Despite providing effective treatment, antimalarial drugs available to date are inefficient 
at reducing transmission. Almost all currently used antimalarial drugs have been 
introduced based on their activity against the pathogenic asexual blood stages for 
treatment of the disease. They inhibit for example various synthetic or metabolic 
processes of the parasite detoxification of haem in the parasites food vacuole, folate 
synthesis, the electron transport chain of the mitochondria, protein synthesis in the 
chloroplast-like apicoplast (reviewed by Greenwood et al., 2008). Whilst effective against 
asexual blood stages and often also against young gametocytes, mature gametocytes 
remain insusceptible to the majority of antimalarial drugs. Treated individuals therefore 
remain infectious to mosquitoes and are able to contribute to transmission. Treatment 
using certain antimalarial drugs (e.g. Chloroquine) has in fact been shown to be capable 
of having the effect of enhancing transmission by increasing gametocyte production 
(Hogh et al., 1998).  
 
Mature gametocytes are halted in development, with their continued life cycle 
progression taking place only upon removal from the bloodstream. Their reduced 
metabolism and state of cell cycle arrest renders them refractory to the effects of many 
antimalarial drugs (Sinden and Smalley, 1979). Some 8-aminoquinolines (e.g. 
Primaquine) are able to kill mature gametocytes, eliciting a cytotoxic effect by interfering 
with the electron transport chain in the mitochondria, yet largely due to side effects and 
costs, a transmission-blocking drug that can be widely used is yet to be developed. The 
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development of further drug combinations that can effectively reduce gametocyte 
populations or inhibit sporogony are thereby among the aims of future antimalarial drug 
approaches. Prospective targets include kinases, proteases, electron transport in the 
mitochondria, or DNA/protein synthesis in the parasite’s endosymbiont-derived 
apicoplast (a non-photosynthetic plastid homologous to the chloroplasts of plants). Drugs 
that are active against both sexual and asexual stages may be beneficial, although a 
transmission-blocking drug could be used in combination with drugs targeting asexual 
stages. Administered purely to individuals requiring treatment, however, impacts on 
gametocyte numbers at a population level may be limited in areas of high transmission 
since many of the individuals in a population may be semi-immune, carrying infective 
parasites and contributing  significantly to transmission, yet are asymptomatic for disease, 
so are not treated with drugs (Drakeley et al., 2000). Transmission-blocking drugs may 
thereby be more suited to areas of low transmission intensity, although the addition of a 
drug with transmission-blocking activity to any treatment regime would bring the added 
major advantage of helping to limit the spread of drug resistance. 
 
1.2.2. Genetic control of vector competence 
The possibility of vector-targeted genetic control has emerged following the ability to 
achieve stable germline transformation of mosquitoes through transposable element-
based transfections (Catteruccia et al., 2000) along with the capacity perform functional 
RNA interference studies by injecting double-stranded RNA into the body cavity of 
mosquitoes (Blandin et al., 2002). These advances have given rise to the opportunity to 
develop novel ways to reduce vectorial capacity: for example by the release of genetically 
engineered sterile male mosquitoes (to reduce vector populations) or by genetically 
altering mosquito olfactory behaviour (to reduce mosquito blood feeding). It also 
provides the opportunity of targeting vector competence, since mosquitoes may be 
rendered refractory to infection by the genetic manipulation of mosquito immune 
responses. With this in mind, considerable progress has been made towards the 
identification of mosquito refractory mechanisms (discussed in section 1.6). Yet 
numerous obstacles exist between the progression from laboratory studies and application 
of the technology in the field (discussed by Collins and Besansky, 1994; Curtis, 1994; 
Spielman, 1994; Carlson, 1996; O'Brochta and Atkinson, 1997). The development of a 
practical mechanism to drive mosquito transgenes through the natural vector population is 
perhaps the major technical challenge, particularly since genetic alteration often confers 
reduced fitness and a competitive disadvantage against wild mosquitoes. Furthermore, 
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considerable logistical barriers associated with the release of transgenic vectors must also 
be overcome.  
 
An interesting alternative to the genetic alteration of mosquitoes is the use of 
paratransgenesis, involving the genetic modification of symbiotic bacteria of the 
mosquito midgut such that they express and secrete molecules that kill the parasite or 
block parasite invasion of the midgut (Riehle et al., 2007). Such an approach was 
developed as a potential means of controlling the transmission of Trypanosoma cruzi (the 
causative agent of Chagas disease) by Rhodnius prolixus (triatomine bug). A bacterial 
symbiont of the vector was genetically transformed to secrete the antimicrobial peptide 
cecropin A, or a single chain antibody, to render vectors carrying the genetically altered 
bacteria refractory to T. cruzi infection (Durvasula et al., 1997; Durvasula et al., 1999).  
Similar approaches to target Plasmodium in Anopheles mosquitoes are under 
investigation (Riehle et al., 2007). The success of a paratransgenic approach requires a 
symbiont closely associated with the vector and in contact with the targeted pathogen, 
which is cultivable and amenable to genetic transformation whilst retaining its fitness, 
plus a suitable method for its introduction and spread in the vector population. As with 
approaches based on transgenic mosquitoes, much further research is required into vector 
population dynamics and how interventions could be integrated into existing control 
strategies. 
 
1.2.3. Transmission-blocking vaccines 
The development of transmission-blocking vaccines (TBVs) has been initiated based on 
the recognition that a proportion of parasites developing in a mosquito blood meal are 
killed by vertebrate immune components (e.g. complement, leukocytes and antibodies) 
from the sera of a malaria-infected individual (Sinden and Smalley 1976; Grotendorst et 
al., 1986; Margos et al. 2001). Leukocytes and components of the complement system 
remain active in the blood meal for a few hours after ingestion (Kaslow, 1997; Ranawaka 
et al., 1994) whilst antibodies remain undigested in the blood meal for 24 hours after 
ingestion (Beier et al., 1989; Carter, 2001). There is therefore the opportunity to induce 
transmission-blocking immunity during the entirety of the 24 hours over which by 
Plasmodium develops in the mosquito midgut by provoking the production of anti-
parasitic antibodies against parasite surface antigens.  
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The development of vaccines against ticks (Gavac, TickGARD and TickGARDPlus) — 
based on a recombinant form of a Boophilus microplus tick midgut protein, Bm86 (Rand 
et al., 1989; Fragoso et al., 1998; de la Fuente et al., 2000) — provides proof-of-concept 
for the development of a vaccine in which antibodies are produced in an immunised 
subject, with effects in the vector, and furthermore deomonstrates the possibility of 
developing a vaccine based on a single recombinant protein (see 1.3.1). As with the anti-
tick vaccine, potential exists to induce an antibody response which is lethal against the 
mosquito vector, but attempts to develop a mosquitocidal vaccine have not been fruitful 
(Jacobs-Lorena and Lemos 1995) and targeting the parasite remains the focus of research. 
Possible mechanisms of antibody-mediated antimalarial transmission blockade include 
parasite agglutination, steric interference of crucial parasite interactions, or lysis of 
parasites conferred by complement or cellular factors (Kaslow, 1997; Tsuboi et al., 2003). 
For example, a block in fertilisation may be mediated by limiting gamete motility through 
agglutination, preventing cell-cell contact through surface coating, promoting 
lysis/phagocytosis by interactions between antibodies and leukocytes, or by initiating 
complement-dependent lysis. The developing zygote/ookinete may be a target of lysis for 
as leukocytes and complement remain active in the blood meal. Thereafter, the continued 
presence of antibodies in the blood meal enables ookinete interactions with the mosquito 
midgut to be targeted, for example by steric interference of receptor ligand interactions to 
block ookinete invasion (targeting either parasite or mosquito-derived antigens).  
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1.3. Overview of antimalarial vaccine development 
1.3.1. Vaccination strategies 
Vaccination is traditionally achieved by immunisation with whole, killed/inactivated or 
live attenuated forms of a pathogen to induce an adaptive immune response that elicits 
protection from infection. For example, the Salk polio vaccine comprises formalin 
inactivated poliovirus and the Bacillus Calmette-Guérin (BCG) vaccine for tuberculosis is 
prepared from live attenuated Mycobacterium bovis. In the case of malaria, the promise of 
a vaccine has long been demonstrated based on experimental immunisations with whole 
parasite preparations: 
 Injection of sporozoites attenuated by radiation conferred sterilising immunity that 
fully protected against challenge with live intact sporozoites in experimental 
immunisations of mice (Nussenzweig et al., 1967), monkeys (Nussenzweig et al., 
1970) and humans (Clyde et al., 1973).  
 Immunisations with preparations containing merozoites protected against RBC 
infection and clinical disease in monkeys (Mitchell et al., 1977a; Mitchell et al., 
1977b). 
 Immunisation with gametocytes/gametes induced the production of antibodies that 
suppress infectivity to mosquitoes, thereby eliciting transmission-blocking 
immunity (Huff, 1957; Gwadz, 1976; Carter and Chen, 1976). 
Despite these experimental achievements, antimalarial vaccines using a whole vaccine 
approach have been generally regarded as infeasible — principally considering the 
difficulties and impracticalities of growing and purifying parasites in large enough 
quantities. A more cost-effective sub-unit vaccine approach is possible by the application 
of recombinant DNA technology, through which antigens may be produced as 
heterologously-generated recombinant proteins. Whereas it is costly and difficult to 
produce and isolate natural parasite antigens, recombinant antigens can be produced 
relatively cheaply in large quantities, particularly using bacterial expression systems such 
as Escherichia coli. Furthermore, whereas considerable variation may exist among 
natural antigens, recombinant proteins can be produced consistently without genetic and 
biological variation. Heterologously-produced proteins can be extracted and purified from 
the host cells used for expression in a form suitable for immunisations. Recombinant 
vaccines can also take the form of viral vectors (e.g. attenuated vaccinia virus strains can 
be engineered to express recombinant proteins) or DNA vaccines, in which the 
immunogen is a DNA plasmid encoding an antigen, inducing expression of the antigen in 
cells of the immunised host.   
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Pre-erythrocytic development, erythrocytic development and infectivity to the mosquito 
can all be inhibited by targeting various life cycle stages:   
 
CSP: Circumsporozoite protein, TRAP: Thrombospondin-related anonymous protein, SALSA: Sporozoite 
and liver stage antigen, STARP: Sporozoite threonine- and asparagine-rich protein, LSA: Liver stage antigen, 
EXP1: Exported antigen 1, AMA1: Apical membrane antigen 1, MSP: Merozoite surface protein family, 
 
Table 1.1. Malaria vaccine strategies and candidate antigens 
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EBA-175: Erythrocyte binding antigen-175, BAEBL: BA erythrocyte binding-like protein, MAEBL: 
Membrane antigen erythrocyte binding-like protein, RAP2: Rhoptry associated protein-2, PfEMP1: P. 
falciparum erythrocyte membrane protein-1, SERA5: Serine repeat antigen-5, GLURP: Glutamate-rich 
protein, GPI: Glycosyl phosphatidyl inositol glycan, Ps230: Sexual stage 6-Cys 230 kDa protein, Ps48/45: 
Sexual stage 6-Cys 48/45 kDa protein, HAP2: Male gamete fusion protein, Ps25: 25 kDa zygote/ookinete 
surface protein, Ps28: 28 kDa zygote/ookinete surface protein, CHT1: Chitinase, CTRP: Circumsporozoite 
and TRAP-related protein, SOAP: Secreted ookinete protein, WARP: von Willebrand Factor A domain-
related protein. MAOP: Membrane-attack ookinete protein, PPLP: Plasmodium perforin-like protein, 
AgAPN: An. gambiae aminopeptidase N. 
  
1.3.2. Summary of antimalarial vaccines in development  
 Approximately 100 candidate antimalarial vaccine formulations were in development in 
2008, around 1/3 of which reached clinical trials. As depicted in Figure 1.4, more than 
half of all candidates were based on just three antigens: circumsporozoite protein (CSP), 
merozoite surface protein 1 (MSP1) and apical membrane antigen 1 (AMA1). The vast 
majority of candidates fail to reach Phase IIb endemic-country trials, reflecting the 
difficulties of vaccine development and highlighting the need for new candidates.  
 
 
 
 
Figure 1.4.  Representation of the status of malaria vaccine development 
A representation of the status of malaria vaccine development in 2008 depicting the number of pre-
erythrocytic vaccine candidates (yellow), asexual blood-stage vaccine candidates (red), and transmission-
blocking vaccine candidates (purple) in clinical development. Candidate antigens are CSP: Circumsporozoite 
protein, TRAP: Thrombospondin-related anonymous protein, LSA1&3: Liver stage antigen 1&3, AMA1: 
Apical membrane antigen 1, MSP1&3: Merozoite surface protein 1&3, GLURP: Glutamate-rich protein, 
EBA-175: Erythrocyte binding antigen-175, SERA5: Serine repeat antigen 5, Ps25: 25 kDa zygote/ookinete 
surface protein. The number of vaccines are indicated in brackets. Data is taken from the World Health 
Organisation (WHO) table of vaccines in clinical development (2008). 
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1.3.3. Progress and challenges in antimalarial vaccine development 
1.3.3.1. Pre-erythrocytic vaccines 
The first large-scale Phase III clinical trials of a malaria vaccine candidate (RTS,S) —
currently ongoing at 11 sites in Africa — represents a major landmark in the development 
of a  vaccine against malaria. RTS,S is a pre-erythrocytic vaccine based on the major 
sporozoite surface protein, circumsporozoite protein (CSP), and was designed in the 
1980s in view of the successful hepatitis B vaccine. A fragment of CSP (amino acids 207-
395) that includes B-cell epitopes within the central conserved repeat region (R) and the 
c-terminal containing T-cell epitopes (T) is fused to the amino-terminal of hepatitis B 
surface antigen (S) to form RTS, which is expressed simultaneously with S in 
Saccharomyces cerevisiae to form virus-like particles. Delivered with an adjuvant termed 
AS02A, clinical trials have demonstrated that the vaccine provides partial immunity 
(Stoute et al., 1997; Bojang et al., 2001) associated with around a 50% suppression in the 
rate of infection and delay in the onset of disease (Alonso et al., 2004). It has been 
hypothesised that by limiting the number of hepatic schizonts, levels of pathological 
blood stage infection are reduced, and vaccinated individuals may be able to acquire 
asexual blood stage immunity (Guinovart et al., 2009).  
  
The partial protection provided by immunisation with RTS,S appears to be mediated by 
humoral immune responses, yet sterile immunity  — as induced by radiation attenuated 
sporozoites  — involves induction of both antibody and cell-mediated immune responses 
(Hoffman et al., 1998; Hoffman and Doolan, 2000; (Weiss et al., 1990; Doolan and 
Martinez-Alier, 2006). Accordingly, an emphasis of pre-erythrocytic vaccine 
development is on the induction of broadened immune responses, for example by 
incorporating multiple antigens (both sporozoite surface antigens and liver stage antigens) 
in one vaccine and by utilising heterologous prime-boost immunisation strategies. Among 
the vaccines under investigation are those based on ME-TRAP, a polyepitope construct 
which encodes multiple liver stage epitopes (ME) fused to P. falciparum TRAP (Moorthy 
et al., 2003). ME-TRAP may be delivered in the form of a DNA vaccine, or by the use of 
attenuated virus vectors such as modified vaccinia virus Ankara (MVA) or attenuate 
poxvirus FP9. Heterologous prime-boost immunisation regimens, involving sequential 
administration of different antigen delivery systems (reviewed by Dunachie and Hill, 
2003) have successfully enhanced cellular immune responses (Wang et al., 2004). An 
ME-TRAP DNA prime immunisation followed by an MVA ME-TRAP recombinant viral 
vector boost has been shown to elicit a degree of protection against sporozoite challenge 
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(McConkey et al., 2003; Moorthy et al., 2004; Dunachie et al., 2006) although was 
ineffective at reducing infection rates in semi-immune Gambian adults (Moorthy et al., 
2004). Other heterologous prime-boost strategies include DNA prime immunisation 
encoding P. falciparum CSP followed by RTS,S (Epstein et al., 2004).  
 
An alternative approach to induce the strong and broad immune responses necessary for 
protection has been re-investment in whole sporozoite vaccines. Previous trials 
demonstrated that a radiation attenuated sporozoite vaccine can elicit sterile protection, 
but required bites from 1000 mosquitoes (Hoffman et al., 2002). As a result the approach 
has been deemed infeasible, but current endeavours aim to meet the challenges associated 
with large-scale production of purified sporozoites, purification from salivary glands, 
cryopreservation of sporozoites, injection of parasites of undefined genetic composition, 
and establishing a vaccine delivery route. Sporozoites attenuated by radiation are able to 
invade hepatocytes but are incapable of nuclear division and therefore arrest during liver-
stage development (Hoffman et al., 2002). The application of parasite genetic 
manipulation techniques has enabled the production of genetically attenuated sporozoites, 
rendered defective in liver-stage development by gene disruption. Immunisation with 
such genetically attenuated sporozoites deficient in liver-stage development has been 
shown to elicit protection in Plasmodium berghei rodent models. For example, targeted 
disruption of P. berghei genes named upregulated in infective sporozoites (Pbuis3 and 
Pbuis4) are unable to develop into liver stage schizonts (Mueller et al., 2005a; Mueller et 
al., 2005b). Immunisation with ∆Pbuis3/∆Pbuis4 double knockout sporozoites conferred 
complete protection in mice for six months after the last immunisation (Jobe et al., 2007). 
Sporozoites deficient in the surface protein, P36p, also elicit long-lasting protection 
against P. berghei infection in rodents. It is thought the mutant parasites are unable to 
prevent host cell apoptosis, leading to parasite clearance (Van Dijk et al., 2005; 
Douradinha et al., 2007). A vaccine based on genetic attenuation would overcome the 
concerns associated with unknown genetic composition, yet the main technical challenges 
associated with manufacture and delivery still remain. 
 
The study of sporozoite migration, liver infection, and hepatocytic schizogony utilising 
rodent malaria models and intravital microscopy have revealed that only a proportion of 
sporozoites enter the bloodstream after their injection into the skin − others may remain in 
the skin for some time or enter the lymphatic system (Vanderberg and Frevert, 2004; 
Amino et al., 2006). It has been estimated that ~35% of P. berghei sporozoites invade 
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blood vessels, whilst ~50% remain in the dermis for up to seven hours after injection and 
~15% enter lymphatic vessels (Amino et al., 2006). Parasites remaining in the skin and 
entering the lymph nodes have the potential to shape host immunity, with important 
implications for vaccine development. Parasites that enter the draining lymph nodes can 
surprisingly partially differentiate into exoerythrocytic stages and prime T-cells to 
recognise parasite peptides presented on the surface of infected hepatocytes (reviewed by 
Good and Doolan, 2007). The entry of parasites into lymphatic vessels can therefore 
make a vital contribution to the induction of a protective immune response, as is 
demonstrated by the removal of the draining lymph nodes from mice, which abolishes 
protective immunity (Chakravarty et al., 2007). It is also possible that the skin stage of 
infection could act to suppress vaccine-generated immune responses since it is suggested 
that the pre-existence of parasites in the skin may induce regulatory T-cells, providing a 
possible explanation as to why vaccines may fail in semi-immune individuals (Guilbride 
et al., 2010). 
 
1.3.3.2. Vaccines against asexual blood stages 
Asexual blood stages of malaria are naturally suppressed in semi-immune individuals, 
inhibiting clinical symptoms and protecting from severe forms of the disease (Butcher, 
1989; Molineaux et al., 2002; Snow and Marsh 2002). Immunity develops with repeated 
exposure to parasite antigens and naturally acquired antibodies to various parasite 
antigens have been shown to be prevalent in residents of malaria-endemic areas and are 
capable of protecting from severe disease (see for example Riley et al., 1992). These 
antigens have formed the basis for development of a blood stage vaccine. Leading targets  
of protective antibody responses are merozoite surface protein 1 (MSP1; Blackman et al., 
1991; Blackman and Holder, 1992), apical membrane antigen 1 (AMA1; Thomas et al., 
1994; Bannister et al., 2003), merozoite surface protein 3 (MSP3) and glutamate-rich 
protein (GLURP); see Nebie et al. (2008).  
 
Despite the promise for blood stage vaccine development (see for example Blackman et 
al., 1990; Chappel and Holder 1993; Pasloske and Howard, 1994; Daly and Long, 1995) 
several issues have compromised their development. These primarily include: i) the 
existence of antigen polymorphism (e.g. at least 50 polymorphic nucleotide positions 
have been identified in the gene encoding P. falciparum  AMA1 (Marshall, 1996), which 
may enable rapid evasion of immune recognition (Gupta et al., 1994; Genton et al., 2002); 
ii) a lack of understanding of the mechanisms of natural acquired immunity (reviewed by 
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Doolan et al., 2009); and iii) the lack of translation from experimental systems (e.g. 
primate models) to humans, and again from non-immune to semi-immune human 
volunteers. 
 
1.3.3.3. Transmission-blocking vaccine development  
TBV development has lagged behind the development of pre-erythrocytic and blood stage 
vaccines, with only one candidate antigen (Ps25) reaching clinical trials. In clinical trials, 
immunisation with P. falciparum zygote/ookinete surface protein Pfs25 or its P. vivax 
homolog Pvs25 — expressed as recombinant proteins in S. cerevisiae — resulted in 
generation of transmission-blocking antibodies, but at a level too low for a practical 
vaccine (Malkin et al., 2005). Other TBV candidates in development include the Ps25-
related zygote/ookinete surface protein Pfs28 or its P. vivax homolog Pvs28. As discussed 
further in section 1.5.5, antibody-mediated transmission blockade has also been 
demonstrated experimentally with antibodies against proteins secreted from ookinete 
micronemes, (Langer et al., 2002; Li et al., 2004) and with antibodies targeting mosquito 
midgut antigens (Kotsyfakis et al., 2005; Dinglasan et al., 2003; Dinglasan et al., 2007b) 
 
It is thought that the low antibody titres elicited by immunisation with Pfs25 or Pvs25 
recombinant proteins (Malkin et al., 2005) may be related to a combination of poor 
immunogenicity and lack of a boosting effect. Generating long-lasting antibody responses 
against proteins expressed exclusively in mosquito stages is a challenge since there is no 
natural boosting effect if the antigen is not expressed in vertebrate stages of the parasite. 
For this reason, antigens expressed in gametocytes may be more desirable as vaccine 
candidates than those expressed only in the mosquito. Established TBV candidates 
include the gametocyte/gamete surface proteins Pfs230 and Pfs48/45. Pre-synthesised in 
gametocytes in preparation for gametogenesis upon uptake in a mosquito blood meal, 
Pfs230 and Pfs48/45 are not exposed whilst the parasite resides in the RBC, but may be 
recognised by the vertebrate immune system following the death of gametocytes. 
Naturally-occurring antibodies against Pfs230 and Pfs48/45 have been identified in 
populations where malaria is endemic and correlate with reduced infectivity to 
mosquitoes (Rener et al., 1983; Vermeulen et al., 1985; Graves et al., 1988; Carter et al., 
1989; Riley et al., 1994; Roeffen et al., 1995; Bousema et al., 2007; Bousema et al., 
2006). The antibodies have their effect in the mosquito when the antigens become 
exposed on the surface of the parasite following RBC egress. 
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Considerable potential exists in the development and implementation of antimalarial 
transmission-blocking strategies, particularly since some of the main difficulties 
associated with pre-erythrocytic and blood stage vaccine may not be encountered with 
TBV approaches approaches (Sauerwein, 2007; Saul, 2007; Carter et al., 2000). Amongst 
the main benefits of targeting mosquito-stage parasites rather than blood-stages are 
associated with the small number of parasites in the blood meal relative to the large 
number of parasites in the blood and the reduced selective pressures in the mosquito 
compared to within the vertebrate host. Genetic variation and antigenic polymorphism is 
accordingly considered to be lower and as such resistant mutants are less likely to 
emerge. The parasites are also more vulnerable to intervention simply since there are 
fewer targets to eliminate. Furthermore, mosquito-stage parasites are extracellular for an 
appreciable time, compared to only a few minutes per cycle for vaccines targeting the 
surface of the blood stage merozoites. The longer exposure time means that lower 
antibody affinities or concentrations can still be effective in targeting mosquito stage 
parasites, while ineffective in the host. 
 
TBVs may also bring several advantages regarding the practicalities of developing a 
vaccine. Primarily, transmission-blocking immunity is expected to be entirely antibody-
mediated, as has been suggested to be the case for Ps25 transmission-blocking antisera 
(Miura et al., 2007). This eliminates the need for a more complex vaccine strategy to 
drive both cellular and antibody based immunity. In addition, reliable assays to assess 
transmission-blocking activity both in vitro and in vivo already exist. Lastly, since 
malaria transmission is localised: distribution analysis predicts that 20% of host 
population may be responsible for 80% of infections (Woolhouse et al., 1997), 
appreciable reductions in transmission could be possible with relatively low TBV 
coverage, providing the ‘hotspots’ of malaria transmission can be identified and targeted 
and those individuals responsible for the majority of transmission can be vaccinated 
(Bejon et al., 2010; Bousema et al., 2010).  
 
Exploiting the opportunity to target the parasite in the vector by transmission-blocking 
vaccination will be aided by both the identification and characterisation of novel 
candidates and an improved understanding of the development of Plasmodium in the 
mosquito in addition to the research on existing candidates. 
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1.4. Use of rodent malaria parasites in the study of transmission 
The experimental analysis of human malaria parasites is very much restricted by the lack 
of compatible small animal models as a result of host specificity (Herrera et al., 2002). 
The advent by Trager and Jensen (1976) of a continuous in vitro culture system for P.  
falciparum blood stages revolutionised research on the disease (Trager and Jensen, 1997), 
but the experimental infection of mosquitoes with human malaria parasites remains 
wrought with technical difficulties and safety issues. Furthermore, there is no animal 
model for P.  falciparum sporozoite infectivity. These limitations have led to the adoption 
of a number of experimental models based on the use of primate, avian and rodent 
malaria parasites.  
 
Identified soon after the discovery of human malaria by Laveran in 1880, avian malaria 
parasites were commonly used as models for chemotherapeutic studies from the 1890s to 
the 1940s and have been fundamental to elucidation of the basic aspects of Plasmodium 
biology. The Plasmodium gallinaceum/domestic chicken system (initially described by 
Émile Brumpt in 1935) has been used extensively and remains a valuable model, 
particularly for studies regarding transmission (see for example Alavi et al., 2003; Vinetz 
et al., 1999) but also for the study of blood stages (e.g. Nagao et al., 2008). By far the 
most widely used experimental systems however are those that utilise rodent malaria 
parasites and laboratory mice. 
 
Four closely related species of rodent malaria parasites (P. berghei, P. chabaudi, P. 
vinckei, and P. yoelii) naturally infect African thicket rats and can be maintained in 
laboratory rodents. P. chabaudi shows antigenic variation during long-lasting, non-lethal 
infections, making it invaluable in the studies of antigenic variation and drug resistance. 
P. yoelii is frequently used in the study of pre-erythrocytic stages, particularly since its 
sporozoites exhibit high levels of infectivity to laboratory rodents (Weiss, 1990; Khan 
and Vanderberg, 1991; Khusmith et al., 1991). P. vinckei, due to its synchronicity has 
proven useful in studying chronobiology of the asexual cycle in the blood (Gautret et al., 
1994). P. berghei dominates investigations of the biology of mosquito stages of 
Plasmodium and provide an important experimental system for assessing transmission-
blocking activity. 
 
P. berghei was identified by Vincke and Lips in 1948 in the blood of Grammomys 
surdaster (a tree-dwelling rat) some years after it was initially found in its vector 
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Anopheles dureni millecampsi (reviewed by Killick-Kendrick and Peters, 1978). It was 
the first rodent malaria parasite to be discovered. The natural vector proved difficult to 
maintain in the laboratory, but an experimental transmission system became established 
by Vanderberg and Yoeli in 1964 using the North American species Anopheles 
quadrimaculatus (Vanderberg and Yoeli, 1965). The Asian mosquito Anopheles stephensi 
was subsequently identified as a more effective vector (Yoeli et al., 1965). Since then, the 
P. berghei/An.stephensi and P. berghei/An. gambiae systems have become widely 
established. Parasite development in the mosquito is achieved by maintaining conditions 
reflecting those of the forested habitat of the natural environment from which the 
parasites were isolated (i.e. temperature of 18-22°C and relative humidity 90%). These 
systems provide the most attractive means for studying the biology of malaria in the 
mosquito;  
 P. berghei can be reliably maintained in laboratory mice to attain gametocytes and 
mosquito infections can be efficiently achieved by allowing mosquitoes to feed 
directly on an infective mouse or by using an artificial feeding using a membrane 
feeding apparatus.  
 Methods for the in vitro production of P. berghei zygotes and ookinetes from 
gametocyte-infected blood (initially described by Weiss and Vanderberg (1977)) 
have since been modified and established as routine (Janse et al.,1985; Janse and 
Waters, 1995; Rodriguez et al., 2002). More recently, a method for in vitro 
cultivation of oocysts and sporozoites has also been developed (Al-Olayan et al., 
2002) meaning that it is possible for the entire mosquito phase of the parasite’s life 
cycle to be completed in vitro. 
 The relative ease of genetic modification through the use of well-established 
transfection and selection techniques (Janse et al., 2006) and simple means of 
characterising transgenic parasites permits functional analysis of mosquito-stage 
genes.  
 The system provides an amenable approach for studies of mosquito responses to 
infection and evaluation of transmission-blocking effects, which can be facilitated 
by the availability of well characterised clones and genetically modified mutant 
lines, such as the constitutively expressing GFP parasite line (Franke-Fayard et al., 
2004).  
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Figure 1.5. P. berghei life cycle stages for the study of transmission 
P. berghei blood-stage infections (i) may be induced in mice by inoculation with schizonts. A proportion of 
blood-stage parasites develop into gametocytes; male (M) and female (F). Gametocyte-infected blood 
removed from mice may be used to study exflagellation (ii), culture zygotes/ookinetes (iii) or infect 
mosquitoes using a membrane feeding apparatus. Mosquitoes can also be infected by allowing them to feed 
on an anaesthetised gametocyte-infected mouse. Oocysts can be observed on the wall of dissected mosquito 
midguts, preferentially 10-12 days post-infection (iv) and sporozoites can be extracted from dissected 
mosquito salivary glands, optimally approximately 21 days post-infection (v). The use of a transgenic parasite 
line expressing GFP can be used to aid visualisation of infections (iv and v). 
 
The genomes of three rodent malaria parasites; P. yoelii (Carlton et al., 2002), P.berghei 
(Hall et al., 2005) and P. chabaudi (available through PlasmoDB) have been sequenced. 
Inter-species comparison of the genomes of these rodent malaria with that of the human 
malaria parasite P. falciparum (Gardner et al., 2002) revealed that around 4,500 genes out 
of the 5,268 encoded in the P. falciparum genome had an ortholog in at least one of the 
rodent malaria species (Hall et al., 2005), reflecting conserved biological features and 
validating the relevance of studies on rodent malaria parasites to human malaria 
(reviewed by Kooij et al., 2006).  
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1.5. Molecular basis of Plasmodium sexual & sporogonic development  
Using experimental systems, together with molecular and post-genomic approaches, the 
cellular and molecular processes involved in parasite development are being elucidated, 
revealing the biological roles, expression and localisation of prospective TBV candidates, 
and identifying possible targets for immunological interventions. 
1.5.1. Gametocyte development 
Gametocytes, which are equipped to mature into gametes and initiate fertilisation in a 
mosquito blood meal, develop in a small percentage of infected red blood cells. As would 
be expected considering the functional differences between asexual blood stages and 
gametocytes, the transition from asexual to sexual development is associated with 
considerable cellular changes, reflected by transcriptomic and proteomic analyses 
confirming major differences in transcription and translation (Hall et al., 2005; Florens et 
al., 2002; Lasonder et al., 2002; Le Roch et al., 2003; Young et al., 2005; Silvestrini et al., 
2005). The switch from asexual multiplication to sexual differentiation is likely to involve 
a combination of both parasite genetic factors and environmental cues. High parasitemias, 
anti-parasitic antibodies, depletion of fresh erythrocytes and chloroquine treatment are all 
associated with an increase in  gametocyte formation (reviewed by Talman et al., 2004). 
The molecular mechanisms involved in the switch are not yet understood, but deciphering 
the associated signalling pathways represent a major goal of malaria research, with a view 
to prevent transmission (reviewed by Baker, 2010). 
 
The gametocytes of most mammalian malaria parasite species are round or oval in 
morphology and develop over a time-frame just slightly longer than that of the asexual 
blood-stages (gametocyte development in P. berghei takes around 30 hours). There are 
however intriguing differences associated with the biology of P. falciparum and P. 
reichenowi gametocytes. P. falciparum and P. reichenowi comprise the sub-genus 
Laverania and are unusual among mammalian malaria parasites in that gametocytes are 
crescent shaped once mature, possessing a subpellicular complex. Furthermore, 
gametocytogenesis is prolonged (maturation of P. falciparum gametocytes takes around 
9-12 days and can be divided as five stages: I-V).  
 
All but mature (stage V) P. falciparum gametocytes sequester, most often in the bone 
marrow (reviewed by Day et al., 1998; Rogers et al., 2000; Alano, 2007). Proteins that are 
targeted to the gametocyte-infected RBC membrane could act as promising candidate 
antigens for a TBV (Sutherland, 2009). As in asexual blood stages, PfEMP1 is localised 
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to knob structures on the surface of stage I-II P. falciparum gametocyte-infected RBCs, 
but surface localisation of PfEMP1 appears absent beyond stage II, indicating that 
adherence, at least of stage III-IV gametocytes occurs by a different process to that 
exhibited by asexual stages (reviewed by Day et al., 1998). A possible involvement of 
STEVOR proteins, which like PfEMP1 are encoded by a multigene family has been 
proposed. During gametocyte maturation, STEVOR proteins are reported to be exported 
to the IRBC membrane (McRobert et al., 2004). Using flow cytometry, Saeed et al. 
(2008) analysed the sera of natural gametocyte carriers and identified the presence of 
naturally occurring antibodies with reactivity against antigens on the surface of 
gametocyte-infected erythrocytes. 
 
Differences between male and female gametocytes begin to become apparent at mid-
stages of maturity. Proteomic analysis of purified P. berghei male and female 
gametocytes highlights the divergence of the male and female gametocytes, with the male 
having 236 male specific proteins and the female 101, and only 69 proteins common in 
both (Khan et al., 2005). Mature male gametocytes are prepared for rapid DNA 
replication and mitosis in order to generate flagellated gametes for fertilisation of female 
cells. They are largely devoid of endoplasmic reticulum (ER) and retain only a low 
ribosome population sufficient for protein synthesis during gametogenesis (Sinden et al., 
1978). Female gametocytes, on the other hand, are not only prepared for gametogenesis 
and fertilisation, but also for subsequent zygote development. Females continue rRNA 
synthesis and have abundant ER, and in common with metazoan oocytes, store a subset of 
mRNA for translation after fertilisation (Le Roch et al., 2003; Mair et al., 2006; Mair et 
al., 2010). An RNA helicase, named development of zygote inhibited (DOZI), is 
recognised as mediating storage of mRNA in cytoplasmic bodies of the female 
gametocyte, allowing for rapid translation after fertilisation (Mair et al., 2006). As 
gametocytes reach mid-stages of maturity, haemoglobin metabolism halts and mature 
gametocytes circulate in a state of developmental arrest, with their continued 
development taking place only upon removal from the bloodstream (Sinden and Smalley, 
1979). 
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1.5.2. Gametogenesis and fertilisation 
Environmental changes associated with the transition from the vertebrate bloodstream to 
the mosquito trigger the activation of mature gametocytes, resulting in differentiation into 
gametes (male microgametes and female macrogametes) and emergence from the host 
RBC. Despite differences in gametocyte biology, P. falciparum appears to undergo 
gametogenesis and fertilisation in a manner similar to other mammalian species of 
malaria. 
 
Whereas the female gametocyte undergoes little change during gametogenesis, the male 
undergoes rapid and dramatic cellular differentiation — from a single immotile cell to 
eight flagellated gametes. These cellular changes are described by Sinden and Croll 
(1975). Differentiation depends on the completion of three mitotic divisions within a 
period of 8 minutes (Janse et al., 1986). Rapid DNA replication is associated with 
upregulation of the chromatin remodelling protein SET (Pace et al., 2006). Microtubule 
organising centres (MTOCs) organise the microtubules that make up the axonemes of the 
flagella. The flagella thrash as the gametes expel from the remnant of the gametocyte 
during the vivid process of exflagellation. In vitro, emerging microgametes draw in 
neighbouring erythrocytes, creating a wobbling clump of cells termed ‘exflagellation 
centres’. RBCs have been described to roll along exflagellating males and become 
retained by the residual body of the gametocyte as the gametes escape (Eksi et al., 2006). 
The formation of exflagellation centres is thought to involve binding to sialic acid on the 
surface of red blood cells (Templeton et al., 1998), but its significance is unknown. 
 
Key triggers for the onset of gametogenesis include a drop in temperature of more than 
5°C and the presence of xanthurenic acid (XA), a by-product of the mosquito eye 
pigmentation pathway (Sinden, 1983; Billker et al., 1998; Billker et al., 1997; Garcia et 
al., 1998). In vitro studies using P. berghei demonstrate that XA acts to trigger a rise in 
cytosolic calcium levels in microgametocytes and a calcium-dependent protein kinase 4 
(PbCDPK4) is involved in  regulating differentiation into gametes by translating calcium 
signals (Billker et al., 2004). 
 
The escape of gametes from RBCs involves the rupture of two membranes; the 
parasitophorous vacuole membrane (PVM) and the infected erythrocyte membrane. 
Egress is aided by osmiophillic bodies (OBs), which release proteins into the PV and may 
be considered as functionally equivalent to the electron dense exonemes of asexual 
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schizonts. OBs are present in both male and female gametocytes, but are much more 
abundant (4-5 fold greater in number) in females (Sinden et al., 1978). This corresponds 
with the absence of mechanical force to assist in female gamete emergence, whereas the 
movement of flagella facilitates escape of male gametes (Alano et al., 1995). Gene 
disruption studies indicate that Pfg377 is required for OB biogenesis and support the role 
of OBs in female gamete egress; ∆Pfg377 female gametes have reduced numbers of OBs 
and emerge from their host erythrocyte significantly less efficiently (de Koning-Ward et 
al., 2008). A second OB-associated protein, known as protein of early gametocyte 3 
(PEG3) (Silvestrini et al., 2005; Furuya et al., 2005; Ponzi et al., 2009) or male 
development 1(MDV1) appears important for both male and female emergence, with a 
proposed role in destabilising the PV membrane (Silvestrini et al., 2005; Furuya et al., 
2005; Ponzi et al., 2009; Lal et al., 2009a). 
 
Following gamete release, fertilisation is usually efficiently completed within one hour. 
As yet, no microgamete-macrogamete recognition mechanisms have been identified, 
although cellular adhesion is predicted to increase the chances of gamete-gamete 
interactions. Upon fertilisation, the plasma membranes of the gametes fuse, the cytoplasm 
of the male gamete enters that of the female, and nuclei subsequently fuse to give rise to a 
zygote (Sinden and Hartley, 1985). Three members of a ‘6-cys motif protein family’, 
Ps230, Ps48/45 and Ps47, are known to be expressed on the surface of gametocytes and 
gametes and are key TBV candidates, with antibodies preventing fertilisation (Healer et 
al., 1997). 
 
The 6-cys family consists of 10 proteins sharing a conserved arrangement of 6 cysteine 
residues (Gerloff et al., 2005). Ps230 is the largest representative of the family, with 7 
cysteine-rich double domains, whilst Ps48/45 and Ps47 each have 1.5 double domains. 
Ps48/45 is a protein doublet of 45 kDa and 48 kDa produced by differential processing of 
the products of a single gene present on the surface of both male and female gametocytes 
and gametes (Kaslow, 2002). Gene disruption of Pfs48/45 and Pbs48/45 significantly 
reduced zygote formation, attributable to the impaired ability of ∆Pfs48/45 and 
∆Pbs48/45 male gametes to bind female gametes (van Dijk et al., 2001). Furthermore, in 
∆Pfs48/45 male gametes, Pfs230 surface localisation is not retained (Eksi et al., 2006). 
Ps230 exists as a 360 kDa precursor protein (Pfs260) on the gametocyte surface 
(Vermeulen et al., 1986) which during gametogenesis is processed to a mature 310 kDa 
protein (Pfs230) and exists as a complex with Pfs48/45 (Kumar and Wizel, 1992). 
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Targeted disruption of Pfs230 leads to inhibition of the formation of exflagellation centres 
due to reduced capacity of male gametes to bind erythrocytes and ∆Pfs230 parasites are 
reduced in their capacity to produce oocysts in mosquitoes (Eksi et al., 2006). Pfs47 is 
expressed on the surface of female gametes but does not appear crucial for female fertility 
(van Schaijk et al., 2006).  P. berghei Pbs47 in contrast is essential for fertilisation, with 
∆Pbs47 parasites producing infertile female gametes (Mair et al., 2006). 
 
A male sterility gene, termed HAP2 (Liu et al., 2008; Khan et al., 2005) or generative cell 
specific (Hirai et al., 2008) has recently been identified as being conserved among higher 
plants and protists, including Plasmodium, and in P. berghei has been shown to be critical 
to male gamete fertility (Liu et al., 2008; Hirai et al., 2008). PbHAP2 localises along the 
length of the male gamete and is required for the fusion of male and female gamete 
membranes (Liu et al., 2008). In further experiments, antiserum against PbHAP2 has been 
shown to inhibit ookinete development and oocyst formation (Blagborough and Sinden, 
2009), thereby identifying promise in the potential of HAP2 as a TBV candidate.    
 
1.5.3. Zygote/ookinete development 
The solitary phase of meiosis in the parasite’s life cycle occurs in the diploid zygote and 
the parasite remains as a tetraploid cell throughout; only at sporulation over a week later 
does cell division and separation into individual haploid genomes occur. Translation of 
gametocyte-derived mRNA, stored via the RNA-helicase DOZI, is essential for zygote 
development; ∆Pbdozi parasites abort zygote development before meiosis (Mair et al., 
2006).  
 
Leading TBV candidates Ps25 and Ps28 are among the proteins translated from DOZI-
stored mRNA transcripts. The two structurally similar glycosylphosphatidyinositol (GPI)-
anchored proteins, containing three and four epidermal growth factor (EGF)-like adhesive 
domains respectively, become the dominant surface proteins of the parasite. Observations 
in P. gallinaceum by cryofracture electron microscopy suggest that they form a bi-layered 
coating on the external surface of the plasma membrane (Raibaud et al., 2001). Crystal 
structures of yeast expressed Pvs25 recombinant protein show that the four EGF-like 
domains form a compact triangular prism that could tile the parasite surface (Saxena et al., 
2004; Saxena et al., 2006). Pbs25 and Pbs28 have been shown to play multiple redundant 
roles in ookinete survival and ookinete-oocyst development, as demonstrated by 
individual and double gene disruptions in P. berghei (Tomas et al., 2001). In the 
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developing ookinete, the proteins appear to play a role in protease-protection, since 
∆Pbs25/∆Pbs28 double knockout is more sensitive to trypsin type I digestion than single 
knockouts of either gene (Tomas et al., 2001). Accordingly, their expression coincides 
with the parasite becoming more resistant to proteases (Kaushal et al., 1983; Margos et 
al., 2001) in parallel with the increase in levels of mosquito digestive enzymes secreted 
into the blood meal (Gass and Yeates, 1979).  
 
Transition into a motile, invasive ookinete begins with the formation of an apical end 
polar ring, which acts as a microtubule organising centre (MTOC) from which numerous 
microtubules extend to form the microtubular cytoskeleton and the elongate shape of the 
ookinete. The ookinete shares cellular features characteristic of all apicomplexan 
invasive-stage parasites (reviewed by Morrissete and Sibley, 2002); the definitive feature 
being the presence of an apical complex comprising secretory organelles which release 
proteins required for motility and invasion. Proteins are secreted from the specialised 
secretory organelles in a sequential manner: micronemes are essential for host cell 
adhesion and invasion (see 1.5.4); rhoptries are vital for formation of a parasitophorous 
vacuole (PV), within which the intracellular parasite resides (Dubremetz et al., 1998); and 
dense granules are required for later host cell modification. Consistent with these roles, 
ookinetes contain only micronemes and lack rhoptries and dense granules. Whilst 
sporozoites and merozoites come to reside within a cell (hepatocytes and erythrocytes 
respectively), ookinetes traverse the midgut epithelia resulting in destruction of the host 
cell and differentiate into oocysts extracellularly. The absence of rhoptries and dense 
granules is indicated by electron microscopy and predicted rhoptry proteins are absent 
from the ookinete proteome (Hall et al., 2005). 
 
An inner membrane complex (IMC) composed of flattened vesicles forms a bi-layer 
beneath the outer plasma membrane to give a three-membraned pellicle. The IMC which 
is associated with cytoskeletal elements including actin, myosin and microtubules and 
contains a lattice of intramembranous particles (IMPs). Cryofracture electron microscopic 
analysis has also identified the presence of pores within the IMC of P. gallinaceum 
ookinetes. The function of these pores remains to be elucidated, but a role in allowing the 
transport of molecules has been hypothesised (Raibaud et al., 2001).  
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Figure 1.6. Representation of the pellicle and apical complex of ookinetes 
A. Diagrammatic representation of a cross-section of the ookinete pellicle. Beneath the plasma membrane sits 
the inner membrane complex, comprising the outer alveolar membrane and the inner alveolar membrane and 
between these the alveolar lumen. The IMC is broken up by a suture and by pores. Beneath the IMC lies the 
subpellicular microtubules. Adapted from (Raibaud et al., 2001) and (Keeley and Soldati, 2004).  
B. Diagrammatic representation of a Plasmodium ookinete depicting the apical complex and three-
membraned pellicle. Adapted from (Baum et al., 2008). The apical region of the cell contains micronemes; 
small, electron dense organelles, with a high protein content that are restricted to the apical third of the cell.  
 
 
1.5.4. Molecular basis of ookinete motility and invasion 
Ookinete motility is driven by a substrate-dependent gliding mechanism common to all 
apicomplexan invasive stages (Kappe et al., 1999; Sibley, 2004; Baum et al., 2006). It 
relies on the apical secretion of adhesins followed by translocation of adhesin-substrate 
complexes along the cell surface of the parasite from the anterior to the posterior, overall 
resulting in a forward locomotion of the parasite. This motility is driven by an actin-
myosin motor, comprising filamentous actin (F-actin) and an IMC-anchored myosin, 
located beneath the plasma membrane (Figure 1.7; reviewed by Keeley and Soldati, 
2004). A structurally-related family of transmembrane adhesins secreted from the 
micronemes provides the link between the actin-myosin motor and the extracellular 
substrate. These adhesive proteins are identified as TgMIC2 in Toxoplasma tachyzoites 
(Wan et al., 1997), thrombospondin-related anonymous protein (TRAP) in Plasmodium 
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sporozoites (Sultan et al., 1997), circumsprozoite and TRAP-related protein (CTRP) in 
ookinetes (Dessens et al., 1999; Yuda et al., 1999) and merozoite TRAP (MTRAP) in 
merozoites (reviewed by Baum et al., 2006). Unifying protein features include von 
Willebrand factor A (vWA) and thrombospondin type I repeat (TSR) extracellular 
adhesive modules, a conserved cleavage site within the transmembrane domain, and a 
cytoplasmic tail domain. The cytoplasmic tail domains are linked to F-actin via the 
glycolytic enzyme aldolase (Jewett and Sibley, 2003), whilst extracellular adhesive 
domains bind substrate. Following translocation of the adhesin, the protein is cleaved 
within the transmembrane domain resulting in its release. This is essential to disengage 
interactions between the parasite and substrate and is mediated by rhomboid (ROM) 
serine proteases (Koonin et al., 2003; Urban and Freeman, 2003; Brossier et al., 2005; 
Buguliskis et al., 2010). 
 
 
 
 
 
Figure 1.7. The conserved molecular basis of apicomplexan motility 
Apicomplexan gliding motility is driven by an actin-myosin motor. The gliding associated proteins (GAP) 45 
and 50, and the MyoA tail domain-interacting protein (MTIP), connect myosin A (Myo-A) to the inner 
membrane complex (IMC) of the parasite. Filamentous actin (F-actin) is connected via aldolase to the TRAP-
like adhesive protein, which, in turn, interacts with host-cell receptors. Myo-A pushes the transient f-actin 
scaffolds back onto another MyoA molecule and the parasite glides forward. Taken and modified from 
(Keeley and Soldati, 2004). 
 
Sub-pellicular
microtubules
IMPs
Direction of force
Direction of movement
Membrane skeleton
IMC
Myo-A
MTIPGAP45
GAP50
Aldolase
F-actin
Host cell membrane
Parasite plasma membrane
TRAP-like adhesive protein(TgMIC2-associated protein)
 
 52 
1.5.5. Traversal of the midgut epithelium 
The blood meal of a mosquito is usually separated from the midgut epithelium by a 
peritrophic matrix, comprised predominantly of chitin and glycoproteins produced by 
midgut secretions following blood feeding (Huber et al., 1991). The peritrophic matrix 
acts to protect from midgut epithelium immune activation (Kumar et al., 2010) and is 
considered the first barrier that the ookinete must bypass. Parasite chitinase activity has 
been shown to be essential for the invasion of P. gallinaceum and P. falciparum 
ookinetes, with addition of the chitinase inhibitor allosamidin preventing infections 
(Shahabuddin et al., 1993). Antibodies against PgCHT1 reduced oocyst formation by 67-
96% (Vinetz et al., 1999; Shahabuddin et al., 1993; Vinetz et al., 2000; Dessens et al., 
2001) and P. falciparum chitinase PfCHT1 is being investigated as a TBV candidate. 
Unlike P. gallinaceum and P. falciparum ookinetes, P. berghei ookinete infectivity is 
insensitive to allosamidin (Dessens et al., 2001). Nevertheless, gene disruption of P. 
berghei chitinase (PbCHT1) significantly reduced oocyst formation in An. stephensi, 
suggesting functions beyond aiding digestion of the peritrophic matrix (Dessens et al., 
2001). 
 
 
Interactions between ookinete surface or secreted proteins and glycans present along the 
microvilli of mosquito midgut epithelial cells appear important in initiating invasion. For 
example, treating midguts with periodate, which removes exposed carbohydrates, reduces 
binding of ookinetes to the midgut (Zieler et al., 1999). Furthermore, RNAi-mediated 
knockdown of An. gambiae OXT1, which is required for glycosaminoglycan biosynthesis, 
markedly reduced parasite development (Dinglasan et al., 2007a). Ookinete attachment 
can also be blocked by lectins that mask carbohydrate midgut ligands. The lectin-binding 
mosquito midgut protein An. gambiae aminopeptidase N (AgAPN1), which can be 
blocked by the lectin jacalin, has become the most advanced mosquito-based TBV 
candidate. Polyclonal antiserum to AgAPN1 has been shown to inhibit both P. berghei 
and P. falciparum oocyst formation by up to 80%.  
 
Two other mosquito proteins, calreticulin and annexin B11 – both present on the apical 
surface of the midgut epithelium  – have been identified as potential ligands for invasion. 
Calreticulin has been identified as a potential ligand using recombinant Pvs25 as a probe 
(Rodriguez et al., 2007) and annexin B11 was identified by mass spectroscopy in a 
fraction of midgut proteins capable of binding P. berghei ookinetes (Kotsyfakis et al., 
2005). α-annexin B11 antibodies have been shown to be able to interfere with the 
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parasite–midgut interaction, reducing oocyst formation by 30-40% (Kotsyfakis et al., 
2005).  
 
Ookinete-epithelial interactions can also be blocked by genetic alteration of the mosquito 
midgut barrier, for example by inducing gene expression from a blood-inducible and gut-
specific carboxypeptidase promoter (Jacobs-Lorena, 2003). Identified effector genes 
include bee venom phospholipase A2 (PLA2), which possibly modifies the properties of 
the midgut epithelial membrane (Zieler et al., 2001) and salivary gland and midgut 
binding peptide 1 (SM1), a 12-amino acid peptide which binds to receptors required for 
ookinete midgut invasion (Ghosh et al., 2001). P. berghei oocyst formation is 
substantially reduced and transmission impaired in transgenic An. stephensi expressing 
either PLA2 (Moreira et al., 2002) or SM1 (Ito et al., 2002).  
 
Key ookinete transmission-blocking antigens include the major ookinete surface proteins 
Ps25 and Ps28 and several ookinete micronemal proteins. A number of proteins have 
been identified that are secreted from the micronemes and transported to the surface of 
the parasite where they may mediate important roles in invasion and/or be targeted by 
transmission-blocking antibodies. These include:  
– Membrane attack ookinete protein (MAOP) – also known as Plasmodium 
perforin-like protein 3 (PPLP3) – and a related protein Plasmodium perforin-like 
protein 5 (PPLP5), both of which contain a membrane-attack complex and 
perforin (MACPF)-related domain and are thought to facilitate ookinete entry to 
the lumen of the epithelial cells by disrupting the cell membrane. ∆pplp3 and 
∆pplp5 P. berghei ookinetes are able to attach to the midgut epithelium but are 
unable to enter the cytoplasm (Kadota et al., 2004; Ecker et al., 2007).  
– Secreted ookinete adhesive protein (SOAP) has been identified as being 
important to host adhesion (Dessens et al., 2003). 
– Circumsporozoite and TRAP-related protein (CTRP) is critical for ookinete 
motility (Dessens et al., 1999, Yuda et al., 1999).  
– Cell traversal protein of Plasmodium ookinetes and sporozoites (CelTOS) is 
critical to host cell traversal (Kariu et al., 2006).   
– von Willebrand factor A domain related protein (WARP), which although has a 
non-essential role in ookinete infectivity is a target of transmission-blocking 
immunity: anti-WARP antibodies reducing infectivity of both P. gallinaceum and 
P. falciparum (Yuda et al., 2001; Li et al., 2004 ).  
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With extensive opportunities to elicit transmission blockade the inhibition of midgut 
invasion is a major focus of transmission-blocking strategies. Antibodies against ookinete 
surface proteins, antibodies against mosquito midgut ligands present on the apical surface 
of the midgut epithelium, or genetic modification of the mosquito midgut all represent 
viable approaches.  
 
1.5.6. Mosquito responses to midgut invasion 
Ookinete invasion of the midgut triggers both local reactions in the mosquito epithelium 
and systemic responses in the mosquito haemolymph, resulting in significant parasite 
losses occur during and following midgut invasion. A ‘time bomb model’ of ookinete 
invasion has been developed, depicting invaded midgut cells as ‘bombs’, since the 
parasite has only a limited time frame before it is killed by cell toxicity or destroyed by 
apoptotic processes (Han et al., 2000). Ookinete invasion triggers upregulation of nitric 
oxide synthase (NOS) followed by increased peroxidase activity and causes cellular 
damage that ultimately leads to apoptosis culminating in an actin–based extrusion of the 
invaded cell from the midgut epithelia (Han et al., 2000; Zieler and Dvorak, 2000; Gupta 
et al., 2005). Cell membrane protrusion is mediated by Arp2/3 and Wilskott-Aldrich 
syndrome protein (WASP) has been identified as an important regulator of actin-based 
local epithelial responses (Vlachou et al., 2001; Mendes et al., 2008). 
 
Two immune effector mechanisms have been identified that can render mosquitoes 
completely refractory to Plasmodium infection – parasite development can be completely 
blocked by lysis, as in the An. gambiae SUAF2 strain (Vernick et al., 1995) or by 
melanisation, as in the An. gambiae L3-5 strain (Collins et al., 1986). Understanding the 
molecular basis of these refractory mechanisms is a key focus of investigations into 
vector-parasite interactions, driven by the possibilities of genetic control of vector 
populations, and molecular pathways are slowly being deciphered in laboratory models. 
Lysis is mediated by complement-like killing involving a mosquito thioester-containing 
protein 1 (TEP1), which is homologous to the mammalian complement protein C3 and 
directly binds to ookinetes (Blandin et al., 2004). Melanisation is a widespread 
mechanism of pathogen killing among arthropods,  initiated by a serine protease cascade 
that culminates in the conversion of prophenoloxidase (PPO) to phenoloxidase (PO), 
which then causes the production of melanin and protein cross-linking around ookinetes 
in the sub-epithelial space (Lemaitre and Hoffmann, 2007; Meister et al., 2004; 
Christensen et al., 2005). Two leucine-rich repeat-containing molecules; leucine-rich 
 55 
repeat immune gene 1 (LRIM1) and Anopheles Plasmodium-responsive leucine-rich 
repeat 1 (APL1; or LRIM2) have been identified as key mediators of both complement-
like lysis and melanisation (Osta et al., 2004; Riehle et al., 2006; Povelones et al., 2009).  
It has been shown that LRIM 1 and 2 exist as a multimeric protein complex in the 
mosquito haemolymph and directly interact with TEP1, leading to TEP1 activation 
(Povelones et al., 2009; Fraiture et al., 2009). Several serine proteases have been 
identified as being (positive or negative) regulators of melanisation, including Clip 
domain serine proteases (CLIPs) and serine protease inhibitors (SRPNs) (Dimopoulos et 
al., 2000). Furthermore, two C-type lectins (CTL4 and CTLMA2) have been identified as 
negative regulators, acting to protect parasites from LRIM1-dependent melanisation 
(Osta et al., 2004). 
 
The molecular basis of immune effector mechanisms is therefore beginning to be 
deciphered in laboratory models, providing considerable potential for control via 
approaches to render mosquitoes refractory to infection. However, many immune-related 
genes identified in laboratory models, such as LRIM1, CTL4 and SRPN2, have not been 
confirmed natural Anopheles/Plasmodium associations in the field (Cohuet et al., 2006; 
Michel et al., 2006). It is recognised that considerable variation may exist in different 
parasite-vector combinations. For example, mosquito immune responses triggered by     
P. falciparum may differ significantly from those induced by P. berghei (Dong et al., 
2006; Mendes et al., 2008) and silencing of certain immune molecules may cause marked 
phenotypic changes in one mosquito strain but negligible effects in another (Dong et al., 
2006).  
 
1.5.7. Oocyst formation and maturation 
Oocyst formation occurs in the sub-epithelial space beneath the basal lamina of the 
midgut epithelium. It is suggested that binding to laminin, a major component of the basal 
lamina, may promote ookinete-oocyst differentiation and oocyst growth and perhaps 
protect the parasite against mosquito immune responses (Adini and Warburg, 1999; 
Vlachou et al., 2001; Nacer et al., 2008). Several studies indicate that ookinete surface 
proteins interact with mosquito laminin. For example, GST pulldowns and/or yeast-two-
hybrid studies demonstrated interactions between An. gambiae laminin γ-1 and the 
ookinete surface proteins Pbs25, Pbs28 (Vlachou et al., 2001), CTRP (Mahairaki et al., 
2001) and SOAP (Dessens et al., 2003). The importance of laminin binding is supported 
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by RNAi-mediated knockdown of An. gambiae laminin γ-1, which led to a 60% decrease 
in P. berghei oocyst formation (Arrighi et al., 2005).   
 
Beginning with disassembly of the cytoskeleton, apical complex and IMC, the motile, 
invasive ookinetes differentiate into a sessile, replicative oocyst, which grows over 
several days, reaching 50-60 µm in diameter.  An oocyst wall, probably synthesised via 
secretion from golgi-derived vesicles and composed of protein / glycoprotein and an 
extracellular fibrous coat, surrounds the cell and lies in direct contact with the basal 
lamina of the mosquito midgut (Sinden et al., 2004). PbCAP380 (oocyst capsule protein) 
is the first identified oocyst wall protein. It localises to the outer layer of the oocyst wall 
and gene disruption studies indicate an essential role in oocyst survival (Srinivasan et al., 
2008). Repeated rounds of mitosis generates in the region of 2000-8000 haploid nuclei. 
At 6-8 days, the cytoplasm subdivides by expansion of the ER cisternal space and 
invagination of the plasmalemma to form sporoblasts; ‘germination centres’ from which 
sporozoites bud (Terzakis et al., 1967; Sinden and Strong, 1978). MTOCs localising just 
underneath the sporoblast membrane are involved in the positioning of nuclear lobes at 
the periphery of sporoblast periphery and initiate formation of the apical complex (Thathy 
et al., 2002). Sporozoites bud from centres of apical complex formation by the extension 
of microtubules from polar rings (Bannister and Sinden, 1982). Nuclei move into the 
developing sporozoites and fully formed, uninucleate sporozoites separate from the 
residual sporoblast.  
 
The expression of circumsporozoite protein (CSP) begins in the developing oocyst 
(Hamilton et al., 1988), the protein accumulates at the oocyst plasma membrane, and as 
the plasma membrane invaginates localises to the developing sporoblast, from where it is 
incorporated into the membrane of the developing sporozoite (Hamilton et al., 1988; 
Thathy et al., 2002). Gene disruption shows that CSP plays an essential role in 
sporoblast/sporozoite formation in the developing oocyst (Menard et al., 1997). It is also 
implicated in roles in sporozoite egress since targeted gene disruption of region II of CSP 
prevents sporozoite release (Wang et al., 2005). Sporozoites appear to emerge from 
mature oocysts via a protease-dependent process, as indicated by the essential role of P. 
berghei egress cysteine protease 1 (ECP1) by gene disruption (Aly and Matuschewski, 
2005).  
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1.5.8. Sporozoite migration and invasion of salivary glands 
Sporozoites are released into the haemocoel, within which they are though to be passively 
carried with the flow of the haemolymph. Many are destroyed in the environment of the 
haemocoel; it has been estimated that around 1 in 5 eventually enter the salivary glands 
(Hillyer et al., 2007). Initial attachment of sporozoites to the salivary glands involves 
interaction between parasite surface proteins and the basal lamina of salivary gland cells. 
Following breach of the basal lamina, sporozoites invade salivary gland acinar cells via 
formation of a tight junction and a transient parasitophorous vacuole and accumulate in 
the secretory cavity (Pimenta et al., 1994). CSP and TRAP are implicated with essential 
roles in sporozoite attachment and the SM1 peptide, which inhibits ookinete invasion, 
also blocks salivary gland invasion (Ghosh et al., 2001). The SM1 receptor has been 
identified in An. gambiae as saglin and TRAP-saglin binding appears crucial for invasion 
(Ghosh et al., 2009). TRAP forms a central part of the motility and invasion machinery as 
demonstrated by gene disruption; Pbtrap sporozoites are unable to invade An. stephensi 
salivary glands and are impaired in gliding motility (Sultan et al., 1997). The inner 
membrane complex protein IMC1, is also critical for sporozoite motility. Targeted 
disruption of IMC1 in P. berghei results in mis-shaped sporozoites that are defective in 
motility.  
 
Sporozoites may undergo significant changes in the salivary glands to prepare for host 
infection. Sporozoites isolated from salivary glands and inoculated into the haemocoel of 
uninfected mosquitoes are unable to re-invade salivary glands and whilst salivary gland 
sporozoites readily establish infections upon injection into hosts, sporozoites isolated 
from oocysts are regarded as being uninfective to the vertebrate host (Touray et al., 
1992). A proportion of sporozoites enter the salivary duct and are injected upon blood 
feeding along with saliva, the secretion of which is induced during uptake of the blood 
meal. The salivary glands release a number of components including antihistamines, 
vasodilators, anticoagulants and immunomodulators, which aid uptake of a blood meal 
and facilitate sporozoite infection (reviewed by Dhar and Kumar, 2003). Sporozoites 
residing in the salivary glands are thought to increase their transmission success by 
modulating mosquito behaviour, for example by decreasing mosquito apyrase activity. 
Apyrase is a secretory protein which has been shown to inhibit platelet recruitment and 
aggregation. Reduction in its activity thereby causes difficulties in obtaining a full blood 
meal and as a result the mosquito probes both more frequently and for a longer duration 
(Smartt et al., 1995). 
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1.6. The Plasmodium LCCL/lectin adhesive-like protein (LAP) family 
1.6.1. Identification of LAPs as potential TBV candidates 
The ability to select potential vaccine targets based on predicted properties as encoded by 
genetic sequence data provides promising opportunities for vaccine development. 
Putative surface or secreted proteins, which may be accessible to antibodies and thereby 
logical choices for vaccine candidates, can be identified by in silico analysis of sequences 
encoded by the genome using computer algorithms to predict characteristics common of 
surface proteins, e.g. presence of signal peptides, transmembrane domains or 
glycosylphosphatidylinositol (GPI) anchors, and absence of typical intracellular domains 
or targeting sequences. Such a ‘reverse vaccinology’ approach (selecting candidates 
based on bioinformatic analysis of a pathogen’s genome, rather than the organism itself) 
has emerged as a potent approach for the identification of new vaccine candidates − 
compellingly demonstrated in the development of a vaccine against serogroup B 
meningococci. Bioinformatic screening for putative surface-associated proteins encoded 
by the Neisseria meningitides genome led to the discovery of meningococcal factor H-
binding protein (fHBP) and resulted in the generation of a promising multi-component 
recombinant vaccine against Meningitis B (reviewed by Rappuoli and Covacci, 2003;  
Mora et al., 2006; Seib et al., 2009). 
 
Proteomic analyses of distinct stages of the malaria parasite’s life cycle provide key 
datasets which can be screened by in silico approaches in order to select candidates for 
further study. In the case of TBV development, candidates can be selected from proteome 
datasets of gametocytes and ookinetes. Among the proteins that stand out as potential 
TBV candidates are a family of six putatively secreted proteins containing predicted 
LCCL and/or lectin domains. Termed the LCCL/lectin adhesive-like proteins (LAPs), the 
proteins were first described as a family after their identification in a proteomic analysis 
of P. falciparum asexual stages and gametocytes (Lasonder et al., 2002). Five proteins, 
each containing signal peptides and a number of predicted adhesive domains, were 
recognised as being detected in gametocytes but absent from asexual stages  and were 
grouped as a family (LAP1-5) (Lasonder et al., 2002). A sixth LAP (LAP6) with the 
predicted presence of an LCCL domain, a lectin domain and a signal peptide was 
subsequently identified in the Plasmodium genome by BLAST analysis (Trueman et al., 
2004). Although LAP6 was not detected in the P. falciparum sexual stage proteome 
(Lasonder et al., 2002), all six LAPs have subsequently been detected in a P. berghei 
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ookinete surface-enriched proteome (R. Stanway, PhD thesis 2007), indicating that all are 
expressed in mosquito stages of the parasite.    
 
The LCCL domain — the primary feature of the LAP family — has been named after the 
best characterised proteins that were found to contain it, namely Limulus factor C, 
vertebrate cochlear protein cochlin and mammalian late gestation lung protein (Trexler et 
al., 2000). The LCCL domain is defined by four conserved cysteine residues and a 
conserved C-terminal region containing a highly conserved histidine (Trexler et al., 
2000). The domain is found predominantly in metazoan multidomain proteins, many of 
which are extracellular adhesive proteins, containing domains such as complement-type 
domains, lectin domains and/or von Willebrand type A domains (Bateman and Sandford 
1999; Patthy 1999; Trexler et al., 2000; Bikker et al., 2002; Muller 2001; Templeton et 
al., 2004).   
 
LAPs comprise distinct arrangements of predicted LCCL domains and/or putative 
adhesive domains, including carbohydrate-binding domains and domains characteristic of 
cell adhesion proteins, including coagulation factors. LAP1 also contains a lipoxygenase 
homology (LH) domain, with putative roles in lipid interactions (e.g. membrane 
attachment; Ponting et al., 1999; Bateman and Sandford, 1999) and furthermore, a 
tandem array of scavenger receptor cysteine-rich (SRCR) domains. SRCR domains 
appear highly conserved across a number of metazoan secreted or membrane-bound 
proteins, within which SRCR domains are thought to mediate protein-protein interactions 
and ligand binding (Bikker et al., 2002; Muller, 2001). The array of putative adhesive 
domains found in the protein family (summarised in Table 1.2.) together with the 
prediction of N-terminal signal peptides strongly suggests that the LAPs have 
extracellular roles. Predicted domain architectures are reviewed by Dessens et al. (2004) 
Trueman et al. (2004) and Pradel et al. (2004) and are described in further detail in 
Chapter 3 of this thesis.   
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Table 1.2. Properties of putative extracellular adhesive domains identified in LAPs  
Domain Properties Protein examples 
 
Limulus factor 
C, Coch-5b2, 
late lung 
gestation 
(LCCL) 
 
 
 
Characterised by four conserved cysteine 
residues and a conserved C-terminal motif: 
YxxxSxxCxAAVHxGVI containing a highly 
conserved histidine (Trexler et al., 2000). 
Roles in lipopolysaccharide (LPS) binding 
have been suggested (Wang et al. 2009).   
 
 
Multiidomain adhesive proteins, e.g. Limulus 
factor C serine protease; Cochlear protein 
COCH-5B2; Mammalian late gestation lung 
protein; Endothelial and smooth muscle cell-
derived neuropilin-like protein; and CocoaCrisp 
proteins (reviewed by Dessens et al., 2004). 
 
 
Lipoxygenase 
homology (LH) 
 
 
Homologous to a non-catalytic domain of 
lipoxygenases, with proposed roles in 
facilitating lipid binding (Ponting et al., 
1999). May mediate membrane attachment 
and may contain a conserved surface lysine 
or arginine, which possibly represents a 
ligand-binding site (SMART)  
 
 
Membrane-bound proteins, e.g. Polycystin-1 
which may act as a cell-surface receptor or form 
part of a large membrane-associated complex 
(Bateman and Sandford, 1999). 
 
 
Scavenger 
receptor 
cysteine rich 
(SRCR) 
 
Can be traditionally subdivided into two 
groups: group A SRCR domains have six 
conserved cysteine residues, whilst those of 
group B are characterised by eight cysteine 
residues (reviewed by Vilà et al., 2000).  
 
Membrane-bound and secreted proteins with 
roles in ligand binding, e.g. Macrophage 
scavenger receptor type 1; Complement factor 
1; CD5 T-cell surface glycoprotein; Mac-2 
binding protein; Deleted in malignant brain 
tumors-1; Sea urchin SPERACT egg-peptide 
receptor (reviewed by Vilà et al., 2000). 
 
 
Pentraxin 
 
 
Comprises a flattened β-jellyroll structure 
similar to laminin G and concanavalin A-like 
lectin domains, containing calcium-binding 
residues (Srinivasan et al., 1994) 
 
Proteins involved in cell recognition and 
adhesion, including viral and bacterial toxins 
such as Cholerae neuraminidase; laminins; 
neurexins; and sialidases; and proteins involved 
in complement activation, including C-reactive 
protein and Serum amyloid P component 
protein (reviewed by Gewurz et al, 1995). 
 
 
Neurexin and 
collagen-like 
(NEC)  
 
 
A collagen-binding domain with similarities 
to a portion of fibrinogen or fibrillar collagen 
globular domains (identified as a distinct 
module by Pradel et al., 2004) 
 
 
Neurexins are neuronal receptors that involved 
in adhesion and signalling between neurons. 
Other proteins containing fibrinogen domains 
include ficolins e.g. Limulus tachylectins), with 
roles in innate immunity, and intelectins (e.g.  
Xenopus cortical granule lectin), with roles in  
fertilisation and embryogenesis. 
  
 
Anthrax 
protective 
antigen-like  
 
 
A carbohydrate-binding domain with a beta-
barrel structure (reviewed by Rigden et al., 
2004). 
 
Cell binding proteins, including anthrax 
protective antigen (PA) and yeast adhesins 
(reviewed by Rigden et al., 2004). 
 
Fibronectin 
type 2 (FN2) 
  
 
A collagen-binding domain containing four 
conserved cysteine residues; related to the 
Kringle domain family (reviewed by 
Ozhogina et al., 2001) 
 
 
Proteins involved in blood coagulation, 
including fibronectin and blood coagulation 
factor XII. 
 
 
Ricin B lectin  
 
A carbohydrate- binding domain similar to 
the legume lectin ricin from the seeds of the 
castor bean plant, Ricinus communis. 
Characterised by the presence of three QxW 
repeats (see Hazes, 1996). 
 
 
Carbohydrate-recognition proteins, including 
plant and bacterial AB-toxins (see Hazes, 1996). 
 
 
Discoidin 
 
Also known as F5/8 type C domain; a ligand 
binding domain usually containing two 
conserved cysteines, with diverse ligand 
recognition mediated by highly variable 
loops (Fuentes-Prior et al., 2002),  . 
 
 
Found in a number of functionally unrelated 
proteins (Ichikawa et al., 2007) including 
Dictyostelium discoideum cell adhesion protein 
and the coagulation factors V and VIII. 
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The identification of LAPs as multidomain lectin-like proteins immediately led to the 
suggestion that the protein family may be involved in extracellular functions. It is known 
that lectin-like properties play important roles in recognition, adhesion and invasion 
mechanisms of parasites and other pathogens. For example, the negative charge of cell 
surface glycosaminoglycans or proteoglycans is utilised to enter and infect cells (Rostand 
and Esko, 1997). In Plasmodium, lectin-carbohydrate interaction are expected to be 
important in mediate cell invasion be ookinete, sporozoites and merozoites (Siden-
Kiamos and Louis, 2004). Differentiation into oocyst is also thought to require specific 
binding to sugars (of the basal lamina) (Arrighi and Hurd, 2002). 
 
1.6.2. Studies on the LAP family 
Genes encoding orthologs of each of the six LAPs are found in all sequenced 
Plasmodium genomes; P. falciparum, P.vivax, P.yoelii, P.berghei and P.chabaudi 
(Gardner et al., 2002; Carlton et al., 2002; Gardner et al., 2005; Hall et al., 2005). 
Furthermore, homologs of LAP1-5 are identified in all sequenced apicomplexan 
genomes. This includes two species of Cryptosporidium (Cryptosporidium parvum and 
Cryptosporidium hominis), two species of Theileria (Theileria parva and Theileria 
annulata) and Toxoplasma gondii. Although domains found in LAPs are individually 
found widely among eukaryotes and other taxa, the domain architectures that make up the 
LAPs are unique to Apicomplexan parasites.  
 
Studies on the LAP family have been most comprehensively performed in Plasmodium, 
and at the onset of this PhD, a number of studies had been carried out characterising 
members of the family in both P. falciparum (Delrieu et al., 2002; Pradel et al., 2004; 
Pradel et al., 2006) and P. berghei (Claudianos et al., 2002; Trueman et el., 2004; Raine 
et al., 2007). LAP1 has been named the Plasmodium scavenger receptor cysteine rich 
LCCL adhesive-like protein (PSLAP), and Plasmodium scavenging receptor protein 
(PxSR) (Claudianos et al., 2002; Delrieu et al., 2002). The protein family is now 
generally known as the LAPs (LCCL/lectin adhesive-like proteins: Lasonder et al., 2002; 
Trueman et al., 2004; Raine et al., 2007) or also as the CCps (Limulus coagulation factor 
C domain-containing proteins): the five LCCL domain containing proteins are termed 
CCp1-5 and the single member of the family lacking an LCCL domain is referred to as 
FNPA (Pradel et al., 2004; Pradel et al., 2006) 
 
 62 
In P.falciparum, where the proteins are commonly referred to as the PfCCp protein 
family, cellular localisation studies have been performed, strengthening the potential of 
the proteins as vaccine candidates. Through immunofluorescence analyses using 
antibodies generated against PfCCp recombinant proteins, PfCCp1, 2 and 3 have been 
shown to be expressed in a stage-specific manner in gametocytes (detectable from stage II 
onwards). Antibody staining was associated with the plasma membrane, the PV and the 
PV membrane (Figure 1.7; Pradel et al., 2006). Therefore, following parasite egress from 
the RBC, it is envisaged that the proteins would be exposed on the surface of the parasite 
where they may be accessible to immune attack from blood meal components. Studies 
analysing antibody labelling post-fertilisation indicate that the proteins appear to be 
secreted from the parasite and thereafter localised extracellularly, with only low level 
labelling detected post-fertilisation (Delrieu et al., 2002; Pradel et al., 2004). 
  
 
 
 
 
 
 
 
 
 
 
 
Figure1.8. Immunofluorescent labelling of PfCCp1  
Confocal medial section images of mouse polyclonal anti-PfCCp1 antibody in combination with Alexa488 
secondary antibody depicting labelling in association with the parasite surface and parasitophorous vacuole. 
Taken from Pradel et al. (2006). 
 
 
Antibody labelling studies of select PfCCps therefore suggest that the proteins are 
specific to gametocytes: expression beginning during gametocytogenesis and ceasing 
after fertilisation. Accordingly, roles in aiding fertilisation have been suggested. It is 
proposed that the proteins may act as adhesive molecules on the surface of female 
gametes: perhaps acting to increase encounters between male and female gametes, or 
possibly, by promoting cell clustering, aiding gamete survival by surrounding them by 
cells to shield them from immune attack (Pradel et al., 2006). Yet interestingly, the 
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outcomes of gene disruption studies, in both P. falciparum and P. berghei, show that 
fertilisation is appears to occur normally in Pblap or Pfccp knockout parasites. Gene 
disruption of Pblap1, Pblap2, Pblap4 and Pblap6 results in oocysts defective in 
sporulation (Figure 1.9; Claudianos et al., 2002; Raine et al., 2007).   Meanwhile, 
∆Pfccp1, ∆Pfccp2, and ∆Pfccp3 parasites are capable of forming ookinetes, oocysts and 
sporozoites in comparable numbers to wild-type parasites, yet sporozoites were unable to 
invade salivary glands (Pradel et al., 2004). From gene knockout studies it is thereby 
concluded that the proteins are not essential for asexual blood stage, gametocyte or 
ookinete development, but are essential for oocyst maturation and sporozoite 
production or infectivity. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.9. Representative morphology of wild-type and ∆Pblap oocysts  
Images of ∆Pblap and wild-type (wt) day 14 oocysts in An. stephensi mosquitoes. The ∆Pblap oocysts grow, 
but whereas mature wild-type (wt) oocysts contain thousands of sporozoites, ∆Pblap oocysts fail to sporulate. 
 
In cross-fertilisation experiments in which ∆Pblap gametocytes are crossed with wild-
type  parasites, infectious sporozoites  are formed (Raine et al., 2007; Trueman et al., 
2004) as would be expected for a gene with functions after zygote formation (Ranford-
Cartwright et al., 1991). Furthermore, experiments in which ∆Pblap gametocytes are 
crossed with parasite lines deficient in either male or female fertility demonstrate that 
critical function of Pblap1, Pblap2, Pblap4 and Pblap6 depends on molecules inherited 
from the female gametocyte (Raine et al., 2007). Development is rescued when crossed 
with ∆Pbs48/45 gametocytes, specifically deficient in male gamete fertility (van Dijk et 
al., 2001), whereas crossing with a ∆Pbs47 parasite line, in which the function of female 
gametes is disrupted (Khan et al., 2005; Mair et al., 2006) fails to rescue sporulation 
(Raine et al., 2007).  Therefore although the effect of gene disruption is not detected until 
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sporulation in the oocyst, it is suggested that functions are mediated through the 
inheritance of transcripts or protein from the female gametocyte (Raine et al., 2007). This 
is supported by proteomic analyses of separated male and female P. berghei gametocytes, 
though which LAPs are reported to be female specific (Khan et al., 2005). The LAP 
family have therefore been identified as candidates of interest both in their potential as 
TBV candidates, and in terms of deciphering aspects of Plasmodium developmental 
biology.  
 
 
1.7. Thesis aims  
General objectives of this thesis were to: 
1. Investigate the possibility that anti-LAP antibodies might interfere with parasite 
development in the mosquito.  
2. Gain insights into the biological roles of the LAP family and the molecular 
processes by which Plasmodium completes its development in its mosquito 
vector.  
 
Using P. berghei as a well established system for the study of mosquito stages of the 
parasite, specific aims were to i) generate LAP recombinant proteins, ii) produce 
antiserum with anti-LAP activity, iii) evaluate transmission-blocking activity through in 
vitro and in vivo assays, and iv) study LAP localisation and other aspects of LAP biology 
considered relevant. 
 
Results are presented as two chapters: Chapter 3 deals with the generation of antisera 
against LAPs and evaluates activities in transmission-blocking assays; Chapter 4 
addresses cellular localisation and attempts to further investigate LAP biology.  
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2 MATERIALS AND METHODS 
 
2.1. Maintenance of Plasmodium berghei  
2.1.1. Parasite strains and clones 
P. berghei ANKA strain parasites clone 2.34 (wild-type) were used throughout studies. A 
second clone, 2.33 (defective in the production of mature gametocytes) was used for the 
purpose of generating gametocyte depleted infections. In addition, the following 
transgenic parasite lines were used: PbconGFP, Pblap gene knockout parasites (available 
for all but Pblap3) and Pb814-myc. All transgenic parasites were derived from clone 2.34 
parental lines. Details are given in Table 2.1. 
  
Table 2.1 P. berghei clones  
Name 
 
Description 
 
clone 2.34 Wild-type (wt) 
 
clone 2.33 Defective in the production of mature gametocytes  
 
PbconGFP Constitutively expresses GFP (Franke-Fayard et al., 2004) 
 
∆Pblap1 Pblap1 knockout (Trueman et al., 2004) 
 
∆Pblap2 Pblap2 knockout (Raine et al., 2007) 
 
∆Pblap4 Pblap4 knockout  (Raine et al., 2007) 
 
∆Pblap5  Pblap5 knockout (Ecker et al., 2008) 
 
∆Pblap6  Pblap6 knockout (Raine et al., 2007) 
 
Pb814-myc  Pb814 myc epitope tagged (Dr. M. Delves, unpublished) 
 
2.1.2. Infection of mice  
Female Theiler's Original (TO) mice (Harlan, UK) aged 6-10 weeks old were routinely 
used as hosts for the maintenance of P. berghei by cyclical passage. Mice were infected 
by inoculation with schizonts: approximately 5 x 107 parasites in a volume of 100-200 µl 
were injected intraperitoneally. Parasites were obtained either directly from the blood of 
an infected donor mouse or from a cryopreserved solution (100 µl infected blood in     
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200 µl 90% (v/v) Alsever’s solution (Sigma) and 10% (v/v) glycerol). To stimulate a 
quick rise in parasitemia and high gametocytemias, mice were injected 2-3 days prior to 
P. berghei infection with 200 µl phenylhydrazinium chloride (PH; 6 mg/ml in PBS, 
Sigma). Treatment with PH induces hyper-reticulocytosis and since P. berghei 
preferentially invades reticulocytes, results in an increase of initial cell infection rates and 
enhanced gametocyte production (Gautret et al., 1996). 
 
2.1.3. Assessment of parasitemias  
Parasitemias of infected mice were monitored from 3 days post-infection by microscopic 
examination of Giemsa-stained thin blood smears. A drop of tail blood was spotted and 
smeared onto a frosted slide. Air-dried blood smears were fixed in methanol and stained 
with a 1 in 5 Giemsa stain solution (Fluka) for approximately 10 minutes at room 
temperature. Smears were examined using an Olympus BH2 light microscope at an 
objective magnification of x100. Parasitemias were quantified by counting the number of 
infected red blood cells as a percentage of total red blood cells in observations of three 
random fields.  
 
2.1.4. Collection of blood  
In order to harvest parasites, mice were anaesthetised by intramuscular injection with a 
lethal dose (150 µl) of a mixture of xylazine and ketamine; one volume of Rompun®    
(20 mg/ml xylazine hydrochloride; 5,6Dihydro-2-(2,6-xylidino)-4H-1,3-thiazine-
hydrochloride; Bayer) and two volumes of Vetalar® (100 mg/ml ketamine; Fort Dodge 
Animal Health Ltd.) in three volumes of phosphate buffered saline (PBS). Mice were 
swabbed with alcohol and a 26 gauge needle and syringe containing approximately 50 µl 
of heparin (30 units/ml, Sigma) was used to remove blood by cardiac puncture. Typically 
0.8-1.0 ml of blood was collected from each mouse.  
 
2.1.5. In vitro cultivation of ookinetes  
Ookinetes were cultured from blood containing mature gametocytes (day 3-4 post-
infection). Mice were infected and parasitemias were assessed by observation of Giemsa-
stained smears as in 2.1.2. To test for the presence of mature male gametocytes (capable 
of exflagellation), a drop of tail blood was spotted on a microscope slide, mixed with a 
drop of ookinete medium (see below), and covered with a Vaseline®-edged coverslip. 
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Exflagellation typically occurs from 8-12 minutes after removal of blood and can be 
observed under the microscope as clumps of red blood cells moving in a wobbling 
motion. Cells were viewed using an Olympus BH2 light microscope under phase contrast 
at x40 objective magnification.   
 
Parasites were cultured in 20% (v/v) Foetal Bovine Serum (FBS) and 80% (v/v) ookinete 
culture medium (25 mM HEPES containing 2 mM L-glutamine (Sigma), 0.2% (w/v) 
Na2CO3, 5U/ml penicillin (Gibco), 5 µg/ml streptomycin (Gibco), 50 mg/ml 
hypoxanthine (Sigma) and 100 µM XA; pH 8.4). 10 ml culture volumes were prepared 
for the addition of 0.4 ml of blood, 30 ml culture volumes were used for up to 1.2 ml of 
blood, and 140 ml culture volumes were prepared when larger quantities of ookinetes 
were required. Blood was collected by cardiac puncture and transferred to the tissue 
culture flask. Cultures were maintained at 19°C, 70% humidity for 24 hours for ookinete 
development.   
 
2.1.6. Mosquito infections 
Anopheles stephensi SD500 mosquitoes were reared by Ken Baker and Mark Tunnicliff. 
Adult females (3-6 days post-emergence) were collected using a battery-powered 
aspirator and potted in cardboard cups (typically 70-80 per pot) covered by mesh netting 
and secured with a cardboard lid. Mosquitoes were starved overnight to increase the 
probability of blood feeding. For direct feeds, mice with a parasitemia of 5-10% 
containing mature gametocytes were anaesthetised with a low dose (40-50 µl) of 
Rompun®/Vetalar® (mixed as described in 2.1.1.2) and placed onto the mesh netting of 
mosquito pots. Mosquitoes were allowed to feed for 20-30 min at 19°C, preferably in the 
dark. Unfed mosquitoes were removed within 24 hours of feeding. Fed mosquitoes can be 
easily distinguished from unfed mosquitoes since the blood meal is visible in the 
mosquito abdomen. Mosquitoes were briefly anaesthetised with CO2 and kept on ice 
while all unfed mosquitoes were removed. Fed mosquitoes were then maintained on 
fructose (8% (w/v) fructose, 0.05% (w/v) p-aminobenzoic acid) at 19°C and 70% relative 
humidity under a 12 h light / 12 h dark cycle. 
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2.2. Construction of plasmid vectors  
DNA plasmids were constructed for the purpose of recombinant protein expression and 
for tagging endogenous proteins. 
2.2.1. Sequence retrieval and bioinformatic analysis 
DNA sequences of P. berghei laps and corresponding protein sequences were retrieved 
from PlasmoDB (http://plasmodb.org/plasmo) using the gene ID numbers as follows;   
Pblap1:  PB000977.02.0 
Pblap2:  PB000652.01.0 
Pblap3:  PB001172.01.0/PB000635.02.0 
Pblap4:  PB000504.02.0 
Pblap5:  PB001084.00.0  
Pblap6:  PB000955.03.0 
Putative protein domains were predicted using InterproScan (Quevillon et al., 2005) and 
SMART sequence analysis (Schultz et al., 1998). Nucleotide and protein BLAST 
searches were conducted using the BLASTN and BLASTP tools 
(http://www.ncbi.nlm.nih.gov/blast). 
  
2.2.2. Cloning strategy for the generation of vectors for protein expression   
Constructs for the heterologous expression of portions of PbLAPs were generated by 
cloning gene fragments into a pET-46 Ek/LIC vector (Novagen) by ligation independent 
cloning (LIC). Primers (Table 2.2) were designed with 5’ extensions 
GACGACGACAAGATX (sense) and GAGGAGAAGCCCGGT (antisense) compatible 
for annealing into the Ek/LIC vector. Target gene fragments were amplified by PCR from 
template parasite DNA (2.2.4.1); genomic DNA was used when the target lacked introns, 
whilst cDNA was used when introns were present in the target sequence. PCR products 
were purified (2.2.4.4), eluting into TlowE buffer in accordance to the requirements for 
Ek/LIC cloning. TlowE contains EDTA for sequestration of metal ions and the reducing 
agent DTT required for cloning steps.  
 
Target gene sequences were inserted into the pET-46 Ek/LIC vector by an annealing 
reaction following the generation of compatible overhangs by T4 DNA polymerase 
treatment. The 3’5’ exonuclease activity of T4 DNA polymerase results in single strand 
removal of nucleotides from the 3’ end. Since dATP is the only nucleotide available, 
polymerase activity is only initiated when the first adenine is encountered 
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(complementary to the thymidine in the 5’ extensions) thereby generating vector-
compatible 13-14 base overhangs. pET-46 Ek/LIC vector and T4 DNA polymerase 
treated inserts were then annealed by a 10 min incubation at 22°C. Both T4 DNA 
polymerase treatment and annealing reactions were performed as stated in the Novagen 
Ek/LIC cloning kit user protocol (#TB163).  
 
Plasmids were initially transformed into E.coli strain NovaBlue Gigasingles (Novagen). 
Following sequencing, plasmids confirmed to contain an in-frame target of correct 
sequence were transformed into E. coli expression strains: BL21 (DE3) pMico or Rosetta 
(DE3) PLysS, allowing for T7 RNA polymerase-mediated expression. An empty vector 
negative control was generated by transformation of pET-15b. The pET-15b vector is 
similar to the pET-46 Ek/LIC vector, each containing an N-terminal His•Tag® sequence.  
 
2.2.3. Cloning strategy for generating vectors to tag endogenous genes 
All tagging constructs were designed to integrate into the endogenous Pblap locus via 
single homologous recombination. C-terminal gene portions (minus the stop codon) were 
PCR-amplified using forward primers equipped with KpnI restriction sites and reverse 
primers with ApaI restriction sites (see Table 2.2 for primer sequences). Intermediate 
cloning of purified PCR products was performed using the pGEM® T-Easy vector 
system (Promega) for ligation into the pGEM® T-Easy vector. Plasmid DNA confirmed 
by sequencing to contain an in-frame target gene was digested with the restriction 
enzymes ApaI and KpnI for subsequent ligation into ApaI/KpnI-digested GFP and c-Myc 
tagging vectors (pDR0007-myc and pDR0008-gfp). Each plasmid encodes the respective 
tag downstream of the ApaI/KpnI restriction sites and a selection cassette encoding a 
modified Toxoplasma gondii dihydrofolate reductase / thymidylate synthase gene 
(Tgdhfr/ts), which confers high levels of resistance to the antimalarial drug 
pyremethamine.  
 70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Schematic representation of the strategy for GFP or myc tagging of endogenous genes 
The targeting construct corresponds to the sequence of a c-terminal portion of the target gene, lacking the 
stop codon, in frame with a 3’ eGFP or c-Myc tag and Tgdhfr-ts. The plasmid is linearised at a restriction site 
unique to the region of homology (absent in the vector). The linearised vector integrates into the targeting 
locus by single homologous recombination, resulting in the tagging of the endogenous gene copy (asterisk = 
stop codon). Modified from Tufet Bayona (2005). 
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2.2.4. Primers 
Primers were synthesised by Invitrogen. Stock solutions of 100 mM and working 
solutions of 10 mM were prepared and maintained at -20°C.   
 
Table 2.2. Primer sequences 
 
Primer name Primer sequence 5’-3’ 
  
RA11216F GACGACGACAAGATAAAAAGTAATATTAGAATCGTTGATTC 
RA12121R GAGGAGAAGCCCGGTTTAAAATATATCTCCAACATTTCCTTTGC 
RA12539F GACGACGACAAGATATGGCTAGCTCCATCTTCATTTGCTGG 
RAl3157R GAGGAGAAGCCCGGTTTAACATGGAGTAATACAATCTCGCCC 
ABLAP2F GACGACGACAAGATGAAAATATTAAGTTCATTAGATGAAAAATTTTTATCG 
ABLAP2R GAGGAGAAGCCCGGTTCAATTGATATGTTTTTCTTTTTTTTGGTTTGGATGC 
RA2424F GACGACGACAAGATAAAAATAGGGTTAAAAAATGCCATTCAC 
RA21323R GAGGAGAAGCCCGGTTTACCAGCTTTCTAAATTGTTGGTTG 
ABLAP3F GACGACGACAAGATATCAAAGAGGGTATCTAACCCTATTGAATTAATAG 
ABLAP3R GAGGAGAAGCCCGGTTCAAAATTTATTTATTTGAACAGGCTTTTTAAAATATATTG 
RA3643F GACGACGACAAGATGACTGGAGAAGAAGAAATATTATCATCTCC 
RA31443R GAGGAGAAGCCCGGTTTAAGATAATACATTATTTTGTAACTTTCCG 
RA41777F GACGACGACAAGATGAAAATTGGAAGTATGTATTATATTCCATC 
RA42616R GAGGAGAAGCCCGGTTTAAAGGGGATGGTTATTGTTTTCGATG 
RA43718F GACGACGACAAGATATCAAACTGGAATTATGCAAATAATATAGG 
RA44876R GAGGAGAAGCCCGGTTTATAGTTTAATGTTTGAAGTAAGTAAATCAGG 
ABLAP5F GACGACGACAAGATGCCAACAACTTTTATTATATTTATCATGCAAAATG 
ABLAP5R GAGGAGAAGCCCGGTTCAAGTGGTTAAATTGCTTTCTTTTTTACATTCTAA 
RA5289F GACGACGACAAGATGGAATATAAAAAATTAGGAGGTGTATATG 
RA51227R GAGGAGAAGCCCGGTTTAACTGCGTATAGCTTTCGATTTTTC 
ABLAP6F GACGACGACAAGATATCCTTTTCCATATTTTGGAGTAGTAAAAATATTCC 
ABLAP6R GAGGAGAAGCCCGGTTTAATCTGAAATATACCTTTTAGACAAATCTCTTTTTG 
RALAP6.2F GACGACGACAAGATGGAACAAACTAGTATAGTAATAGACACATTTG 
RALAP6.2R GAGGAGAAGCCCGGTTTAGTGCATATTATACAACTGGTTTTGTAAAG 
  
RA1_Kpn_2929F GGTACCGGAGATTTAACTATTGGTAGATCAAAC  
RA1_Apa_3892R GGGCCCATATAAGCGTTTCAAAAAGGT 
RA2_Kpn_2809F GGTACCGATGCTATTCATGGAGTTGATTCATCAGTAATTTCC 
RA2_Apa_4842R GGGCCCTTCAGTAATTCCATGAGTTACTTTGCAC 
RA3_Kpn_1321F GGTACCAATGTAAATGACAAAGATGTTAATAATTTAAATGAG 
RA3_Apa_2064R GGGCCCATTTTTAATAATTTGTATCGAAAGTATAGTTGTTCG 
TagRAlap4F GGTACCAGCATTATCTTTATACATCCATTTGAC 
TagRAlap4R GGGCCCTTTAATGTTTGAAGTAAGTAAATC 
TagRAlap5F GGTACCATTAGTGTGATATCGAAGCCATTAACTTGG 
TagRAlap5R GGGCCCATTGTGGAGAATATAATTTGTATAGATTGTATAAC 
RA6_Kpn_3376F GGTACCAGAACATACATAAACAAAACATTTGGAGCTGG 
RA6_Apa_4416R GGGCCCATCTTTATGAGGAATAAATAAAATGTTTTTAAACATTGAT 
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2.2.5. Preparation of template DNA 
In most cases, genomic DNA extracted from wild-type P. berghei parasites was used as 
template for PCR-amplication of target gene fragments; the exception being when the 
target for protein expression contained introns, in which case DNA was amplified from 
synthesised cDNA. 
2.2.5.1. Extraction of genomic DNA 
Genomic DNA was extracted from mixed blood stages or ookinetes. Cells were harvested 
by centrifugation (500g for 10 min at 4°C) and resuspended in 40 ml ice-cold 0.17 M 
ammonium chloride and incubated on ice for 30 min to lyse red blood cells. Parasites 
were then collected by centrifugation (500g for 10 min at 4°C). Genomic DNA was 
extracted using the Promega Wizard® Genomic DNA Purification Kit. The parasite pellet 
was mixed in 600 µl Nuclei Lysis Solution and RNA removed by incubation with RNase 
Solution (15 min at 37°C). Protein and DNA were removed by precipitation (as described 
in the Promega Wizard® Genomic DNA Purification Kit protocol). The resulting pellet 
was air-dried for 15 min then the DNA was rehydrated in 100 µl DNA Rehydration 
Solution for 1 h at 65°C and afterwards stored at 4°C.  
2.2.5.2. Synthesis of cDNA  
Single-stranded cDNA was produced from extracted RNA using M-MLV Reverse 
Transcriptase kit (Invitrogen). In order to extract RNA, parasite pellets (prepared as in 
2.2.5.1) were homogenised in TRIzol® reagent (Invitrogen) to disrupt and dissolve 
cellular components. RNA was separated into an upper aqueous layer by the addition of 
chloroform, and precipitated by isopropanol and ethanol according to the manufacturer’s 
protocol. The pellet was air-dried and the RNA solubilised in 50 µl Ultrapure™ DNAse 
and RNAse-free distilled water (Gibco) by incubation at 65°C. Contaminating DNA was 
removed by DNAse treatment using Ambion’s TURBO DNase.   RNA samples were 
incubated for 3 min at 37°C with 1x TURBO DNase buffer and 1 µl TURBO DNase. The 
reaction was terminated by the addition of DNase Inactivation Reagent. RNA samples 
were used immediately or snap-frozen and stored at -80°C. The M-MLV Reverse 
Transcriptase kit (Invitrogen) was used for cDNA synthesis, using oligo(dT) primers to 
bind the polyA tails of mRNA and Moloney murine leukaemia virus reverse transcriptase 
(M-MLV RT)  to catalyse the reaction in the presence of RNaseOUT recombinant 
ribonuclease inhibitor (40 U per µl, Invitrogen). Synthesis was allowed to proceed for 50 
minutes at 37°C then the reaction was stopped by heating to 70°C for 15 min. Reverse 
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transcriptase negative reactions were carried out in parallel, from which it could be 
determined if contaminating gDNA was present by PCR amplification.  
 
2.2.6. Polymerase chain reaction (PCR) 
To assess the integrity of DNA and/or to check for primer amplification, analytical PCRs 
were performed using GoTaq® Green Master Mix (Promega) which contains GoTaq® 
DNA polymerase in GoTaq® Reaction Buffer, dNTPs and MgCl2. 15 µl reactions were 
carried out, containing 1x Master Mix, 1 mM of each forward and reverse primers and     
1 µg of template DNA. For cloning purposes, DNA was amplified using the Advantage® 
2 PCR system (Clontech). Typically 50 µl reactions were carried out, containing 1 µg of 
template DNA, 0.2 mM of each dNTP (Promega), 1 mM forward and 1 mM reverse 
primers, 1x Advantage PCR buffer, and 1 µl Advantage Taq polymerase. Where errors in 
sequences were frequently detected in amplified DNA, the Phusion PCR system (NEB) 
and/or PWO PCR (Roche) were utilised (reactions were carried out as described in the 
respective protocols).  
 
The following standard program was used for all PCRs and adapted if necessary: 94°C 
for 5 min (initial denaturing step); 94°C for 45 s (denaturing step), 50°C for 45 s 
(annealing step), 62°C for 1.5 min (elongation step), repeated for 30 cycles; 62°C for 5 
min (final elongation step) and then held at 4°C.  The annealing temperature was 
modified as appropriate for each primer pairing, depending on the Tm. The elongation 
time and number of cycles were altered according to the expected product size. PCR 
products were visualised by agarose gel electrophoresis (see 2.2.7).  
 
Components of the QIAquick® Gel Extraction Kit were used for direct purification of 
PCR products. The supplied binding buffer was added directly to the PCR sample and the 
mixture was applied to the spin column. Nucleic acids become adsorbed to the silica-gel 
membrane in the high-salt conditions provided by the buffer. Impurities and short DNA 
fragments were washed out and purified DNA was eluted in 30 µl of miliQ water. 
 
2.2.7. Agarose gel electrophoresis 
DNA was resolved using 0.8 % (w/v) agarose gels containing ethidium bromide (BDH 
Chemicals Ltd.) at a final concentration of 0.5 µg/ml to enable visualisation under UV 
light. Tris-acetate-EDTA (TAE; 40 mM Tris-HCl, 1 mM EDTA, 20 mM acetic acid) was 
used both in the agarose gel and as running buffer. Samples were loaded in Green 
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GoTaqTM Reaction Buffer (Promega) and 5 µl HyperLadder™ I (Bioline) was loaded 
alongside samples to allow estimation of fragment sizes and for approximate 
quantification. Gels were run at 100 V for 30-60 minutes and photographed using a UV 
imager box (300-360 nm).  
 
The QIAquick® Gel Extraction Kit (Qiagen) was used to solubilise and purify DNA from 
agarose gels where required. Excised gels slices were dissolved in Qiagen Solubilisation 
Buffer QG by incubating at 37°C for 10-20 minutes and QIAquick® spin columns were 
used to bind DNA according to the manufacturer’s protocol. DNA was eluted in 30 µl of 
miliQ water or for LIC cloning in TLoweE buffer. Eluates were stored at -20°C if not 
used immediately.  
 
2.2.8. DNA ligations 
PCR products were cloned intermediately in the pGEM® T-Easy vector (Promega) which 
is supplied linearised with single 5´-deoxythymidine (dT) overhangs. Since the terminal 
transferase activity of Taq polymerase results in the preferential addition of single 
deoxyadenosine (dA) to the 3´ ends of amplified DNA, PCR products can be directly 
cloned into the pGEM® vector without the need for digestion with restriction enzymes. 
Ligations were carried out in 10 µl reaction volumes, comprising 5 µl 2x Ligation Buffer, 
1 µl T-Easy vector, 1-3 µl purified PCR product (2.2.4.5) and 1 µl T4 DNA ligase. 
Reactions were incubated at 16°C for 4 hours and then at 4°C overnight.  
 
Ligations into the tagging vectors pDR0007-myc and pDR0008-gfp were performed 
using T4 DNA ligase (Roche) or the Roche Rapid DNA Ligation Kit. Concentrations of 
vector and insert DNA were measured on a NanoDrop® ND-1000 Spectrophotometer. 
Ligations were typically carried out in 20 µl reaction volumes containing 9-90 fmol of 
insert and 3-30 fmol vector, at an insert: vector at a ratio of 10:1, 1x ligase buffer and    
0.1 U T4 DNA ligase. Reactions were incubated at 16°C for 4 hours and then at 4°C 
overnight. When using the Rapid DNA Ligation Kit (Roche), reactions comprising 1 µl 
vector, 3 µl insert, 5 µl buffer and 1µl (0.5 U) T4 DNA ligase were incubated for 5 min at 
25°C and then at 4°C overnight.   
 
2.2.9. Transformation of E. coli and selection of transformed cells 
All transformations were performed using heat shock to facilitate entry of plasmid vectors 
into bacterial and transformed cells were selected for by growth on Luria-Bertani (LB) 
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agar containing appropriate antibiotic. All LB agar and media was prepared from 
premixed powder (Merck) according to manufacturer’s instructions.  
 
Expression vectors were initially transformed into E. coli NovaBlue Gigasingles™. 25 µl 
of competent cells were thawed on ice and added to 1µl of annealed vector/insert. The 
suspension was incubated on ice for 5 min, then heated for 20 s at 37°C and subsequently 
placed back on ice for 2 min. 800 µl of salt optimised and carbon (SOC) medium 
(Invitrogen) was added and cultures were incubated for 1 h at 37°C with agitation at    
200 rpm to permit initial bacterial cell growth in absence of selection. Cells were 
collected by centrifugation (10,000g for 2 min) and a volume of approximately 150 µl 
was plated onto LB agar plates containing carbenicillin (50 µg/ml) to select for growth of 
transformants with ampR genotype.   
  
Once the presence of insert had been confirmed, plasmids were subsequently transformed 
into E. coli BL21 (DE3) pMico or Rosetta (DE3) pLysS for protein expression. 25 µl of 
competent cells were thawed on ice and added to 1µl of annealed vector/insert and 
incubated on ice for 1 hour. Cells were transformed by heat shock for 30 s at 42°C, and 
after which were incubated back on ice for 2 min. Initial bacterial cell growth was 
mediated by culture in 1 ml LB media for 1 h at 37°C with agitation at 200 rpm. Cells 
were plated as above.   
 
All other transformations were performed using Subcloning Efficiency DH5α competent 
E. coli cells (Invitrogen). 50 µl of competent cells were thawed on ice and added to 10 µl 
of ligation mixture and incubated on ice for 30 min. Cells were then heat-shocked for 20 s 
at 37°C and placed on ice for 2 mins. Cells were allowed to recover as above and were 
plated onto LB agar plates containing ampicillin (50 µg/ml).  
 
2.2.10. Preparation of plasmid DNA  
Plasmid DNA was extracted from 5 ml overnight E. coli cultures using a QIAprep® spin 
miniprep kit (Qiagen). Five bacterial colonies were picked under sterile conditions using 
a P20 pipette tip (Starlab) and the whole pipette tip was placed into a 30 ml Universal 
tube (Sterilin) containing 5 ml LB broth with ampicillin (150 µg/ml). Cultures were 
incubated at 37°C with agitation at 200 rpm for 8 h or overnight. Plasmid DNA was 
isolated from 5 ml overnight cultures using a QIAprep® spin miniprep kit (Qiagen). 
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Alkaline lysis, followed by neutralisation/DNA renaturation with acetate and purification 
by binding to the silica gel column was performed as described in the manufacturer’s 
instructions. DNA was washed with an ethanol-containing buffer and eluted in 30 µl of 
miliQ water. Glycerol stocks of transformed cells were prepared by mixing 500 µl of 
bacterial culture (prepared as described above) with 500 µl 50% glycerol. Stocks were 
maintained at -80ºC. 
 
2.2.11. Restriction digests 
Restriction digests were typically carried out using 1 µg plasmid DNA, 2 U of enzyme 
(NEB or Promega) and 1x compatible buffer (NEB or Promega). Diagnostic restriction 
digests, to assess for the presence of inserts in plasmid preparations, were carried out in 
15 µl reactions and were incubated at 37°C for 2.5 h. Samples (2 µl) were analysed by 
agarose gel electrophoresis (2.2.6.2.) alongside a sample of uncut plasmid.  
 
ApaI/KpnI digestions for cloning were carried out in 60 µl reactions using 1x multicore 
buffer. Reactions were incubated overnight at 37°C. For plasmid digests, the possibility 
of plasmid re-ligation – which is possible when double-digestion does not occur with 
100% efficiency – was prevented by dephosphorylation of 5’ ends by incubating for 1 h 
at 37ºC with 1 µl shrimp alkaline phosphatase (Promega). The reaction was terminated by 
incubation for 15 min at 65ºC.  
 
2.2.12. Sequencing 
Fully-automated sequencing was carried out by the Molecular Biology Unit at the Natural 
History Museum. The sequencing of DNA cloned into pET-46 was performed from the 
T7 promoter and T7 terminator. The sequencing of DNA cloned into pGEM® T-Easy 
vector was carried out using T7 and SP6 primers. Sequences were analysed manually by 
alignment of the obtained sequence with that predicted from genomic sequence using 
ClustalW (http://www.ch.embnet.org/software/ClustalW.html). 
 77 
2.3. Production of antisera 
2.3.1. Expression of recombinant proteins in E. coli  
E. coli expression strains containing recombinant plasmid (or empty plasmid as control) 
were grown overnight in 5 ml LB containing 50 µg/ml carbenicillin. Each culture was 
then diluted to the desired volume (between 250-1000 ml) and incubated at 37°C on a 
shaking platform set at 250 rpm until the bacteria reach mid-late log growth phase 
(optical density at 600 nm of 0.6 or higher, i.e. ≥ 60 million cells). Overexpression of the 
target protein was induced by the addition of isopropyl-1-thio-β-D-galactopyranoside 
(IPTG) to a final concentration of 0.2-1.0 mM. Cultures were incubated for 4 h at 37°C or 
overnight at 28°C on a shaking platform set at 250 rpm. Cells were collected by 
centrifugation (13,000 rpm for 20 min at 4°C) and either stored at -20°C or lysed 
immediately.  
 
2.3.2. Extraction of protein  
Novagen’s BugBuster® Protein Extraction Reagent was used to release soluble protein 
by gentle disruption of the bacterial cell wall. Harvested cell pellets were resuspended at 
5 ml per gram in BugBuster® HT Protein Extraction Reagent (Novagen) and soluble 
protein was separated from insoluble protein and cellular debris by centrifugation (13,000 
rpm for 20 min at 4°C). To obtain the insoluble protein fraction, the cell pellet was 
resuspended in 8 M urea buffer (100 mM NaH2PO4, 10 mM tris-HCl, 8 M Urea, pH 8.0) 
at 2.5 ml per gram and placed on a rotary shaker at room temperature for at least 1 h for 
cell lysis and protein solubilisation. Benzonase® nuclease (Novagen) was added to a final 
concentration of 2.5 U/ml to digest nucleic acids and reduce viscosity. The urea-
solubilised protein was separated from cellular debris by centrifugation (13,000 rpm for 
20 min at 4°C). 
 
2.3.3. Purification of histidine-tagged proteins  
Histidine-tagged fusion proteins were purified by nickel affinity using Ni-NTA agarose 
beads (Qiagen). To purify soluble fractions, 1 ml of Ni-NTA slurry was added to 4 ml of 
extracted protein in a falcon tube and mixed on a rotary shaker overnight at 4ºC. The 
flow-through was separated by centrifugation (13,000 rpm for 5 min) and removed. 
Beads were washed four times with 20-50 ml of wash buffer (50 mM NaH2PO4, 300 mM 
NaCl, 20 mM imidazole; pH 8.0) and were transferred to a microcentrifuge tube. Bound 
protein was eluted by increasing imidazole concentration; eluates were collected by 
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adding 500 µl of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole; pH 
8.0) followed by centrifugation (13,000 rpm for 2 min). Purification of urea-solubilised 
fractions (denatured protein) was performed at room temperature. 1 ml of Ni-NTA slurry 
was added to 4 ml of extracted protein in a falcon tube and mixed on a rotary shaker for 1 
h. The flow-through was separated by centrifugation (13,000 rpm for 5 min) and 
removed. Beads were washed four times with 20-50 ml of wash buffer (100 mM 
NaH2PO4, 10mM tris-HCl, 8 M urea; pH 6.3) and were transferred to a microcentrifuge. 
Bound protein was eluted by decreasing pH; eluates were collected by adding 500 µl of 
elution buffer (100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea; pH 5.4 for eluates 1-4 and 
pH 4.5 for eluates 5-8) followed by centrifugation (13,000 rpm for 2 min).  
 
2.3.4. Dialysis and concentration of protein solutions 
Proteins were dialysed into PBS in a stepwise manner. Samples were injected into a 
Pierce Dialysis cassette with a molecular weight cut-off (MWCO) of 20 kDa and capacity 
of 0.5-3.0 ml. The cassette was placed into a 2 litre beaker, initially containing phosphate 
buffer with 6 M urea. The solution was stirred at 4ºC and the buffer replaced with a 4 M 
after 2 hours, a 2 M after 4 hours, and with PBS after 6 hours and dialysed in PBS 
overnight. Protein solutions were concentrated using Centricon® centrifugal filter units 
(Millipore).  
 
2.3.5. SDS- PAGE  
Proteins were separated by Tris-glycine sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). 12% SDS polyacrylamide gels (80 mm x 73 mm x 1 mm) 
were cast according to Sambrook et al. (1989) using the Biorad Mini Protean III 
Electrophoresis System. Protein samples were heated to 98°C for 5 minutes in SDS 
sample buffer (4x stock solution: 250 mM Tris-HCl; pH 6.8, 40% (v/v) glycerol, 8% 
(w/v) SDS, 0.1% (w/v) bromophenol blue) with the addition of 1% (v/v) β-
mercaptoethanol (βME) and loaded into the gel. Dual colour pre-stained Precision Plus 
protein standard (BioRad) was used as a molecular weight marker. Gels were run in 1x 
Tris-glycine running buffer (10x stock: 250 mM Tris base, 1.92 M glycine, 10% (w/v) 
SDS) at 100V until the bromophenol blue dye front reached the bottom of the gel. For 
visualisation of separated proteins, gels were stained in Coomassie blue stain solution 
(40% (v/v) methanol, 10% (v/v) acetic acid, 0.1% (w/v) Coomassie brilliant blue R250) 
for at least 30 minutes. Bands were visualised by applying destain solution (40% (v/v) 
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methanol 7% (v/v) acetic acid) for 20 minutes and 5% (v/v) methanol 7% (v/v) acetic 
acid overnight.  
 
2.3.6. Extraction of SDS-PAGE-separated protein  
Proteins were separated by SDS-PAGE and stained by Coomassie (see 2.3.1.6). The gel 
was rinsed in PBS and the target band was excised. Attempts were made to acquire a 
form suitable for immunisations by cutting the gel into small pieces and fragmenting 
further by passing it through progressively smaller needles, but elution of protein from 
the gel matrix was considered a preferred approach. To elute protein from the gel, the gel 
slice was immersed in elution buffer (50 mM Tris-HCl, 150 mM NaCl, and 0.1 mM 
EDTA; pH 7.5), crushed using a pestle, and incubated overnight at 30ºC. Supernatant was 
separated by centrifugation (8,000g for 10 min); a sample was tested by SDS-PAGE and 
the remainder was used in immunisations. 
 
2.3.7. Detection of histidine-tagged proteins by Western blot 
SDS-PAGE separated proteins were transferred onto a nitrocellulose membrane using a 
semi-dry electroblotter (LKB Bromma, Novablot). A Tris-glycine buffer containing 20% 
methanol was used as transfer solution (25 mM Tris base, 192 mM glycine, 0.1% (w/v) 
SDS, 20% (v/v) methanol). The gel was blotted at 220 mA for 20 minutes per gel. His-
tagged fusion proteins were detected using His-Probe™-HRP (Pierce); a nickel-activated 
derivative of horseradish peroxidase (HRP). Nitrocellulose membrane containing 
transferred proteins were blocked either overnight at 4°C or for 1 hour at RT in BSA 
blocking buffer (1% BSA in TBST; 1% (v/v) tween-20 in Tris-buffered saline (50 mM 
Tris-HCl; pH 7.4, 150 mM NaCl). Membranes were incubated for 1.5 hours in His-
Probe™-HRP at a 1 in 3000 concentration in BSA blocking buffer and then washed 3 
times for 10 minutes in TBST. Probed blots were developed using the enhanced 
chemiluminescence ECL Plus Western Blotting Detection System (GE Healthcare). 
Membranes were removed from TBST and placed onto transparent film (Niceday), 
lumigen mixture (prepared according to the manufacturer’s instructions) was pipetted 
onto the blot and incubated for 5 minutes. Sandwiched between two pieces of transparent 
films in an X-ray cassette, blots were briefly exposed in the dark to Kodak BioMax MS 
Scientific Imaging film and developed using an Agfa Curix 60 developing machine. 
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2.3.8. Immunisation schedule for antibody production 
Groups of female BALB/c mice, 6-8 weeks old, were used as hosts for antibody 
production. Initial immunisations were performed by subcutaneous injection with 40-60 
µg of antigen emulsified at a 1:1 ratio in Freund’s complete adjuvant. Boosts were 
administered with the same dose of antigen emulsified in Freund’s incomplete adjuvant, 
14, 28 and 56 days after the primary immunisation. Test bleeds were taken 10 days after 
each boost immunisation for analysis (see 2.3.9). Mice were placed in a heat box set at 
35°C to induce tail vein dilation and approximately 100 µl of tail blood was collected in 
1.5 ml microcentrifuge tubes by repeated tail drops. Blood was stored at 4°C overnight to 
allow for coagulation and sera was subsequently collected following centrifugation 
(13,000 rpm at 4°C for 20 min). Samples were tested for recognition of recombinant 
protein by immunoblotting (see 2.3.9). When a specific antibody response was detected 
sera was collected by a final bleed. Blood was collected by cardiac puncture as in 2.1.2 
but without the use of heparin to allow for coagulation of blood and subsequent collection 
of sera. The blood was allowed to clot at 4°C overnight and sera was collected following 
centrifugation at 13,000 rpm at 4°C for 20 min. Serum was stored in aliquots at -80°C. 
Mice whose sera did not display specific antigen binding in immunoblots were re-
immunised with a boost injection. A maximum of three boosts were given (14, 28 and 56 
days after the primary immunisation) before a final bleed.  
 
2.3.9. Characterisation of antisera by immunoblot 
Immunoblots were performed to test serum samples for the presence of antibodies against 
recombinant LAP (rLAP). 5 ml overnight cultures of bacterial cells transformed with 
rLAP or empty vector were prepared and split; one to serve as IPTG-induced sample and 
the second to provide an uninduced sample. Cultures were centrifuged and resuspended in 
10 ml fresh LB medium containing carbenicillin and further incubated at 37°C. Protein 
expression was induced by the addition of 1mM IPTG and incubation for 4 h at 37°C. 
Cells were collected by (4°C, 8000g for 15 min), resuspended in 200 µl PBS and lysed in 
reducing sample buffer, heating at 95°C for 10 min.  Protein lysates were separated on a 
12% SDS-PAGE gel and transferred onto a nitrocellulose membrane. Membranes were 
blocked in 5% fat-free milk powder (Waitrose) in TBST for one hour at room 
temperature or overnight at 4°C. Membranes were cut into 2-lane strips (corresponding to 
rLAP and empty vector). After washing with TBST, the membranes were incubated with 
serum samples diluted 1 in 1000 in 1% milk in TBST. Serum collected from a naïve 
mouse was used as a negative control. Membranes were washed three times for 10 min 
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each in TBST then a sheep anti-mouse IgG antibody conjugated to horseradish 
peroxidase (Pierce) (1 in 10,000 dilution in 5% milk in TBST). The membrane was 
washed again three times for 10 minutes each in TBST, then developed using the ECL 
Plus Western Blotting Detection System (GE Healthcare) as described in 2.3.7. Western 
blots for the detection of histidine-tagged protein (see 2.3.7) were performed in parallel to 
assess and compare the size of the target protein. 
2.3.10. Characterisation of antisera by ELISA 
Overnight cultures of bacterial cells transformed with rLAP or empty vector were 
prepared as decribed in 2.3.10 and whole cell lysates were used as antigen. A 96-well 
ELISA plate (Nunc) was coated with 100 µl/well antigen or 100 µl/well control at 
concentration of ~1-10 µg/ml. The plate was covered with clingfilm and incubated 
overnight at 4°C. Wells of the plate were washed twice with PBS and remaining protein-
binding sites were blocked with 100 µl/well 1% BSA. The plate was incubated for 2 h at 
room temperature 37°C. Wells of the plate were subsequently washed twice with PBS 
and 50 µl of antibody at a range of dilutions were added. Dilutions were made in 1% 
BSA, starting at 1:50, with the final well without any sera as a background control for 
non-specific binding of the secondary antibody. The plate was incubated for 2 h at room 
temperature. Wells of the plate were then washed twice with PBS and 50 µl of HRP-
conjugated anti-mouse IgG secondary antibody (GE Healthcare) was added at a 1:10,000 
dilution and incubated for 1 h at room temperature. Freshly prepared o-phenylenediamine 
(OPD) was used as substrate for the detection of peroxidise activity. Using the 
SIGMAFAST™ OPD tablet set (Sigma), one OPD tablet and one urea hydrogen peroxide 
tablet were dissolved in 20 ml of water to form a solution containing 0.4 mg/ml OPD in 
0.05 M phosphate-citrate buffer with 0.4 mg/ml urea hydrogen peroxide, pH 5.0. After 
washing the wells of the plate twice with PBS, the OPD substrate solution was added at 
50µl/well. Reactions were allowed to develop for 30 min at room temperature in the dark, 
after which the reaction was stopped by addition of 50µl/well 3M H2SO4.  Stopped 
reactions were read at 492 nm.  
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2.4. Transmission-blocking assays  
2.4.1. Exflagellation assays 
A PH-treated mouse injected with P. berghei clone 234 (day 4 or 5 post-infection) 
provided mature gametocytes to assess the affects of antisera on exflagellation. Assays 
were carried out as follows: 2.5 µl of tail blood containing parasites capable of 
exflagellation was added to 2.5 µl sera and 5 µl of ookinete medium. The mixture was 
pipetted onto a microscope slide and covered with a Vaseline®-rimmed coverslip and 
allowed to stand for 20 minutes. Exflagellation centres were defined as a cluster of cells 
comprising exflagellating male parasite(s) binding three or more red blood cells (Figure 
2.2). The number of exflagellation centres in 20 microscopic fields at 40× objective 
magnification was counted and experiments were performed in duplicate. Results were 
expressed as the number of exflagellation centres per field of view and as a percentage 
compared to the number of exflagellation centres in negative controls (serum from an 
unimmunised mouse in place of test serum).  
 
 
 
 
 
 
 
Figure 2.2. P. berghei exflagellation centres   
Exflagellation centres are observed and counted as clumps of red blood cells. Representative light microscopy 
image (40x objective). See text for details. 
 
2.4.2. Ookinete development assays  
Mice were injected with PH and 2-3 days later infected with wild-type parasites (as in 
2.1.2). Blood containing mature gametocytes, day 3 or 4 post-infection, was used to 
assess the effects of antisera on ookinete development. Ookinete mini-cultures containing 
70 µl of ookinete media + 20% FBS and 25 µl test sera (αLAP), control sera (from an 
unimmunised mouse) or PBS were prepared in duplicate in the wells of a 24-well plate 
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(Nunc). 5 µl of heparinised blood was added to each well and cultures were incubated at 
19°C for 24 h to allow for ookinete development. The numbers of ookinetes per well 
were subsequently determined using a haemocytometer (Naubauer) using an Olympus 
BH2 light microscope at x40 objective magnification. For each test sample, the number of 
ookinetes was calculated as a percentage of the average number of ookinetes in normal 
mouse sera negative controls.  
 
2.4.3. Membrane feeding assays 
Mosquito membrane feeds were performed in order to examine the affects of antisera on 
parasite development in the mosquito. The PbconGFP transgenic line, which expresses 
GFP constitutively throughout the life cycle (Franke-Fayard et al., 2004) was used to aid 
in oocyst counting. Mice without prior PH treatment were infected with PbconGFP and 
on day 3 were assessed for parasitemia and exflagellation. Enough mice were infected to 
supply infected blood for the required number of test groups (assuming a maximum of 1 
ml of blood is acquired for each mouse and accounting for less). The membrane feeding 
apparatus was prepared by connecting plastic membrane feeders to each other with 
silicon tubing. A water bath heated to 39ºC with pump was used to generate a continuous 
flow of water through each feeder. Thinly stretched Parafilm® (Pechiney Plastic 
Packaging Company, VWR), through which mosquitoes can probe, was stretched over 
the underside of each feeder. 125 µl of test sera, pre-warmed to 37°C in a heat block, was 
used per feed. Blood containing mature gametocytes was removed from mice and, to 
control for variation in gametocytemia and general health status between different mice, 
all blood was pooled into a pre-warmed 50 ml nunc tube. Procedures were carried out as 
quickly as possible to avoid exflagellation before ingestion of blood meal. For each 
feeder, 375 µl of pooled blood was added to 125 µl of test sera at 37° C. Blood/antisera 
mixtures were then added to membrane feeders using a blunt-ended syringe and 
mosquitoes were allowed to feed for 30 min in the dark.  
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Figure 2.3. Schematic of a mosquito membrane feed to assess the effect of antisera on infectivity to 
mosquitoes. 
The membrane feeding apparatus consists of plastic membrane feeders that can be connected with silicon 
tubing to a heated water bath to generate a continuous flow of 37°C water through each feeder to attract the 
mosquitoes. Thinly stretched Parafilm® (Pechiney Plastic Packaging Company, VWR), through which 
mosquitoes can probe, is stretched over the underside of each feeder. Aliquots of test serum to were prepared 
in eppendorf tubes and pre-warmed to 37°C in a heat block. Blood containing mature gametocytes is removed 
from mice and pooled into a pre-warmed 50 ml nunc tube. Gametocyte-containing blood is added to serum 
aliquots at 37°C such that serum is diluted to the desired concentration. Blood/antisera mixtures are then 
added to membrane feeders using a blunt-ended syringe. Mosquitoes, within pots covered with a mesh net 
top, are allowed to feed for around 30 minutes in the dark. 
 
 
Mosquitoes were maintained as described in 2.1.3. Ten or eleven days following 
infection, midguts were dissected and oocysts counted. Mosquitoes were anaesthetised 
using CO2 and maintained immobilised on ice. The foregut, hindgut and malpighian 
tubules were removed under a dissecting microscope in a drop of PBS. Dissected midguts 
were transferred to a 24-well plate containing 4% paraformaldehyde (PFA) prepared (in 
PBS) from 16% methanol-free formaldehyde (Polysciences Inc.). Midguts were fixed in 
PFA for 45 min then washed three times in PBS before being mounted onto a slide. GFP-
expressing oocysts were counted using a Leica DMR fluorescence microscope under 40x 
objective magnification. 
Pooled gametocyte-infected blood
Test sera
Gametocyte-infected 
blood + antisera
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Prevalence of infection was calculated as the percentage of infected mosquitoes out of 
those dissected. The number of oocysts per midgut (number of oocysts divided by total 
number of mosquitoes) and infection intensities (number of oocysts divided by number of 
infected mosquitoes) were calculated as arithmetic means, as described in (Medley et al., 
1993). Mann-Whitney-U tests were carried out to establish if oocyst numbers/intensities 
in test groups differed significantly from feeds in the presence of sera from an 
unimmunised mouse. Analyses were performed using GraphPad Prism 5.  
 
2.4.4. Intra-thoracic microinjection of antisera 
Antiserum was injected into the thorax of mosquitoes to assess if it could neutralise 
sporozoites released in the haemocoel. Mosquitoes were fed on gametocyte-containing 
blood and infections were observed from day 14. Intra-thoracic injections were performed 
when sporozoites were observed to be released in the haemocoel. Three days post-
injection, mosquitoes were anesthetised using CO2 and salivary glands were removed into 
PBS by dissection under a light microscope using forceps and a 26 gauge needle. The 
glands from between 8 and 10 mosquitoes were transferred into a 1 ml glass homogeniser 
(Jencons) using a Hamilton Microliter syringe. Salivary glands were disrupted to release 
sporozoites by three turns of the homogeniser and transferred into a 1.5 ml 
microcentrifuge tube on ice.  Sporozoites were counted using a haemocytometer and 
prevalence of infection was determined by examination of mosquito midguts. Sporozoite 
numbers were calculated per salivary gland pair per infected mosquito (i.e. total number 
of sporozoites divided by number of infected mosquitoes).   
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2.5. Generation of transgenic P. berghei parasites 
2.5.1. Preparation of DNA for transfection 
Plasmids generated as described in 2.3.3 were linearised by restriction digest and purified 
for transfections. Unique restriction sites were as follows; Lap3: AarI (Fermentas); 1x 
buffer Tango 37°C Lap 1, 4, 6; BsmI (NEB) 1x buffer 2 65°C Lap5; SpeI (Promega) 1x 
buffer B 37°C. Digests were performed in 50 µl reaction volumes, containing 40 µl 
plasmid DNA, 5 µl buffer, 3.5 µl miliQ water, 1.5 restriction enzyme overnight. 
Following digestion, DNA was precipitated by addition of 0.3 M sodium acetate pH 5.2 
and neat ice-cold ethanol and washed once in 70% ethanol. Precipitated DNA was 
resuspended in 12 µl miliQ water and concentration was estimated by agarose gel 
electrophoresis; 3-5 µg of DNA in a volume of 5-10 µl was used for each transfection. 
 
2.5.2. Preparation of schizonts for transfection 
Purified mature schizonts containing fully developed merozoites provided parasites for 
transfections. To limit the passage number of potential transgenics, schizont cultures were 
set up from parasites that had been passaged only once before (P1). A liquid nitrogen 
stock of P0 passage parasites (i.e. parasites directly after mosquito transmission) were 
grown up in a donor mouse and then passaged into the required number of mice, with one 
mouse producing enough schizonts for 2-3 transfections. Blood with a parasitaemia of 3-
5% was added to schizont culture medium (RPMI 1640 containing 25 mM HEPES and 2 
mM L-glutamine (Sigma) supplemented with 25% (v/v) FBS, 50U/ml penicillin and       
50 µg/ml streptomycin (Gibco). The culture was set up in 500 ml Erlenmayer flasks in a 
total volume of 120 ml. A 3%O2, 5% CO2 and 92% N2 gas mix was blown over the 
surface of the culture for 5 min, the flask sealed and the parasites were cultured for       
16-20 h at 37°C with gentle agitation (50 rpm). Schizonts were harvested by 
centrifugation at 180g for 15 min, resuspended in around 2-3 ml of culture and layered 
onto a 5 ml 15.2% Nycodenz gradient (27.6% Nycodenz) in 15 ml Nunc tubes. 
Centrifugation was performed at 300g for 30 min, with slow brake and acceleration, and 
the schizonts collected at the interface were removed, washed once with schizont culture 
medium and pelleted by centrifugation at 300g for 8 min.  
 
2.5.3. Electroporation of parasites  
Transfections were performed by electroporation using an AMAXA Human T-Cell 
Nucleofector system as described by Janse et al. (2006). Briefly, 1-5 µg of digested DNA 
 87 
prepared for transfection was mixed with 100 µl supplemented T-cell Nucleofector 
solution, 100 µl of this mixture was transferred into an AMAXA electroporation cuvette, 
purified schizonts were added to the Nucleofector–DNA solution, and electroporation 
was performed using the U33 program of an AMAXA Nucleofector. Electroporated 
parasites were incubated at 37°C in 150-200 µl of naïve blood from a PH-treated mouse 
to allow parasites to invade reticulocytes. After incubation for 20-30 minutes, blood was 
injected i.p. into PH-treated mice. 
  
2.5.4. Drug selection of transgenic parasites 
Transfected parasites will contain the mutated Tgdhfr-ts gene, conferring pyrimethamine 
resistance. 24-48 h after transfection, mice were treated with pyrimethamine in drinking 
water prepared by dilution of 100x stock (7 mg/ml pyrimethamine in DMSO) to 1x in tap 
water (resulting pH 3.5-5). The growth of parasites was monitored by Giemsa-stained 
smears of tail blood. Stocks of resistant parasites were obtained and parasites were 
subjected to a second round of drug selection in another mouse. 
 
2.5.5. Diagnostic PCR 
Diagnostic PCRs were carried out on genomic DNA extracted from the blood of infected 
mice. To amplify DNA from any transgenic parasites, forward primers designed to anneal 
approximately 200 bp upstream of the target site for homologous recombination were 
used in combination with one of the following reverse primers: 
Tgdhfr-ts 5'UTR:  GATGTGTTATGTGATTAATTCATACAC 
GFP_R:    GCGGCCGCTTATTTGTATAGTTCATCCATGCC 
Myc_R: GGCCGCTTATAAGTCTTCCTCACTTATTAACTTCTGTTCCAGATCCTC 
TTCTGAGATGAGTTTTTGTTCGGGCC  
Forward primers were as follows: 
Lap1:  ATTGATGAAGAAAATGAATTAGTAATAGAACAAAATTGTAATCC 
Lap2:  ATCTCAAGATTGTCCAATCGATTTATTTG 
Lap3:  AGATGTAGTAGATTGTGATAATACTTTAAACGACATTCC 
Lap4:  ATGTTAACGTTAATATGG 
Lap5:  TCTATATCACCAGGGCACCATAAATATAAAC 
Lap6:  ATTGGAGAATTGAAAAATACACAAGTGG  
GoTaq Green DNA polymerase Master Mix (Promega) was used to amplify DNA from 
genomic DNA extracted from the blood mice containing potential transgenics. Reactions 
were carried out in volumes of 12.5 µl. 
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2.6. Immunodetection of parasite proteins  
2.6.1. Sample preparation for immunoblot analysis  
Samples of P. berghei asexual blood stages, gametocytes, ookinetes and sporozoites were 
prepared as described in 2.6.1-2.6.4. Parasite numbers were quantified using a 
haemocytometer and where necessary purity was determined by Giemsa-stained smears. 
Samples were suspended in non-reducing sample buffer containing protease inhibitor 
(prepared from Roche complete, EDTA-free protease inhibitor cocktail tablets) and stored 
at -20°C if not used immediately.  
2.6.1.1. Asexual blood stages 
Mice were infected with P. berghei ANKA clone 233 (non-gametocyte producing strain). 
Blood was collected 3-4 days post-infection and white blood cells were removed by 
passing blood through a CF11 column, comprising glass wool and dry cellulose powder 
(Whatmann) in a 10 ml syringe. The column was equilibrated using PBS and blood was 
washed through in 10 ml of PBS. Cells were collected by centrifugation (500g for 5 min 
at 4°C) and resuspended in 40 ml ice-cold 0.17 M ammonium chloride to lyse red blood 
cells. After a 30 minute incubation period on ice, parasite pellets were obtained by 
centrifugation (500g for 5 min at 4°C) and washed three times in PBS.  
2.6.1.2. Gametocytes 
Gametocyte-enriched samples were prepared by a combination of asexual blood stage 
depletion and separation of gametocytes by density centrifugation. P. berghei-infected 
mice with parasitemia exceeding 5% (typically 3 days post-infection) were treated with 
sulphadiazine (Sigma), a schizonticide. Either drinking water was supplemented with 20 
mg/L sulphadiazine or mice were i.p. injected each day with     0.24 mg sulphadiazine in 
PBS. The level of asexual blood-stage parasitemia and gametocytemia were monitored 
over the following 2-3 days by analysing Giemsa-stained smears. Gametocyte-containing 
blood was collected when asexual blood-stage parasitemia had sufficiently decreased 
relative to gametocytemia. The parasites were  immediately transferred to 5 ml 
coelenterazine loading buffer (CLB), containing 20 mM Hepes, 20 mM glucose, 4 mM 
sodium bicarbonate, 1 mM EDTA and 0.1% BSA in PBS (pH 7.25). Within CLB, 
gametocytes remain suspended in an unactivated state provided maintenance at 22°C. 
Cells were passed through a CF11 column equilibrated with CLB and following removal 
of white blood cells, parasites were collected by centrifugation (600g for 5 min at 22°C) 
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and resuspended in 2-3 ml of CLB. Gametocytes were further enriched by separation on a 
Nycodenz step (5 ml 48% Nycodenz stock solution; 27.6% (w/v) Nycodenz (Axis-
Shield), 3.8 mM Tris-HCl, 300 nM Ethylenediamine tetraacetic acid (EDTA), 3 mM 
potassium chloride, pH 7.5). Enrichment was performed by centrifugation (1000g for 20 
min at 22°C with slow brake and acceleration). Gametocytes contained at the interface 
were collected and transferred to a 1.5 ml microcentrifuge tube, within which they were 
washed three times in CLB.  
2.6.1.3. Ookinetes 
Ookinete-enriched samples were prepared by the collection of ookinetes produced by in 
vitro cultivation. Blood was collected from a P. berghei infected mouse 3-4 days post-
infection, white blood cells were removed by passing blood through a CF11 column at 
19°C and ookinetes were cultured as described in 2.1.2. After 24 hours, cells were 
harvested by centrifugation (500g for 10 min at 4°C), resuspended in 40 ml ice-cold 0.17 
M ammonium chloride and incubated on ice for 30 min to lyse red blood cells. Parasites 
were collected by centrifugation (500g for 10 min at 4°C) and resuspended in 2-3 ml of 
ookinete culture medium. Ookinetes were enriched by Nycodenz density separation (5 ml 
48% Nycodenz stock; as in 2.6.3), performing centrifugation at 500 g for 20 min, with 
slow brake and acceleration. Ookinetes contained at the interface were transferred to a 1.5 
ml microcentrifuge tube and washed three times in PBS at 4°C.  
2.6.1.4. Sporozoites 
Mosquitoes harbouring salivary gland sporozoites, typically 21 days following infection, 
were anaesthetised and salivary glands were removed into PBS using forceps and a 26 
gauge needle. Dissected glands were homogenised in a 1 ml glass homogeniser (Jencons) 
and sporozoites were transferred into a 1.5 ml microcentrifuge tube on ice. 
2.6.2. Detection of parasite proteins by immunoblot 
Parasite preparations were heated for 10 minutes at 95°C in sample buffer (with the 
addition of βME for reducing conditions) and were separated by SDS-PAGE on an 8% 
polyacrylamide gel. Pre-cast Tris-glycine native 7.5% polyacrylamide gels (Invitrogen) 
were used for analysis under native conditions. Samples were loaded and run in buffer 
without denaturing SDS (4x stock sample buffer solution: 250 mM Tris-HCl; pH 6.8, 
40% (v/v) glycerol, 0.1% (w/v) bromophenol blue; 10x stock running buffer: 250 mM 
Tris base, 1.92 M glycine). Separated proteins were transferred onto a nitrocellulose 
membrane as in 2.3.7 and membranes were incubated for 1.5 hours at room temperature 
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or 4°C overnight in blocking solution (5% (w/v) dried fat-free skimmed milk powder 
(Waitrose, UK) or 1% BSA in TBST). Primary antibodies were used as follows: anti-lap 
at 1 in 100; αMyc Rabbit mAb (Cell Signalling) at 1 in 1,500; α-Tubulin Mouse mAb 
(Prof. Keith Gull) at 1 in 10,000. Incubations were performed for 2 hours at room 
temperature or overnight at 4°C at the desired dilution in blocking solution.  HRP-
conjugated anti-mouse IgG (Pierce) or HRP-conjugated anti-rabbit IgG (Sigma), each 
raised in sheep, were used as secondary antibodies, at dilution 1 in 10,000. Blots were 
developed using the enhanced chemiluminescence ECL Plus Western Blotting Detection 
System (GE Healthcare) as described in 2.3.7. 
2.6.3. Fixed-cell immunofluorescence assays  
2.6.3.1. P. berghei gametocytes, zygotes and ookinetes  
Mixed blood stages containing unactivated gametocytes were prepared from blood 
suspended and washed in CLB. Mixed blood stages post-gametocyte activation were 
prepared by incubating blood in ookinete media for up to 20 minutes and washed twice in 
PBS. Zygotes and ookinetes were prepared from ookinete cultures (zygote formation 
occurs within 1 hour and mature ookinetes are formed within 24 hours) and washed twice 
in PBS. In each case, parasites were resuspended in PBS / FBS at a 1:1 ratio and 1 µl was 
spotted and smeared onto frosted glass slides. Following air-drying, a liquid-repellent 
PapPen (liquid blocker, Daido Sangyo Co. Ltd.) was used to draw sample areas on each 
slide. Cells were fixed by: i) protein precipitation using either methanol or 50% methanol: 
50% acetone (5 minutes at -20°C) or ii) cross-linking using 4% (w/v) PFA in PBS (10 
minutes at RT). For permeabilisation of PFA-fixed parasites, cells were washed once with 
TBS and incubated with 0.2% (v/v) Triton X-100 in PBS for 5 min at RT.  All following 
steps were carried out at RT, and all washes were 5 minutes. Slides were washed three 
times in TBS, quenched in 0.1% (w/v) sodium borohydride in TBS for 5 min, rinsed in 
TBS and then blocked for 1 hour in blocking buffer (5% (v/v) goat serum (Jackson 
Immuno Research), 3% (w/v) BSA in PBS). For antibody incubation, slides were placed 
in a humidifying chamber and antibody at desired dilution in blocking buffer was pipetted 
onto sample areas. The slides were incubated overnight at 4°C. The next day, slides were 
washed 3 times in TBS and secondary antibody incubation (in blocking buffer) was 
carried out for 1 hour in the dark. Slides were washed three times in TBS and mounted 
with Mowiol containing DAPI. Slides were kept at 4oC in the dark and were examined 
using a Leica DMR microscope and Axiovision software. 
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2.6.3.2. P. berghei oocysts  
Infected mosquito midguts were dissected in PBS, fixed for 45 seconds in 4% (w/v) PFA, 
and then opened and blood meal was removed before fixation for 35 minutes in 4% (w/v) 
PFA at RT. Guts were washed twice in PBS at RT, blocked for 90 min in blocking buffer 
(1% (w/v) BSA and 0.1% (v/v) Triton X-100 in PBS) and incubated overnight with 
antibody in blocking buffer at 4°C. Midguts were then washed three times for 20 minutes 
with PBS and incubated with secondary antibody in blocking buffer for 1 hour at RT. 
Midguts were then washed as before and mounted in Vectashield/DAPI (Vector Labs). 
2.6.3.3. P. berghei sporozoites 
Sporozoites were dissected into RPMI 1640 and a calculated 3,000 sporozoites in 20µl 
were incubated on multiwell microscope slides in a wet chamber at 37°C for 30-45 min. 
The liquid was then taken off and slides dried at RT overnight. Slides were then fixed in 
1% (w/v) PFA in PBS for 5 min, blocked in 1% (w/v) BSA in PBS for 20 min and 
incubated with primary antibody. After three washes with PBS, slides were incubated 
with secondary antibody for 1 h, washed as before and mounted with Vectashield/DAPI. 
2.6.3.4. P. falciparum gametocytes 
Mature P. falciparum gametocytes (strain 3D7) were produced in culture by Dr. A. 
Blagborough, A. Talman or M. Delves. Parasites were cultured in RPMI 1640, 50 mg/l 
hypoxanthine, 24 mM NaHCO4 and 10% (v/v) heat inactivated human AB serum. 
Cultures were gassed for 20 seconds with 3% O2, 5% CO2 and 92% N2 gas mix and were 
maintained at 37°C, either manually with daily medium changes or in a semi-automated 
tipper (Ponnudurai et al., 1982).  Day 14 parasites were used for immunofluorescence 
analyses. 500 µl of gametocyte culture was centrifuged (1 min, 2000g), washed in PBS 
and 1.5 µl drops were immediately smeared onto a microscope slide and air dried. For 
activated gametocytes, cells collected by centrifugation were incubated in ookinete 
medium for 10 min, 15 min or 20 min before being smeared onto microscope slides as 
above.   
2.6.4. Live immunofluorescence assays  
Live immunofluorescence assays were performed on parasites collected from 
gametocyte-containing blood or from ookinete cultures. Samples of 100 µl were washed 
in PBS and resuspended in 100 µl of PBS. Cells were blocked in 100 µl 2 % BSA in PBS 
then incubated for one hour in 2 % BSA containing serum diluted at 1 in 50- 1 in 500. 
Cells were then washed three times in PBS, each time collecting the parasites by 
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centrifugation at 500 g for 2 min. The resulting cell pellet was resuspended in 100 µl 1 % 
BSA in PBS containing AlexaFluor® 488 goat anti-mouse IgG (Molecular Probes) and 
cells incubated for one hour in the dark. Cells were then washed in three changes of PBS 
as above and the final cell pellet resuspended in 50 µl PBS containing Hoechst 33258 
(Molecular Probes) at a 1 in 100 dilution. A liquid blocker super PAP pen (Daido Sangyo 
Co., Ltd) was used to make 15 mm² square wells on glass slides and for each cell sample, 
20 µl cell suspension was pipetted into one of the above wells. Cells were then covered 
with a Vaseline®-edged coverslip and examined by microscopy.  
2.6.5. Antibodies 
Table 2.3.  List of antibodies 
Antibody dilution 
Antibody Host animal Immunoblot Immunofluorescence 
Primary    
αrPbLAP1SRSR Mouse  1:100 1:50 - 1:500 
αrPbLAP3AB Mouse  1:100 1:50 - 1:500 
αrPbLAP3LCCL Mouse  1:100 1:50 - 1:500 
αrPbLAP4LCCL Mouse  1:100 1:50 - 1:500 
αPbrLAP6LCCL Mouse  1:100 1:50 - 1:500 
αPbMDV (Dr. K. Lal) Rabbit  - 1:1,000 
αFormin (Dr. J. Baum) Rabbit  - 1:50 
αPfCCp2rp3 (Dr. G. Pradel) Mouse  - 1:100 
αPfCCp3rp3 (Dr. G. Pradel) Mouse  - 1:100 
αPfCCp4rp1 (Dr. G. Pradel) Mouse  - 1:50 
αPfFNPArp1 (Dr. G. Pradel) Mouse  - 1:50 
αMyc (Cell Signalling) Rabbit  1: 1,500 1:200 
αGFP (Molecular Probes; Invtrogen) Rabbit  1: 1,000 1:400 
αTubulin (Prof. K. Gull) Mouse  1: 10,000  
Secondary    
HRP-conjugated anti-mouse IgG (Pierce) Sheep 1: 10,000 - 
HRP-conjugated anti-rabbit IgG (Sigma) Sheep 1: 10,000 - 
Alexa Fluor 488 anti-mouse IgG (Invitrogen) Goat  - 1:2,000 
Alexa Fluor 488 anti-rabbit IgG (Invitrogen) Goat - 1:2,000 
Alexa Fluor 546 anti-mouse IgG (Invitrogen) Goat - 1:2,000 
Alexa Fluor 546 anti-rabbit IgG (Invitrogen) Goat - 1:2,000 
 
2.6.6. Imaging 
Parasites were viewed using a Leica fluorescence microscope under 40x, 65x and 100x 
objective magnification, using the DAPI, FITC and Texas Red filters. Images were 
captured with a Zeiss AxioCam camera using Zeiss Axiovision40 version 4.6.1.0 
software. Post-processing of images was performed using Photoshop version 6.0. 
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2.7. Phenotypic analysis of ∆Pblap parasites  
2.7.1. Intra-thoracic microinjection of ookinetes  
Ookinetes were cultured and counted using a haemocytometer (Naubauer, Germany). A 
culture volume containing 11.6x105 ookinetes were pelleted by centrifugation (500g for 5 
min) and resuspended in 100 µl of ookinete medium. Ookinetes were injected through the 
mosquito thorax into the haemocoel of mosquitoes using glass capillary needles and the 
Nanoject II microinjector apparatus (Drummond Scientific Company). Needle tips were 
created such that the width is large enough to allow enough room for liquid to flow 
through at a reasonable rate but is narrow enough to inflict a minimal wound during 
injection. The microinjector was set to deliver a volume of 69 nl per injection and 
injections were performed with mosquitoes anaesthetised on a CO2 pad. Mosquitoes were 
subsequently maintained as described in 2.1.3. 
 
In parallel to haemocoel injections, ookinetes were fed to mosquitoes using a membrane 
feeding apparatus. To prepare ookinetes for membrane feeds, ookinetes were cultured as 
in 2.1.2 and counted using a haemocytometer to calculate the number of ookinetes per ml. 
4x105 ookinetes were pelleted by centrifugation (500g for 5 min) and resuspended in   
500 µl of heparinised blood collected from a naïve mouse, providing a final concentration 
of 800 ookinetes per µl. The membrane feeding apparatus was prepared as described in 
2.4.3. The ookinete suspensions were loaded onto membrane feeders and mosquitoes 
were allowed to feed for 20-30 min at 19°C, preferably in the dark. Unfed mosquitoes 
were removed the following day and post-feeding maintenance of mosquitoes was carried 
out as described in 2.1.3. 
 
2.7.2. Transcriptional profiling of ookinetes by microarray  
2.7.2.1. Sample preparation 
RNA extracted from P. berghei wild-type and ∆lap1 ookinetes was used for microarray 
analysis. Ookinetes were cultured as described in 2.2.6.2 and magnetic beads conjugated 
to α-Pbs28 monoclonal antibody clone 13.1 were used to purify zygotes and ookinetes, as 
reported in Siden-Kiamos et al. (2000). 200 µl of sheep anti-mouse Dynabeads® (Dynal 
Biotech ASA, Invitrogen) were washed four times with PBS; pelleted using a magnetic 
particle concentrator (Dynal MPC, Invitrogen) and  beads were incubated for 30 min on a 
rotating wheel in 200 µl of α-Pbs28 mAb clone 13.1 (dilution 1:100 in PBS). α-Pbs28-
conjugated beads were washed twice further in PBS and resuspended in 200 µl of PBS. 
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Ookinetes were harvested by centrifugation at 500g for 10 min and resuspended in 8 ml 
ookinete medium in 15 ml Nunc tubes. Cultures were incubated with 10 µl of 13.1-
conjugated beads for 5 min on a rotating wheel. Zygotes and ookinetes expressing Pbs28 
were collected using the magnetic particle concentrator through repeated incubations and 
RNA was extracted from parasite pellets using TRIzol reagent.  
2.7.2.2. Generation of cRNA and Cy-labelling  
All procedures were carried out using reagents from Agilent’s Two-Colour QuickAmp 
labelling kit according to the manufacturer’s instructions. cDNA was generated from 2 µg 
of total RNA as template. Reverse transcription was mediated by MMLV-RT and poly 
dT primer and T7 polymerase promoter sequences were simultaneously incorporated 
into the 3’ end of the cDNA. Double stranded cDNA was then used as a template for 
transcription of cRNA using T7 RNA polymerase. Cy3 labelled CTP was incorporated 
for labelling of ∆lap1 derived cRNA, whilst wt samples were labelled with Cy5. 
Reactions were performed as described in the QuickAmp labelling protocol (Agilent). 
Cy3/Cy5 labelled cRNA was purified using Qiagen RNAeasy purification columns and 
cRNA concentration and dye–incorporation ratios were measured using the Microarray 
application of a NanoDrop® ND-1000 Spectrophotometer. Labelled probes were stored 
at -80°C in the dark. 
2.7.2.3. Hybridisations  
2 µg of Cy3-labelled and 2 µg Cy5-labelled cRNA were mixed and were fragmented in 
Fragmentation buffer at 60ºC for 30 min in the dark. The fragmented probes were mixed 
with Hybridisation solution to a final volume of 80 µl and applied onto the array. All 
reagents used for hybridisations were supplied in the Agilent in situ Hybridisation Kit. 
The array was placed into a HybChamber™ and was incubated for 17 hours in the dark in 
a Hyb oven with rotisserie (65ºC, 10 rpm).  
2.7.2.4. Scanning  
Following hybridisation, slides were washed in Gene Expression Wash Buffer containing 
0.005% Triton X-102 pre-heated to 37 ºC and the HybChamber™ was disassembled 
whilst immersed in the buffer. Once dry, arrays were scanned using a Gene-Pix 4000B 
scanner in conjunction with Gene-Pix Pro 4.0 software (Axon instruments). Grid-
alignment, recording of spot signal intensity and manual spot inspection was performed 
using Gene-Pix Pro 4.0. 
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2.7.2.5. Analysis of microarray data 
Processing of microarray data was performed by Dr. D. Vlachou as described in Vlachou 
et al. (2005). A spot evaluation was carried out whereby the average spot diameter was 
calculated for each spot and spots with diameter differing by more than three times the 
standard deviation were removed. Spots were further evaluated by calculating the ratio 
between spot intensity and local and global background intensity (as defined by negative 
control spots on the array). Only spots which intensity (foreground) exceeded the local 
and global background values (spot intensity > average intensity of negative control spots 
plus one times the standard deviation) were taken forward for further analysis. Following 
spot evaluation, data was normalised by locally weighted linear regression method 
(Lowess) method in GeneSpring 6.1 (Axon Instruments). This created a file of valid data, 
including the expression ratio in fold difference and log transformed expression data for 
both individual and average spot values. Gene annotations were acquired from 
PlasmoDB. Clustering was performed using Cluster 3.0 and viewed using Java Treeview. 
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3 
 
GENERATION OF ANTISERA AGAINST P. BERGHEI 
LAPs & EVALUATION OF ANTIBODY-MEDIATED 
EFFECTS ON PARASITE TRANSMISSION 
 
3.1. Introduction 
Adhesive proteins expressed on the surface of pathogens make prime vaccine targets 
(reviewed by Dinglasan and Jacobs-Lorena, 2005). In the case of malaria, leading 
antimalarial vaccine candidates include CSP and TRAP, which contain lectin-like 
thrombospondin repeats implicated in mediating salivary gland and hepatocyte invasion 
(Robson et al., 1988), whilst MSP1 and Ps25 contain epidermal growth factor repeats 
(Blackman et al., 1991; Kaslow et al., 1988). Potentially extracellular adhesive proteins, 
such as the LCCL/lectin adhesive-like protein (LAP) family, are therefore logical choices 
for investigation as vaccine candidates. 
 
LAPs are predicted by bioinformatic analyses to encode six putatively secreted proteins 
with multiple adhesive domains. The presence of N-terminal secretory signals and the 
absence of predicted transmembrane regions, glycosylphosphatidylinositol (GPI) anchors 
or ER retention signals indicate a possible surface-exposure and a possible association 
with the cell surface mediated by adhesion to components of the plasma membrane. 
Members of the LAP family form four distinct protein arrangements which on current 
evidence appear unique to apicomplexan parasites (Figure 3.1; reviewed by Dessens et al. 
(2004); Pradel et al. (2004); Trueman et al. (2004)). 
 
LAP1 (CCp3) was first described in P. falciparum as the scavenger receptor LCCL 
adhesive-like protein (PfSLAP) (Delrieu et al., 2002) and in P. berghei as the scavenger 
receptor-like protein (PbSR) (Claudianos et al., 2002). Its predicted multidomain structure 
comprises four LCCL domains, a lipoxygenase homology 2 (LH2) domain, two tandem 
scavenger receptor cysteine-rich (SRCR) domains and a pentraxin-like domain. As 
described in Chapter 1, the LCCL domain (Limulus factor C, Coch-5b2, late lung 
gestation Lgl1) is defined by four conserved cysteine residues and a conserved motif at 
the C-terminal end containing a highly conserved histidine, with possible roles in 
lipopolysaccharide (LPS) binding  (Trexler et al., 2000). The LH2 or PLAT (polycystine-
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1, lipoxygenase, alpha toxin homology) is found among bacteria and eukaryotes, 
frequently in membrane or lipid associated proteins and may mediate membrane 
attachment (Bateman and Sandford, 1999). Pentraxin-like domains share similarities with 
laminin G and Concanavalin A-like lectin/glucanase domains and eukaryotic proteins 
containing the domains (e.g. sialidases and laminins) are implicated with functions in cell 
recognition and adhesion (reviewed by Gewurz et al, 1995). The predicted presence of 
SRCR domains, each containing eight conserved cysteine residues, has been noted as 
being particularly striking. SRCR motifs are found in surface-associated proteins across a 
diverse array of metazoans (Muller, 2001). Many are involved in cell-cell adhesion, for 
example the sperm SPERACT egg peptide receptor of sea urchins (Dangott et al., 1989). 
Others are involved in regulation of innate and adaptive immune responses, e.g. 
macrophage SR1 (Freeman et al., 1990) and complement factor 1 (Goldberger et al., 
1987). By analogy, this has led to the suggestion that LAP1 may serve a role in protecting 
the parasite from the mosquito immune response or from complement factors in the blood 
meal (Claudianos et al., 2002; Delrieu et al., 2002; Lasonder et al., 2002). 
 
LAP2 (CCp1) and LAP4 (CCp2) are paralogs, both containing a ricin-B lectin-related 
carbohydrate binding domain. Similar to the legume lectin ricin from the seeds of the 
castor bean plant, Ricinus communis, the ricin-B lectin-related is found in many plant and 
bacterial carbohydrate-recognition proteins. Following the Ricin-B domain, the proteins 
contain a discoidin domain — a domain similar to the coagulation factor 5/8 C-terminal 
domain — and a neurexin and collagen-like domain (NEC) with similarities to fibrinogen 
or fibrillar collagen globular domains. The C-terminal regions comprise two tandem 
levanase-type lectin domains, and two apicomplexan specific cysteine-rich globular 
domains with homologies to zinc finger binding domains.  
 
LAP3 (CCp5) and LAP5 (FNPA) are each predicted to contain a domain related to 
fibronectin type 2 domain (FN2), a collagen-binding domain, followed by a domain 
(Anth) similar to anthrax protective antigen (PA14) with potential roles in carbohydrate-
recognition. LAP3 also contains a single LCCL domain, whereas LAP5 is the only LAP 
family member to lack an LCCL domain. 
 
LAP6 (CCp4) has a single LCCL domain and two tandem levanase domains. In addition, 
the C-terminal region of LAP6 displays homologies to a laminin G domain related 
pentraxin/concanavalin A-like lectin glucanase domain.  
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Figure 3.1. Domain organisation of the LAP/CCp family 
Schematic representations of domain organisations are depicted as in Pradel et al. 2004. All proteins have a 
signal peptide sequence represented by a black box at the beginning of the architectures. Ric, ricin domain; 
Disc, discoidin domain; A, ApicA domain; Anth, anthrax toxin NH2-terminal region domain; FN2, 
fibronectin type II domain; LCCL, Limulus coagulation factor C domain; Lev, levanase domain; LH, 
lipoxygenase domain; NEC, neurexin and collagen-like domain; SR, scavenger receptor domain. See text for 
domain descriptions. 
 
Proteomic analyses (summarised in Table 3.1) provide indications that LAPs are 
expressed — and therefore may be targeted by antibodies — throughout the parasite’s 
development in the midgut. Studies in both P. falciparum (Lasonder et al., 2002; Florens 
et al., 2002) and P. berghei (Hall et al., 2005; Khan et al., 2005) detect all but LAP6 in 
gametocytes. LAP4 and LAP6 are also detected in P. falciparum sporozoites (Florens et 
al., 2002) suggesting the possibility of expression throughout sporogonic development. 
This is supported by studies using P. berghei, in which LAP1 and LAP6 have been 
detected in sporozoites (Hall et al., 2005). Furthermore, through analysing ookinete 
preparations (Hall et al., 2005; R. Stanway, PhD thesis, 2007; Lal et al., 2009b) studies 
using P. berghei have identified LAPs as potential surface/secreted protein of ookinetes: 
LAP1-5 were detected in whole cell proteomic analysis of ookinetes (Hall et al., 2005), 
whilst in subcellular proteomic analyses, all LAP family members were detected in a 
putative surface-enriched ookinete proteome (R. Stanway, PhD thesis, 2007) and LAP1-4 
were detected in a putative microneme-enriched ookinete proteome (Lal et al., 2009b). 
Proteomic expression data relevant to the LAPs is summarised in Table 3.1.  
LAP1
LAP2
LAP4
LAP6
LAP3
LAP5
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Having been identified as potential TBV candidates, this study aimed to determine the 
feasibility of generating immunogenic recombinant antigens and assess the possibility 
that anti-LAP antibodies may block the development of Plasmodium transmission stages. 
The P. berghei rodent malaria parasite system was utilised since it allows for a robust 
evaluation of transmission-blocking activity. Both in vitro and in vivo assays can be 
reliably performed to assess possible anti-parasitic effects of antisera: the effects of serum 
on the process of gametocyte activation and exflagellation can be measured by in vitro 
exflagellation assays; in vitro ookinete development assays can be performed to assess 
the number of ookinetes developing after incubation with different antibodies; and above 
all, in vivo effects can be analysed by membrane feeding assays in which mosquitoes are 
fed on gametocyte-infected blood through an artificial membrane in the presence of test 
and control sera. Use of a rodent model provides the additional advantages of being able 
to confirm transmission-blocking activity by testing infectivity of mosquitoes to mice. In 
contrast, assays with P. falciparum relies on the availability of infectious gametocytes 
produced in culture over 18-20 days, the culture of ookinetes by in vitro culture is not 
well established, and the infection of human malaria parasites in the mosquito vector can 
be technically challenging. Furthermore, the infection of mosquitoes with human malaria 
is wrought with considerable safety issues and there is no animal model for sporozoite 
infectivity. LAP family members are highly conserved between P. berghei and human 
malaria parasites, therefore it is expected that findings in P. berghei could reliably 
correlate with human malaria.  
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3.2. Protein expression and antibody production 
3.2.1. Choice of expression system  
Immunisation of suitable hosts with recombinantly produced proteins is an effective and 
routine method to stimulate the production of antibodies. A number of systems can be 
utilised for the heterologous expression of Plasmodium recombinant proteins. Those 
commonly used for the purpose of vaccine development include bacterial expression 
using Escherichia coli, and eukaryotic expression systems using yeast (Pichia pastoris 
and Saccharomyces cerevisiae) or baculovirus-mediated expression in insect cells.  
 
Difficulties in expressing malarial proteins are well documented. Problems are attributed 
in particular to the highly AT-rich genome of Plasmodium: AT-content is approximately 
80% (Gardner et al., 2002). Codon usage in Plasmodium is therefore strikingly different 
to that utilised by heterologous expression systems, with translation requiring tRNA 
species that are often rare in the expression host (Birkholtz et al., 2008). Furthermore, 
AT-richness is reflected in proteins by the enrichment of asparagine and numerous low-
complexity regions (Aravind et al., 2003), which can trigger mis-translation. Plasmodium 
proteins expressed heterologously are also likely to be processed differently to 
endogenous proteins due to differential post-translational modification patterns (Chang et 
al., 2008).  
 
As a result of these difficulties, expression can be problematic in any heterologous 
expression system.  Escherichia coli remains the most attractive and most frequently used 
host for expression, at least for initial analyses. The use of E.coli offers the advantages of 
ease of modification and high protein yields (Flick et al., 2004). Moreover, the 
availability of codon-enriched E.coli strains reduces some of the problems associated 
with codon biases, to the effect that AT-content has less of an impact on expression 
(Mehlin et al., 2006). E. coli was therefore the selected as the expression system of choice 
for the generation of recombinant LAPs. 
 
3.2.2. Sequence selection and cloning of P. berghei lap gene fragments 
Gene fragments for recombinant protein production were selected in a manner aimed at 
maximising the chance of successful heterologous expression. The Structural Genomics 
of Pathogenic Protozoa group (SGPP, University of Washington) selected 1,000 P.  
falciparum open reading frames for expression in E.coli, of which 30% were expressed 
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successfully. They were able to align physical properties of the protein with expression 
problems and indicated that a relatively low molecular weight is a critical factor in 
maximising the chance of successful cloning and expression of Plasmodium proteins in E. 
coli. 42% of proteins under 20 kDa expressed, while of those over 60 kDa only 20% 
expresses (Mehlin et al., 2006). Similarly, Vedadi et al. (2007) reported a reduction in 
recombinant protein solubility with increasing size. Since the LAPs range in size between 
approximately 90 and 200 kDa, gene fragments predicted to encode protein of size 25-40 
kDa were selected for expression. This represented a compromise between expression 
and immunogenicity: longer protein sequences generally offer a higher probability of 
recognising epitopes exposed on the native protein and tend to be stronger immunogens 
but are more difficult to express than smaller molecules.  
 
Bioinformatic prediction of protein domains using Simple Modular Architecture Research 
Tool (SMART; http://smart.embl-heidelberg.de/) was used to generate predicted domain 
architectures to guide the selection of gene fragments for protein expression. Since 
individual domains can often be folded and stable independently of the rest of the protein 
chain, whole predicted protein domains were chosen. Low complexity regions (LCRs) 
were avoided due to their association with disrupted expression (Vedadi et al., 2007): it 
has been proposed that Plasmodium LCRs may act to regulate protein expression by 
inducing ribosome pausing (Frugier et al., 2010). A number of sequences, including both 
unique and conserved regions, were chosen for expression purposes. Antibodies raised 
against amino acid sequences that are conserved between LAP family members (e.g. the 
LCCL domain) have the potential to cross-react with multiple LAPs. This could have 
both advantages and disadvantages: antibody binding to more than one LAP may act 
synergistically to confer a more potent transmission-blocking activity, but cross-reactivity 
would also prevent immunodetection of specific LAPs.  
 
For each Pblap, two regions of the gene were amplified by PCR. Resulting gene 
fragments were cloned into a pET-46 vector containing a T7 promoter to drive expression 
and an N-terminal tag encoding six histidine residues to facilitate purification. Unlike 
larger tags, such as glutathione S-transferase (GST) and maltose-binding protein (MBP), 
the small size of the histidine tag is not expected to interfere with specific antibody 
production. 
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Recombinant plasmids were generated by ligation independent cloning and transformed 
into E. coli Gigasingles strain. The presence of a correctly sequenced and in-frame gene 
fragment was confirmed by DNA sequence analysis on plasmid preparations extracted 
from transformed cells. As shown in Figure 3.2, gene sections encoding the following 
amino acids of endogenous LAPs were successfully cloned: LAP1SRSR, LAP1PTX, 
LAP2RG, LAP3LCCL, LAP4LCCL, LAP4C, LAP5PA14, LAP6LCCL. In addition, 
LAP2AB, LAP3PA14, LAP5AB and LAP6AB were successfully cloned into the same 
pET-46 expression vector by A. Blagborough and R. Wild and were made available for 
this study. Plasmids are referred to as plap1SRSR, plap1PTX, plap2RG, plap2AB, 
plap3LCCL, plap3PA14, plap4LCCL, plap4C, plap5PA14, plap5AB, plap6LCCL and 
plap5AB.  
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Figure 3.2. Regions of P. berghei LAPs cloned for expression  
Domain architecture of P. berghei LAP proteins was predicted using SMART software. Amino acid 
sequences corresponding to gene portions successfully cloned for expression are shown; represented in red 
for those that were subsequently expressed or grey for non-expressed regions.  Positions of introns are 
indicated I.  
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3.2.3. Protein expression  
E.coli strains carrying the λ DE3 lysogen and mutant lon and ompT proteases were used 
as hosts for expression. The λ DE3 lysogen expresses T7 RNA polymerase from the 
IPTG-inducible lacUV5 promoter for expression of genes under control of the T7 
promoter of the expression vector. Meanwhile, protease deficiency allows for increased 
yield of heterologous proteins. Two E.coli strains, BL21 (DE3) pMico and Rosetta (DE3) 
pLysS, were selected for expression on the basis that their use may overcome the problem 
of Plasmodium codon usage and improve yields of proteins toxic to the bacteria. E. coli 
BL21 (DE3) pMico contains the plasmid pMico, which helps to improve translation of 
Plasmodium proteins by encoding the tRNA genes argU, ileX, and glyT − the products of 
which recognise codons contained in Plasmodium but which are rare in E. coli (Cinquin 
et al., 2001). pMico also encodes for low level expression of the T7 lysozyme, which 
binds and inactivates T7 RNA polymerase to reduce basal levels of expression (occurring 
under uninduced conditions) and thereby allows enhanced bacterial growth and 
subsequently increased yields of toxic proteins. The Rosetta™ (DE3) pLysS strain 
provides similar attributes. The BL21 E.coli derivatives carry the pRARE plasmid, which 
encodes rare tRNAs to provide better codon usage, and the pLysS plasmid, which 
produces low levels of T7 lysozyme.  
 
The following conditions were tested for expression: 
E. coli expression strain:  BL21 (DE3) pMico or Rosetta™ (DE3) pLysS 
Induction temperature/time: 37°C for 4-6 hours or 28°C overnight  
IPTG concentration:  0.2mM, 0.5mM or 1mM 
 
Recombinant protein expression levels were assessed by Coomassie staining and Western 
blot analysis of SDS-PAGE separated bacterial lysates. Expression of target proteins 
could not be distinguished by Coomassie staining but the expression of histidine6-tagged 
proteins was detected by western blot analysis using an HRP conjugated His-Probe for 
eight constructs: plap3PA14, plap5AB, plap6AB, plap1SRSR, plap2RG, plap3LCCL, 
plap4LCCL, and plap6LCCL (Figure 3.3). Proteins generally corresponded with the 
predicted size of the recombinant histidine6-tagged proteins (as shown in Table 3.2) 
exclusively or predominantly expressed in induced preparations were detected. 
Separation of soluble and insoluble bacterial fractions indicated that in every case, 
recombinant proteins were found almost entirely in inclusion bodies. 
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Figure 3.3. Expression of recombinant proteins in E. coli  
E.coli expression strains transformed with recombinant plasmids plap1SRSR, plap2RG, plap3PA14, 
plap3LCCL, plap4LCCL, plap5AB, plap6AB, plap6LCCL, or an empty pET15b (as a negative control), were 
cultured and whole cell bacterial lysates of IPTG induced (+) or uninduced (-) cultures were separated under 
reducing conditions by SDS-PAGE (12% polyacrylamide). Separated proteins were transferred to a 
nitrocellulose membrane and membranes were incubated with anti-HisProbe-HRP® (Pierce) (1:5000) for the 
direct detection of recombinant histidine6-tagged proteins. The figure shows representative Western blot 
analyses of induced (+) and uninduced (-) cultures, indicating the expression of histidine-tagged recombinant 
proteins predominantly in induced samples Approximate sizes in kDa, as indicated by Dual Colour 
PrecisionPlus Protein™ standard, (Bio-Rad) are shown. 
 
 
Table 3.2. Predicted properties of recombinant proteins and E. coli strains for expression 
 
Recombinant  
Protein 
Molecular 
weight 
Isoelectric 
point 
Sequence 
similarity*  
Expression 
strain 
LAP1SRSR aa406-707 37.9 kD 5.6 65% Ros(DE3)PLysS 
LAP2RG aa161-446 37.9 kD 5.5 81% Ros(DE3)PLysS 
LAP3PA14 aa3-284 34.6 kD 8.6 51% BL21 (DE3)pMico 
LAP3LCCL aa215-481 32.3 kD 4.8 56% Ros(DE3)PLysS 
LAP4LCCL aa596-872 33.2 kD 4.4 70% Ros(DE3)PLysS 
LAP5AB aa501-756 31.3 kD 8.7 64% BL21 (DE3)pMico 
LAP6AB aa359-558 24.7 kD 6.0 55% BL21 (DE3)pMico 
LAP6LCCL aa591-819 27.8kD 8.9 42% Ros(DE3)PLysS 
 
*% similarity to P. falciparum ortholog. 
 
+   - +   - +   - +   - +   - +   - +   - +   - +   -
plap1SRSR plap2RG plap3PA14 plap3LCCL plap4LCCL plap5AB plap6AB plap6LCCLp15b
50 -
37 -
25 -
20 -
~kDa
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3.2.4. Protein purification and antigen preparation 
The amino terminal polyhistidine-tag of six histidine residues of recombinant proteins 
facilitated affinity purification of the fusion proteins using nickel coated agarose beads 
(Ni-NTA). Proteins were expressed as described in 3.2.3, insoluble fractions were 
extracted and solubilised in urea, and histidine-tagged proteins were purified under 
denaturing conditions by nickel affinity. Analysis by SDS-PAGE indicated that 
rLAP1SRSR, rLAP3PA14, rLAP3LCCL, rLAP4LCCL and rLAP6LCCL were all 
affinity-purified effectively (Figure 3.4). In each case, proteins bound to the nickel-coated 
agarose beads were eluted using 8 M urea solution, pH 4.5. To prepare antigens for 
antibody production, eluted fractions of affinity-purified proteins were pooled, and the 
collected protein solution was dialysed in a stepwise manner from  an 8 M urea solution 
to a 2 M urea solution, and then into PBS overnight. In this way, urea was removed to 
acquire a non-toxic antigen preparation suitable for immunisations and to allow for 
protein renaturation.  Dialysed proteins were concentrated using a Centricon® column 
and solutions were assessed by SDS-PAGE (Figure 3.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Purification of recombinant proteins  
Histidine6-tagged recombinant proteins were purified from cell lysates by nickel affinity under denaturing 
conditions Samples were separated on 12% SDS-PAGE gels and visualised by coomassie blue staining.        
i) rLAP1SRSR; ii) rLAP3AB; iii) rLAP3LCCL; iv) rLAP4LCCL; v) rLAP6LCCL. For each protein, four 
eluates (1-4) are shown. Molecular weight markers are displayed in kilo Daltons. Following purification, 
eluates were pooled and protein solutions were dialysed in a stepwise manner into PBS and then 
concentrated. Representative examples of resulting protein solutions, separated on 12% SDS-PAGE gels and 
visualised by coomassie blue staining, are shown in  panel vi. 
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Although Western blot analysis indicated that LAP2RG, LAP5AB and LAP6AB were 
expressed, the proteins were either undetectable following affinity-purification, or 
precipitated out of solution following dialysis: proteins failed to be detected by both SDS-
PAGE and Western. The loss of protein during dialysis is a frequently encountered 
problem with the technique, commonly occurring as a result of protein binding to the 
dialysis membrane or protein precipitation. As an alternative to protein purification and 
dialysis, rLAP2RG, rLAP5AB and rLAP6AB immunogens were prepared by extraction 
of affinity purified protein from an excised polyacrylamide gel slice. Proteins were 
expressed and were enriched from inclusion bodies, suspending the protein pellet in PBS 
(see methods for details). Protein solutions were separated by electrophoresis, gels were 
Coomassie-stained to enable visualisation of the protein band and the protein was excised 
as a gel slice. The gel slice was then destained and washed.  Protein was extracted from 
the gel either by fragmentation or solubilisation (see 2.3.6), thereby generating antigen in 
a form suitable for immunisations. 
 
3.2.5. Production of antisera  
Polyclonal antiserum was produced by immunising groups of female BALB/c mice with 
40-60 µg of antigen. Initial immunisations were performed with Freund’s complete 
adjuvant, which contains mycobacterial cell wall components to potently stimulate 
humoral responses. Subsequent boost immunisations were administered 14, 28 and 56 
days after the primary immunisation with the same amount of antigen in Freund’s 
incomplete adjuvant. Serum samples were taken 10 days after each boost immunisation, 
and tested by immunoblot for the presence of antibodies specific to the corresponding 
recombinant antigen. Recombinant proteins were expressed in E.coli alongside an 
uninduced control. Whole bacterial lysates were run on a gel under reducing conditions, 
transferred to a nitrocellulose membrane and probed with sera collected from each 
immunised mouse. Sera from an unimmunised mouse served as a negative control and 
non-specific immune reactions were assessed by testing against protein expressed from 
bacterial cell lysates transformed with an empty plasmid pET-15b. When antibodies 
specific to the corresponding recombinant antigen were detected, the host mouse was 
exsanguinated and serum prepared. When no specific reaction was seen, mice were re-
immunised. At least two, and up to four independent attempts to generate antibodies 
against each antigen were made. The serum collected from different mice but containing 
antibodies reactive against the same antigen was pooled. Antibody reactivity was 
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confirmed by immunoblot (as above) and ELISA (see 1.3.11) on pooled serum. 
Representative immunoblots and ELISAs demonstrating the reactivity of antibodies are 
shown in Figure 3.5. 
 
 
Figure 3.5. Immunoreactivity of antibodies against E.coli-expressed antigens  
A) Immunoblot analysis with pooled mouse antisera: i) αLAP1SRSR, ii) αLAP3AB, iii) αLAP3LCCL,       
iv) αLAP4LCCL and v) αLAP6LCCL. Whole cell bacterial lysates of IPTG induced (+) or uninduced (-) 
E.coli expression strains transformed with recombinant plasmids plap1SRSR, plap2RG, plap3AB, 
plap3LCCL, plap4LCCL, plap5AB, plap6AB, plap6LCCL, or empty vector p15b as negative control, were 
separated under reducing conditions by SDS-PAGE (12% gel) and transferred to nitrocellulose membrane. 
Membranes were probed with anti-LAP serum at a dilution of 1 in 1000 and antibody binding was detected 
by ECL chemiluminescence following incubation with HRP-conjugated anti-mouse IgG secondary antibody 
(1:10,000). Immunoreactivity was demonstrating by the presence of a band in lane 1 (cell lysate in which 
antigen expression was induced), appearing absent from lanes 3-4 (empty vector control). Serum from an 
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unimmunised mouse (NMS) was used as a negative control. Molecular weight markers are displayed in kilo 
Daltons.  
B) ELISA with pooled mouse antisera. Whole cell bacterial lysates (as above) were used as antigens in 
ELISAs. Wells of a 96-well ELISA plate were coated with 10 µg/ml of antigen and antibody incubations 
were performed over a range of dilutions. Antigen-antibody binding was detected by incubation with HRP-
conjugated anti-mouse IgG secondary antibody (1:10,000) followed by o-phenylenediamine (OPD) substrate 
for the detection of peroxidase activity.  Reactions were stopped by the addition of 3M H2SO4 and were read 
at 492 nm. Mean absorbance values from duplicate samples (serum at a dilution of 1:500) are indicated.     
Red = anti-LAP sera; Grey = normal mouse serum (NMS). Error bars represent standard error of the mean.  
 
3.2.6. Summary of recombinant protein expression and production of antisera  
o Eight recombinant proteins, corresponding to 25-40 kDa portions of P. 
berghei LAPs, were successfully expressed in E. coli: LAP1SRSR (aa406-
707), LAP2RG (aa161-446), LAP3PA14 (aa3-284), LAP3LCCL (aa215-481), 
LAP4LCCL (aa596-872), LAP5AB (aa501-756), LAP6AB (aa359-558) and 
LAP6LCCL (aa591-819). 
o Five of the proteins expressed could be purified effectively by Ni-NTA affinity: 
LAP1SRSR, LAP3AB, LAP3LCCL, LAP4LCCL, LAP6LCCL, and these were 
used to immunise mice for antibody production. All were capable of inducing 
antibodies specific to the heterologously expressed recombinant proteins. 
o Remaining antigens were prepared by gel extraction were found to be non-
immunogenic in mice, suggesting that the antigens are either poor immunogens 
or that amounts of antigen were insufficient, resulting in low antibody titre and 
affinity.  
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3.3. Immunoreactivity of antibodies against gametocytes 
Antisera generated were tested by immunoassays (immunoblot and immunofluorescence) 
to assess reactivity to P. berghei gametocytes. 
3.3.1. Detection of gametocyte proteins by immunoblot  
To generate gametocyte extracts for immunoblot analysis, PH-treated mice were 
inoculated with wild-type P. berghei clone 2.34 and once parasitemias were established 
were treated with sulphadiazine to kill asexual blood stages. The P. berghei clone 2.33, 
which is deficient in the production of mature gametocytes, was used for the purpose of 
generating gametocyte depleted samples. Antisera against the SRCR domain of LAP1, 
the PA14 domain of LAP3 and the LCCL domains of LAPs 4 and 6 were all found to 
react with endogenous protein in gametocyte extracts. αLAP1SRCR and αLAP3PA14 
were found to detect parasite proteins exclusive to gametocytes: proteins migrating at 
molecular weights of approximately 150 kDa (αLAP1SRCR) and 120 kDa 
(αLAP3PA14), corresponding with the predicted sizes of the endogenous proteins, were 
detected in gametocyte extracts whilst absent from gametocyte-depleted samples. 
αLAP4LCCL and αLAP6LCCL each recognised multiple protein bands ranging from  
80-175 kDa in gametocyte-enriched samples. It is predicted that the immunoreactivity 
against proteins of different molecular weights may suggest partial protein degradation or 
processing of the endogenous full-length proteins. Proteins detected by αLAP4LCCL and 
αLAP6LCCL were predominantly present in gametocytes, although bands were also 
recognised in gametocyte-depleted samples: at 80 kDa and 85 kDa (αLAP4LCCL) and 
175 kDa (αLAP6LCCL). Neither gametocyte nor asexual blood stage proteins were 
detected by antibodies in the sera from an unimmunised mouse (NMS) or antisera raised 
against LAP3LCCL . Further analysis indicated that most of the gametocyte proteins 
detected were present in the soluble fraction following treatment with triton, indicating a 
possible membrane-bound localisation. Representative immunoblots are shown in Figure 
3.6. 
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Figure 3.6. Detection of gametocyte proteins by immunoblot  
Antibodies were tested for immunoreactivity against asexual blood stages (Abs) and gametocytes (Gc). The 
P. berghei clone 2.33, which is deficient in the production of mature gametocytes, was used for the purpose 
of generating gametocyte depleted (i.e. asexual blood stage enriched) samples. To generate gametocyte 
extracts, PH-treated mice were inoculated with wild-type P. berghei clone 2.34 and once parasitemias were 
established were treated with sulphadiazine to kill asexual blood stages. Parasite proteins were separated 
under reducing conditions by SDS-PAGE (8% polyacrylamide) and transferred to nitrocellulose membrane. 
Membranes were probed with antisera αLAP1, αLAP3, αLAP4, αLAP6, or as a negative control, normal 
mouse sera, each at a dilution of 1 in100. Membranes were reprobed with monoclonal αtubulin antibody (1: 
10,000) to indicate protein loading (lower panel). Antibody binding was detected by use of HRP-conjugated 
anti-mouse IgG secondary antibody (1:10,000) and ECL chemiluminescence.    
 
3.3.2. Detection of gametocyte proteins by immunofluorescence  
Antisera were further analysed by immunofluorescence to visualise the localisation of 
detected proteins. Cells were fixed by either protein precipitation using either methanol or 
50% methanol: 50% acetone or by cross-linking using 4% paraformaldehyde. Fixation 
using paraformaldehyde followed by sodium borohydride treatment was found to be the 
most robust and consistent staining methodology between experiments. Fixation with 
formaldehyde stabilises cells by cross-linking proteins and leads to peroxidation of lipids. 
Resulting aldehyde formation due to lipid peroxidation is a common cause of background 
fluorescence (Stoya et al., 2002) but can be effectively masked by sodium borohydride 
treatment. All antibodies were found to label both unactivated gametocytes (present in 
fixed blood smears from a P. berghei infected mouse) and activated gametocytes 
undergoing gametogenesis (activated by the suspension of gametocyte-infected blood in 
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ookinete media containing xanthurenic acid). Since male gametogenesis involves rapid 
DNA replication, activated males can be easily distinguished from activated females by 
nuclear staining patterns. Anti-LAP1 (Figure 3.7Bi), anti-LAP3 (Figure 3.7Bii) and anti-
LAP6 (Figure 3.7Biv) antisera specifically label female parasites, whilst anti-LAP4 
(Figure 3.7Biii) is also immunoreactive against exflagellating males. 
 
 
 
Figure 3.7. Immunofluorescent labelling of gametocytes and gamete 
A) Indirect immunofluorescence assays using mouse sera against LAP1, LAP3, LAP4 and LAP6 revealed 
labelling of gametocytes. Immunofluorescence analyses were performed on paraformaldehyde-fixed blood 
smears from a P. berghei infected mouse. Antibody binding was detected using Alexa Fluor 488 anti-mouse 
IgG (green) and cells were counterstained with DAPI nuclear stain (blue). Control serum from an 
unimmunised mouse (NMS) showed no labelling of gametocytes. Scale bar represents 2 µm. 
B) Immunofluorescence analyses on activated gametocytes. Gametocytes were activated by suspending blood 
collected from a P. berghei-infected mouse in ookinete media containing xanthurenic acid and 
immunofluorescence assays were performed as above on cells 5 minutes post-activation. Representative 
images of antibody labelling of activated male and female gametocytes are shown.  
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3.4. Transmission-blocking assays  
Having demonstrated immunoreactivity against gametocytes, antisera against the SRCR 
domain of LAP1, the PA14 domain of LAP3 and the LCCL domains of LAPs 4 and 6 
were tested in assays to evaluate antibody-mediated effects on P. berghei exflagellation, 
ookinete development, infectivity to mosquitoes and subsequent transmission.    
3.4.1. Effects of anti-LAP sera on exflagellation and ookinete development 
Antibody-mediated inhibition of P. berghei exflagellation (male gamete release), zygote 
formation and ookinete development and ookinete formation can be simply detected by in 
vitro assays.  
3.4.1.1. Exflagellation assays 
Exflagellation can be induced by suspending gametocytes ookinete media containing XA 
to induce activation. During gametogenesis in vitro, emerging microgametes draw in 
neighbouring erythrocytes, creating a wobbling clump of cells termed ‘exflagellation 
centres’, which are retained by the residual body of the gametocyte (Eksi et al., 2006).  
The functional significance of exflagellation centres remains unknown, but their 
formation can be exploited as a means of measuring male gamete release. To test for 
antibody-mediated effects on exflagellation, tail blood from a P. berghei-infected mouse 
containing mature gametocytes was suspended in ookinete containing test sera (αLAP1, 
αLAP3, αLAP4 or αLAP6) or control sera (normal mouse sera (NMS) from an 
unimmunised mouse). Exflagellation centres were defined as a cluster of cells comprising 
exflagellating male parasite(s) binding three or more red blood cells and were counted by 
microscopic examination (x40 objective magnification) after a 20 minute incubation 
period. The mean number of exflagellation centres per field of view was calculated by 
counting 20 microscopic fields. Results (Figure 3.8) were collected from three 
independent experiments, each performed in duplicate (n=6). 
 
Differences between overall means were negligible (αLAP1: 18.37, αLAP3: 15.44, 
αLAP4: 15.0, and αLAP6: 17.37 compared to NMS: 17.89). Statistical analysis by 
Wilcoxon signed-rank tests concluded that no significant antibody-mediated effects on 
exflagellation were detected with any of the antibodies tested (Figure 3.8). The absence of 
antibody-mediated effects on exflagellation, at least for αLAP1, αLAP3, αLAP4 or 
αLAP6, was consistent with the lack of labelling of male gametocytes: only anti-LAP4 
was found to bind activated male gametocytes (Figure 3.7). 
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NMS PBS αLAP1 αLAP3 αLAP4 αLAP6 
        
Mean 
(±SEM) 
17.89  
(±1.34) 
18.15  
(±2.20) 
18.37  
(±2.93) 
15.44  
(±0.41) 
15.0  
(±0.97) 
17.37  
(±1.32) 
       
Median  
(range) 
19.75 
(10.25-
20.70) 
17.00 
(14.30-
25.85) 
18.50 
(9.700-
26.65) 
15.25 
(7.950-
24.35) 
14.35 
(11.70-
20.40) 
18.05 
(11.80-
19.75) 
       
Number of 
exflagellation 
centres  per 
field of view 
Mean as % 
compared 
to NMS 
100% 
 
104.9 % 
(±6.9) 
102.4%  
(±8.5) 
88.5%  
(±8.2) 
87.6%  
(±11.4) 
102.2%  
(±14.0) 
 
P-value 
 
1.0000 1.0000 0.2188 0.0938 0.5625 1.0000 
 
 
Figure 3.8. Effect of anti-LAP sera on P. berghei exflagellation. 
Gametocyte-containing tail blood from a P. berghei-infected mouse was suspended in ookinete medium 
containing 25% test serum (αLAP). Sera from an unimmunised mouse (NMS) and PBS were used as negative 
controls. After a 20 minute incubation period, exflagellation centres were counted under a light microscope 
(40x objective magnification). The average number of exflagellation centres per field of view was calculated 
by counting 20 microscopic fields. Assays were performed in duplicate. A) Combined results of three 
independent experiments (n=6) showing the mean number of exflagellation events for each group. Error bars 
represent SEM. Values are tabulated in B. P-values were determined by Wilcoxon signed-rank tests 
performed on the combined results of three independent experiments (n=6). 
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3.4.1.2. Ookinete development assays 
The effects of antisera on ookinete development can be simply detected using P. berghei 
since ookinetes can be readily cultured in vitro. Heparinised blood from a P. berghei-
infected mouse containing mature gametocytes was incubated for 24 hours at 19ºC in 
ookinete media containing test sera (αLAP1, αLAP3, αLAP4 or αLAP6) or control sera 
(from an unimmunised mouse). Ookinetes were counted using a haemocytometer to 
calculate the number of ookinetes per 100 µl culture and results (Figure 3.9) were 
collected from three independent experiments, each performed in duplicate (n=6).  
 
The antisera tested did not elicit reductions in ookinete numbers, indicating that the 
antibodies were incapable of inhibiting fertilisation and subsequent ookinete formation. 
Conversely, an increase in ookinete numbers was observed in the presence of αLAP1, 
αLAP3 and αLAP6 (αLAP1: +84.0%, αLAP3: +35.1%, and αLAP6: +57.6% relative to 
NMS control at 100%; Figure 3.9). Statistical analyses by Wilcoxon signed-rank tests 
demonstrated that the presence of αLAP1 was associated with a significant increase in 
ookinete numbers (overall mean number of ookinetes 17,942 compared to 9750 for NMS 
control, P = 0.0313). The unexpected antibody-mediated enhancement of parasite 
development is discussed in 3.5.2. 
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B 
 NMS PBS αLAP1 αLAP3 αLAP4 αLAP6 
        
Mean 9750 
(±1116) 
9058 
(±1518) 
17942 
(±3223) 
14942 
(±5274) 
10250 
(±2334) 
14667 
(±5428) 
Median  
(range) 
9750 
(6000-
13500) 
10500 
(4000-
13500) 
15825 
(9000-
29000) 
10825 
(5000-
40000) 
9500 
(4000-
18000) 
9250 
(5000-
40000) 
       
Number of   
ookinetes 
per 100 µl 
culture 
(±SEM) 
 
Mean as % 
compared 
to NMS 
100.0% 96.95% 
(±8.60) 
184.0% 
(±24.24) 
135.1% 
(±44.72) 
103.7% 
(±14.56) 
157.6% 
(±42.90) 
P-value   0.4375 0.0313 * 0.8438 1.0000 0.8438 
 
Figure 3.9. Effect of anti-LAP sera on P. berghei in vitro ookinete formation  
Gametocytes from a P. berghei infected mouse were suspended in 100 µl ookinete cultures containing 25% 
test serum. Cells were cultured at 19°C for 24 hours and the number of ookinetes culture was calculated by 
counting ookinetes in a haemocytometer. Assays were performed in duplicate. A) Combined results of three 
independent experiments (n=6) showing the mean number of ookinetes per 100 µl culture for each group. 
Error bars represent SEM. Values are tabulated in B. P-values were determined by Wilcoxon signed-rank 
tests performed on the combined results of three independent experiments (n=6).  
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3.4.2. Effects of anti-LAP sera on parasite infectivity in vivo  
Given that LAPs have been implicated with possible interactions with mosquito 
molecules (Delrieu et al., 2002; Claudianos et al., 2002; Trueman et al., 2004) it was 
considered that antibodies raised against the proteins may have effects in vivo even 
though they do not in vitro. Experimental P. berghei mosquito infections have been 
demonstrated to be highly efficient in An. stephensi mosquitoes (Sinden et al., 1996) 
enabling the reliable detection of potential antibody-mediated effects on parasite 
development within the mosquito.  
 
3.4.2.1. Membrane feeding assays 
The effect of anti-LAP serum on parasite infectivity in vivo was assessed by membrane 
feeding assays. The use of a membrane feeding system, whereby serum is added to 
gametocyte-infected blood and mosquitoes are fed through an artificial membrane, 
enables several different mosquito test groups to be fed on the same pool of gametocyte-
infected blood in the presence of different test sera. Counting oocysts (day 10-12 post-
infection) is an accurate measure of transmission success. To determine the effect of anti-
LAP serum on oocyst numbers, a membrane feeding apparatus was used to feed groups of 
mosquitoes on P. berghei conGFP infected blood mixed with anti-LAP serum (or serum 
from unimmunised mice (NMS) as a control) at a 1 in 4 concentration. Mosquitoes were 
dissected 10-11 days post-feed and numbers of oocysts in each midgut were counted by 
fluorescence microscopy. Values were pooled for analysis: since the intensity of infection 
varies between experiments, all values were represented as fold change in oocysts 
compared to NMS treated controls. The combined results of three (for αLAP6 two) 
independent experiments, each consisting of two duplicate feeds, are shown on Figure 
3.10 and the mean values from each experiment are given in Table 3.3. 
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Figure 3.10. Effect of anti-LAP sera on P. berghei development in An. stephensi mosquitoes 
P. berghei conGFP infected blood was mixed with anti-LAP sera or sera from unimmunised mice (NMS) at a 
1 in 4 concentration and fed to mosquitoes in using a membrane feeding apparatus. Mosquitoes were 
dissected 10-11 days post-feed and numbers of oocysts in each midgut were counted by fluorescence 
microscopy. The graph shows the combined results of three (for αLAP6 two) independent experiments, each 
consisting of two duplicate feeds. Values are represented as fold change in oocysts compared to NMS treated 
controls plotted as aligned dotplots on a log2 scale (black=NMS, grey=PBS, red=αLAP). Horizontal lines 
indicate the mean number of oocysts. 
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Table 3.3.  P. berghei infectivity in An. stephensi following membrane feeding assays to assess 
the effects of anti-LAP sera on parasite development in the mosquito 
Serum 
Prevalence 
(infect/total) Range 
Mean number of 
oocysts  per 
mosquito (+/-SEM) P 
Intensity of infection: 
Mean number of 
oocysts per infected 
mosquito (+/-SEM) P 
       
NMS  82.8% (24/29) 0-340 55.03 (±17.4)  66.5 (±20.3)  
αLAP1  97.6% (41/42) 0-286 83.32 (±8.64) *** 85.17 (±8.8) ** 
NMS  76.9% (20/26) 0-57 15.27 (±3.70)  19.85 (±4.3)  
αLAP1 97.4% (38/39) 0-392 71.67 (±14.3) *** 73.55 (±4.5) ** 
NMS  89.4% (42/47) 0-148 24.7 (±4.79)  27.64 (±5.2)  
αLAP1 88.1% (52/59) 0-129 14.25 (±3.09) ns 16.17 (±3.4) ns 
NMS  83.0% (±3.60)  31.7 (±12.0)  38.0 (±14.4)  
αLAP1 94.4% (±3.13)  56.4 (±21.4)  58.3 (±21.3)  
       
NMS  68.0% (17/25) 0-68 8.04 (±3.16)  11.82 (±4.4)  
αLAP3 89.5% (17/19) 0-39 11.21 (±2.78) * 12.53 (±3.0) ns 
NMS  82.8% (24/29) 0-340 55.03 (±17.4)  66.5 (±20.3)  
αLAP3 95.3% (41/43) 0-228 92.98 (±8.63) ** 97.51 (±8.4) *** 
NMS  83.7% (36/43) 0-74 18.95 (±2.94)  22.64 (±3.2)  
αLAP3 90.3% (28/31) 0-87 34.1 (±4.67) ** 37.75 (±4.7) ** 
NMS  78.2% (±5.09)  27.3 (±14.2)  33.7 (±16.7)  
αLAP3  91.7% (±1.82)  46.1 (±24.4)  49.3 (±25.2)  
       
NMS 69.0% (29/42) 0-15 3.31 (±0.60)  4.8 (±0.7)  
αLAP4 69.6% (32/46) 0-54 7.78 (±0.82) ns 11.2 (±16.5) ns 
NMS 82.8% (24/29) 0-340 55.03 (±17.4)  66.5 (±20.3)  
αLAP4 100% (25/25) 4-227 68.6 (±12.3) * 68.6 (±12.3) ns 
NMS  83.7% (36/43) 0-74 18.95 (±2.94)  22.64 (±3.2)  
αLAP4 91.2% (31/34) 0-70 23.65 (±3.94) ns 25.94 (±3.6) ns 
NMS  78.5% (±4.76)  25.8 (±15.3)  31.3 (±18.3)  
αLAP4 86.9% (±9.03)  33.3 (±18.2)  35.3 (±17.2)  
       
NMS  82.8% (24/29) 0-340 55.03 (±17.4)  66.5 (±20.3)  
αLAP6 96.0% (24/25) 0-327 78.88 (±15.4) ** 82.17 (±15.7) * 
NMS  83.3% (35/42) 0-183 16.48 (±5.76)  19.8 (±6.79)  
αLAP6 95.5% (42/44) 0-105 18.55 (±3.28) * 19.4 (±3.37) ns 
NMS  83.1% (±0.25)  35.8 (±19.3)  43.2 (±23.3)  
αLAP6 97.8% (±0.25)  48.7 (±30.2)  50.8 (±31.4)  
       
NMS  69.0% (29/42) 0-15 3.31 (±0.60)  4.79 (±0.7)  
PBS 60.7% (17/28) 0-15 2.54 (±1.97) ns 4.18 (±1.2) ns 
NMS  83.4% (36/43) 0-74 18.95 (±2.94)  22.64 (±3.17)  
PBS 89.7% (35/39) 0-86 28.44 (±3.88) ns 31.69 (±3.97) ns 
NMS  82.8% (24/29) 0-340 55.03 (±17.4)  66.5 (±20.3)  
PBS 85.7% (12/14) 0-116 41.21 (±10.1) ns 48.08 (±10.5) ns 
NMS  78.4% (±4.70)  25.8 (±15.3)  31.3 (±18.3)  
PBS 78.7% (±9.07)  24.1 (±11.4)  28.0 (±12.8)  
 
P refers to the statistical significance calculated by Mann-Whitney U tests.  
Overall mean values are shown in bold.  
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It was surprising to find that the addition of anti-LAP enhanced oocyst development in 
An. stephensi mosquitoes in comparison with serum from an unimmunised mouse (Figure 
3.7 and Table 3.4). Statistical analyses using Mann-Whitney U tests on combined data  
concluded that the presence of anti-LAP1, anti-LAP3, anti-LAP4 and anti-LAP6 sera led 
to a significant increase in the number of oocysts per mosquito (P-values 0.0007, 
<0.0001, 0.0322 and 0.011 respectively). In comparison, feeds in the absence of 
antiserum (PBS control) did not significantly affect infectivity (P = 0.4297). The 
increases in infectivity were most notable for anti-LAP1: in the presence of which, more 
than a two-fold increase was detected (based on the mean of pooled data). The increases 
in infectivity as indicated by higher oocyst densities were mirrored by increases in both 
prevalence of infection (αLAP1: +11.3%, αLAP3: +13.5%, αLAP4: +8.1%, and αLAP6: 
+14.7% compared to NMS control (PBS: +0.3%) and mean differences in intensity of 
infection αLAP1: +85.7.%, αLAP3: +39.8%, αLAP4: +50.4%, and αLAP6: +8.5% 
compared to NMS control (PBS: -8.1%). Infective sporozoites were formed in each case, 
as demonstrated by bite back experiments in which mosquitoes from each test group were 
allowed to feed on anaesthetised mice: in each case leading to  blood-stage parasitemia.  
 
The observed antibody-mediated increase in infectivity was unexpected, but 
transmission-enhancing effects are not uncommon, particularly when antibody 
concentrations are low. For example, Peiris et al. (1988) report that a monoclonal 
antibody against P. vivax gametes can suppress infectivity of the parasites to the vector at 
high concentrations, but at lower concentrations, may have the opposite effect and 
enhance the level of malaria infection in the mosquitoes. Similarly, transmission 
enhancing effects with low titres of anti-Pfs48/45 and Pfs230 antibodies have been 
reported (Healer et al., 1999; Van der Kolk et al., 2006; Carter et al., 1990). More 
recently it was observed that whilst anti-P. berghei HAP2 blocks transmission at high 
concentrations (1 in 5), at low dilutions (1 in 100), its presence appears to promote oocyst 
development within the mosquito host (Blagborough and Sinden, 2009). Molecular 
mechanisms underlying transmission enhancing effects are unknown: possibilities are 
discussed further in the conclusions and discussion section at the end of this chapter 
(3.5.2). 
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3.4.2.2. Direct feeds 
A caveat of membrane feeding assays using P. berghei is that there is no incubation 
period between the antibody and the parasite. Therefore to determine the in vivo efficacy 
of antibodies, direct feeds were performed on mice producing anti-PbLAP1 antibodies. 
Groups of female Balb/c mice were immunised with affinity-purified recombinant LAP1 
and tested for production of anti-PbLAP1 antibodies by immunoblot analysis using sera 
samples acquired from tail bleeds (Figure 3.11A). Following demonstration of antibody 
production, mice were infected with P. berghei and three days post infection, mosquitoes 
were fed directly on anesthetised mice. In comparison to membrane feeds, much higher 
oocyst densities were attained, reflecting the higher efficiency of direct skin feeding 
compared to membrane feeding. Twelve days post-feeding, mosquitoes fed on the blood 
of mice immunised with LAP1 showed no significant difference in oocyst densities 
compared to the unimmunised control (LAP1: 75.8 (±10.3), unimmunised: 92.2 (±11.0), 
P = 0.2511), although when compared to the BSA-immunised control mice a significant 
reduction in transmission-blocking immunity was detected (P=0.0017). Considering 
however that mosquitoes fed on the blood of mice immunised with BSA had significantly 
higher oocyst densities than those fed on unimmunised mice (BSA: 143.4 (±15.4), 
unimmunised: 92.2 (±11.0), P = 0.0085) it was concluded that differences could be 
attributable to variation in mouse parasitemias or antibody concentrations, which cannot 
be standardised in this assay.  
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Figure 3.11. Effect of rLAP1 immunisation on transmission-blocking immunity following direct feeds 
Groups of female Balb/c mice were immunised with 50 µg affinity purified recombinant LAP1SRSR or       
50 µg BSA emulsified in Freund’s adjuvant. Initial immunisations were performed using complete Freund’s 
adjuvant and boosts on days 14 and 28 were performed using incomplete Freund’s adjuvant. Mice were tested 
for antibody responses against corresponding antigens by immunoblot. Two mice with serum containing anti-
LAP1 antibodies and two mice producing anti-BSA antibodies were used in direct feeds alongside two 
unimmunised mice. A) Test sera from two mice immunised with rLAP1SRSR react with LAP1SRSR in 
whole bacterial lysates expressing the protein (plap1SRSR). The corresponding protein band is absent when 
tested against whole bacterial lysates transformed with an empty vector (pE). B) Test sera from two mice 
immunised with BSA are immunoreactive against BSA and negative for PBS. For all immunoblots, proteins 
were separated by 12% SDS-PAGE, transferred to nitrocellulose membranes and membranes were probed 
with serum at a 1:1000 dilution. HRP-conjugated anti-mouse IgG antibodies were used for detection by 
chemiluminescence. Each mouse was infected with P. berghei conGFP from the same donor mouse and at 
day 3 post-infection, groups of mosquitoes were allowed to feed on anaesthetised mice. The graph (C) shows 
the number of oocysts per mosquito 12 days post-feed. Each data point represents the oocyst density of an 
individual mosquito.  Horizontal lines indicate the mean number of oocysts. 
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3.5. Conclusions and discussion 
3.5.1. Summary of findings 
Studies in this chapter represent an initial investigation to evaluate the potential of 
Plasmodium LAPs as candidate transmission-blocking targets. Experiments were 
performed using the rodent malaria parasite P. berghei, which is far more amenable to the 
experimental study of transmission than human malaria parasites. Results are summarised 
as follows: 
o Eight recombinant proteins, corresponding to 25-40 kDa portions of the PbLAPs, 
were successfully expressed in E. coli. 
o Five of the proteins expressed could be purified effectively by Ni-NTA affinity 
and these were used to immunise mice for antibody production. 
o All affinity-purified antigens were capable of inducing antibodies specific to the 
heterologously expressed recombinant proteins. 
o Immunodetection assays indicated that antibodies against the SRCR domain of 
LAP1, the PA14 domain of LAP3 and the LCCL domains of LAPs 4 and 6 were 
all able to bind endogenous P. berghei gametocyte proteins. 
o Transmission-blocking assays showed that none of the antibodies could block P. 
berghei development and transmission when mixed with gametocyte, and 
surprisingly an antibody-mediated increase in oocyst numbers was detected.  
 
3.5.2. Antibody-mediated enhancement of infectivity 
Antibody-mediated increases in infectivity are not unusual and have been detected with 
low concentrations of known transmission-blocking antibodies, including anti-Pfs48/45 
and Pfs230 antibodies (Healer et al., 1999; Mendis et al., 1987; Van der Kolk et al., 2006; 
Carter et al., 1990) and anti-P. berghei HAP2 sera (Blagborough and Sinden, 2009). It is 
hypothesised that low amounts of bound specific antibodies may enhance adherence of 
gametes (to enhance fertilisation) or ookinetes (to enhance midgut invasion), but 
molecular mechanisms explaining concentration dependent changes in antibody efficacy 
have not yet been determined. One possible mechanism is by the induction of 
conformational changes in the antigen by antibody-epitope binding at low concentrations. 
This may have the potential to elicit increased antigen activity as has been observed with 
neutralising antibodies against botulinum neurotoxin (Sheridan et al., 2001): When 
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antibodies are present in excess (antibody:toxin ratio 30:1) internalisation of the toxin is 
inhibited by binding to epitopes to inhibit antigen-receptor binding; but at low 
concentrations, antibody binding has the converse effect of making the toxin more active 
by optimising receptor binding (Sheridan et al., 2001). Another way by which antibody-
mediated increases in infectivity can occur is by the presence of cross-reactive antibodies. 
For example, it is thought that increases in the severity of dengue fever — which is 
associated with increased exposure to dengue virus — may occur by non-neutralising 
antibodies sticking to the virus, allowing it to bind to and subsequently invade cells that it 
would not do normally (Dejnirattijai et al., 2010). Given the polyclonal nature of the anti-
LAP antibodies tested in this study, it is possible that enhancing effects may be mediated 
by antibodies with different specificities against a number of different epitopes. It is 
hypothesised that increased amounts of immunoglobulins may stick to the parasite to 
enhance fertilisation or ookinete invasion. Increased amounts of immunoglobulin may 
also have the potential to inhibit complement binding, thereby increasing infectivity by 
preventing complement-mediated lysis. The increases in infectivity detected with anti-
BSA antibodies (see 3.4.2.2. Figure 3.11) supports the theory that non-specific 
immunoglobulins may enhance infectivity.  
 
3.5.3. Approaches to improve the biological activity of antibodies 
It is possible that the degree of specificity may not have been high enough to elicit 
transmission-blocking activity. The generation of antibodies with increased specific 
affinity could perhaps counteract the transmission-enhancing affects. A much greater 
specificity could be attained by generating monoclonal, rather than polyclonal, antibodies. 
Monoclonal antibodies are derived from a single clone of antibody-producing cells, 
producing antibodies specific to a single antigen. Alternatively, the specificity of 
polyclonal antibodies may be improved by affinity purification of desired antibodies 
and/or by increasing the affinity of binding to native endogenous antigens by modifying 
protein expression procedures for the production of antigens more closely resembling the 
native endogenous protein.  
 
Antibodies generated in this study were found to detect endogenous parasite antigens 
separated by SDS-PAGE but not by native PAGE, and in immunofluorescence assays 
antibodies labelled fixed, but not live cells. This is considered to be due to either 
difficulties encountered with the assays (high levels of background immunofluorescence 
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and problems in the migration of proteins during native–PAGE) or due to the antibodies 
predominantly recognising epitopes which are not exposed on the native endogenous 
proteins. The antibodies may interact with predominantly recognise linear epitopes that 
are absent from the native protein, or the epitopes recognised by the antibodies may be 
hidden when the protein is in its native state. Although a number of E. coli-derived 
recombinant proteins have been shown to elicit anti-parasitic antibodies against 
Plasmodium, it is common for antibodies generated from heterologously produced 
recombinant antigens to interact only weakly with the antigen in its native form (Saul 
2007; Williamson 2003). This is largely considered to be because heterologously 
produced antigens are often conformationally different to the endogenous proteins.  
Antigen conformation is of crucial importance since antigens and antibodies interact by 
complimentarity in shape by non-covalent bonds. Yet since expression in E. coli occurs in 
the absence of post-translational modifications, co-factors and modifications which are 
often required for protein stability and folding are lacking. In addition, the rapidity of 
bacterial protein expression and the highly reductive environment of the bacterial cytosol 
often results in unfolded/misfolded proteins.   
 
A number of reagents and techniques have been developed to improve the chance of 
producing soluble heterologous proteins in E. coli by modifying expression procedures. 
For example, the C-terminal fragment of Pfs48/45 has been generated in its correct 
conformation in E. coli by simultaneous expression with periplasmic folding catalysts 
(Outchkourou et al., 2008). Alternatively, proteins folding can be improved considerably 
by using expression systems utlising mammalian, insect or yeast cells as replacements for 
E. coli. This has been demonstrated with the expression of Pb25 in a baculovirus system 
(Margos et al. 1995), Pf25 in yeast (Barr et al. 1991). Expression of Plasmodium proteins 
in yeast cells (e.g. P. pastoris) is often favoured. Importantly, proteins expressed in yeast 
likely to more closely resemble the conformation of native proteins than if they were 
expressed in E. coli. This is particularly significant for the production of biologically 
active antibodies since the more similar a recombinant protein is to the native protein, the 
more likely it is that resulting antibodies will recognise the native protein. Yet as with 
other heterologous expression systems, expression in yeast has its drawbacks. Most 
notably, Plasmodium genes may contain N-linked glycosylation sites which may be 
utilised by yeast, but do not appear to be processed by Plasmodium since it is believed 
that malaria performs little N-glycosylation or O-linked glycosylation (reviewed in 
Gowda and Davidson, 1999 and Kimura et al., 2000). As a result, yeast expressed 
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proteins could be modified in markedly different way to how they would be in 
Plasmodium and it is possible that glycosylated molecules could mask critical epitopes on 
an antigen.  
 
Alternatively, protein expression may be avoided altogether by DNA immunisations, 
whereby plasmid DNA is injected into an animal and is taken up into antigen presenting 
cells, leading to antibody production and commonly also a cytotoxic T cell response. This 
approach can induce antibody production against more native-like proteins, but as with 
eukaryotic protein expression systems, problems may result from differential processing 
(as described above with glycosylation in yeast) and furthermore antibodies may be 
difficult to characterise since there are no recombinant antigens to test against.  
 
The biological activity of antibodies may be further affected by the choice of adjuvant 
used to increase the efficiency of antigen presentation, enhance immunogenicity and 
prolong antibody responses. For all antisera generated for this thesis, antibody production 
was induced in mice using Freund’s adjuvant; chosen since it is highly effective in 
stimulating the proliferation of antibody-producing cells. However, it is possible that 
antigens may become denatured when emersed in the adjuvant. It has been demonstrated 
for example that antisera generated after immunisation of mice and rabbits with β-
lactamase in Freund’s adjuvant reacted with denatured antigen and only an exposed 
flexible loop region of the native antigen, whilst after immunisation in PBS, the antisera 
reacted only weakly with denatured antigen and bound more epitopes on the native 
antigen (Paus and Winter, 2006).  
 
There are therefore numerous modifications and alternative approaches that could be 
explored in an effort to improve the chance of generating antibodies with anti-parasitic 
activity. Investing in such alternatives would be worthwhile if LAPs were to be 
confirmed as viable TBV candidates. 
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3.5.4. Are LAPs viable TBV targets? 
For a protein to be a viable candidate for inducing antibody-mediated transmission 
blockade, there are three main criteria:  
i) The protein must be able to be produced in a form suitable for immunisation;  
ii) The protein must be an effective immunogen in the immunised host to stimulate 
antibody production;  
iii) The endogenous protein must be accessible to antibodies in the mosquito blood 
meal and antibody-antigen binding must mediate a blockade in parasite 
development.    
 
The studies presented in this chapter demonstrate that regions of the LAPs can be 
produced as E. coli-expressed recombinant proteins that are immunogenic in mice. 
Antibodies produced however lack the necessary properties to mediate a blockade in 
transmission. It is difficult to distinguish whether the anti-LAP antibodies tested fail to 
block transmission because of properties of the targeted epitopes (e.g. inaccessible) or 
because of properties of the antisera (e.g. unable to bind native protein with high affinity). 
During the course of this study, initial assessments of the transmission-blocking potential 
of anti-PfCCp antibodies were made by P. falciparum exflagellation assays, revealing 
that certain anti-PfCCp antibodies mediated a significant decrease (approximately 30-
50%) in the formation of exflagellation centres (Scholz et al., 2008). Antibodies with 
inhibitory activity were raised against PfCCp1 discoidin-NEC domains, PfCCp2 C-
terminal, PfCCp3-SR-LCCL domains, PfCCp4 LCCL domain, and the anthrax like 
domain of PfFNPA, and inhibition was dependent on the presence of complement: 
reductions in the formation of exflagellation centres were detected in the presence of 
active human serum, whilst in the presence of heat-inactived human serum, there were no 
significant differences compared to untreated controls (Scholz et al., 2008). The 
dependency of anti-PfCCp transmission-blocking activity on the presence of complement 
is shared by the transmission-blocking antigen Pfs230: antibodies against Pfs230 block 
fertilisation by complement-dependent lysis (Healer et al., 1997; Graves et al., 1998). 
 
It is uncertain as to how antibodies, which are thought to be raised against female-specific 
proteins, can have an effect on exflagellation. Nevertheless, the results are promising. 
Following support for their potential as transmission-blocking antibodies in P. falciparum 
exflagellation assays, antibodies raised against PfCCp1 discoidin-NEC domains were 
tested in membrane feeding assays as a more robust means of assessing transmission-
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blocking activity (A. Blagborough and R. Frank, unpublished data). These attempts 
highlighted the technical difficulties of P. falciparum membrane feeding assays, with low 
prevalence (8-9%) and infection intensities (<2 oocysts) even for negative control groups. 
Nevertheless, even at these low levels of infection, raised against PfCCp1 discoidin-NEC 
domains had no inhibitory effect on parasite development (mean oocyst intensity 1.83 +/- 
0.44; representing a 1.2 fold increase compared to untreated). Given the advantages of the 
P. berghei system, where realistic repetitions will provide meaningful results, anti-PfCCp 
antisera were tested for cross-reactivity to P. berghei. Immunoblot and 
immunofluorescence analysis indicated possible cross-reactivity with antibodies against 
PfCCp1 discoidin-NEC and antibodies against the anthrax-like domain of PfFNPA, yet 
when tested in a P. berghei membrane feeding assay no transmission-blocking activity 
was observed (A. Blagborough and R. Frank, unpublished data). These results indicate 
that despite observed reductions in exflagellation assays, infectivity to mosquitoes is not 
reduced. Support for candidacy of LAPs as transmission-blocking antigens is therefore so 
far limited to exflagellation assays in P. falciparum. 
 
It is possible that transmission-blocking activity of anti-LAP/anti-CCp antibodies may be 
related to the epitopes targeted. Whilst antisera directed against distinct domains of 
PfCCp1(LAP3), PfCCp2(LAP4), PfCCp3(LAP1), PfCCp4(LAP6) and PfFNPA(LAP5) 
up to a 50% reduction in exflagellation, some antibodies, including those against the 
LCCL domain of PfCCp1(LAP3) and the first SR domain of PfCCp3(LAP1), were not 
associated with a significant decrease in exflagellation (Scholz et al., 2008). It may be 
that only certain epitopes are accessible to antibody, due to for example the topology or 
processing of the native protein, or the formation of protein complexes. Indeed, studies on 
P. falciparum suggest that the PfCCps may interact as a complex; building on the 
discovery that protein expression of certain PfCCps is co-dependent (Pradel et al., 2004; 
Pradel et al., 2006), affinity binding studies using recombinant proteins have revealed 
interactions between the PfCCp proteins, and co-immunoprecipitation studies on parasite 
lysates have detected binding to Pfs48/45, Pfs230 and Pfs25 (Scholz et al., 2008; Simon 
et al., 2009). It is also possible that the binding of antibodies to one epitope site may 
induce formation of the complement membrane attack complex more strongly than 
binding to other epitopes, or that binding to certain epitopes may act to block 
complement-mediated lysis. Alternatively it may be unrelated to the epitopes targeted but 
rather determined by other properties of serum, e.g. immunoglobulin sub-type or 
competing antibodies.  
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3.5.5 Concluding remarks 
Despite the identification of LAPs as possible transmission-blocking candidates based on 
a combination of proteomic data and bioinformatic predictions, studies presented in this 
chapter provided no further evidence to support the candidacy of LAPs as transmission-
blocking antigens. Utilising the rodent malaria parasite P. berghei as a reliable means of 
assessing transmission-blocking activity, recombinant LAPs produced in E. coli were 
unable to elicit P. berghei transmission-blocking immunity in mice. Given the numerous 
ways to improve the biological activity of antibodies — most notably by exploiting 
different protein expression systems — the possibility that different anti-LAP antibodies 
could elicit transmission-blocking activity cannot be excluded. The study does however 
highlight the significance of protein expression as a major barrier to vaccine development 
and raises doubts over the feasibility of generating anti-LAP antibodies with 
transmission-blocking activity. A better understanding of the biological function of LAPs 
would help to decipher their suitability as TBV candidates and aid any future attempts to 
generate anti-LAP sera with transmission-blocking activity.   
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4   INSIGHTS INTO THE BIOLOGY OF LAPs DURING 
DEVELOPMENT IN THE MOSQUITO  
 
4.1. Introduction 
Members of the LAP family are widely conserved among apicomplexan parasites. At the 
start of this study, orthologs had been identified in Cryptosporidium (C. parvum and C. 
hominis), Theileria (T. parva and T. annulata), and Toxoplasma (T.gondii). During this 
PhD, further genome sequencing projects of apicomplexan parasites were completed, 
including those of Babesia bovis, Cryptosporidium muris, Neospora caninum and the 
gregarine Ascogregarina taiwanensis. All these genome sequences are available through 
the NCBI database and the apicomplexan database ApiDB and LAP orthologs have been 
identified in each apicomplexan species. The presence of LAPs in the early-branching 
apicomplexan class of the gregarines (monoxenous parasites of the guts of invertebrates) 
suggests that the proteins arose prior to the divergence of the apicomplexan clade, whilst 
their absence in the free-living ciliated protozoa Tetrahymena thermophila suggests that 
acquisition of the characteristic domain architectures occurred after the apicomplexan 
lineage split from the ciliates, suggesting that the proteins are unique to the Apicomplexa 
(Templeton et al., 2007; Templeton et al., 2010). The conservation of LAPs across the 
entire phylum implies that the proteins may be involved in conserved apicomplexan 
processes, but this has yet to be confirmed.  
 
Investigations into the LAP family have focused on Plasmodium, but a limited number of 
studies have been performed on the protein family in Cryptosporidium, Toxoplasma and 
Babesia. In Cryptosporidium, expression of an ortholog of LAP2, CpCCp1 (also termed 
Cpa135 or SA35 antigen) has been detected by immunolocalisation studies in the apical 
region of sporozoites, from where the protein appears to be secreted (Tosini et al., 2004). 
Accordingly, localisation in micronemes and roles in invasion have been proposed 
(Tosini et al., 2004). Expression in the sporozoite have similarly been indicated in 
Toxoplasma, where members of the protein family (TgSR1, TgSR2, TgCCp5A and 
TgCCp5B) have been shown by immunofluorescent assays to be localised in unknown 
vesicles of sporozoites (Tosini et al., COST Action Conference, May 2008). Meanwhile, 
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initial studies on the proteins in Babesia show that, as in Plasmodium, expression of the 
proteins begins in gametocytes. 
 
A number of studies have examined expression and localisation of LAPs/PfCCps in P. 
falciparum gametocytes and gametes (Delrieu et al., 2002; Pradel et al., 2004; Pradel et 
al., 2006; Scholz et al., 2008). These indicate by immunofluorescence that the proteins 
are expressed during gametocyte maturation, are  secreted into the PV surrounding the 
intra-erythrocytic parasite, and are released or associated with the surface of the 
extracellular gamete, with little detectable protein in fertilised cells (Delrieu et al., 2002; 
Pradel et al., 2004; Pradel et al., 2006; Scholz et al., 2008). It is suggested that the 
proteins form a matrix around macrogametes, possibly acting to enhance fertilisation by 
aiding adherence or perhaps by forming a protective barrier against factors in the blood 
meal (Pradel et al., 2006; Scholz et al., 2008). The molecular interactions between the 
PfCCp proteins have since been investigated by affinity binding studies using 
recombinant proteins comprising selected adhesion domains (Simon et al., 2009). 
Immunoblot analysis of eluted protein complexes revealed interactions between the 
LCCL domains of all PfCCp proteins, the SR domains of PfCCp3 (PbLAP1), and the 
ApicA, NEC, and discoidin domains of PfCCp1 and PfCCp2 (Simon et al., 2009). 
Furthermore, interactions between PfCCps and sexual stage TBV candidates Pfs48/45 
and Pfs230 have been detected by co-immunoprecipitation assays on gametocyte lysates, 
and with Pfs25 on activated gametocytes. This has led to the hypothesis that the PfCCps 
form a large multiprotein complex on the surface of gametes with other sexual stage 
adhesive proteins (reviewed by Kuehn et al., 2010). 
  
Gene knockout studies have been performed in both P. berghei and P. falciparum, 
revealing that — despite their predicted function in gametes — parasites in which 
individual lap gene is knocked out undergo fertilisation and appear function normally 
until sporulation. In P. berghei, the absence of Pblap results in defects in the 
developmental processes associated with cell division in the oocysts/sporozoite formation 
(Claudianos et al., 2002; Raine et al., 2007; Ecker et al., 2008). Meanwhile, in P. 
falciparum, ∆Pfccp disruption leads to deficiency in the transition of sporozoites from 
oocysts to salivary glands (Pradel et al., 2004; Scholz et al., 2008). Following up on these 
gene knockout studies, Lavazec et al. (2009) generated double gene knockout parasite 
lines of Pblap1/Pblap2 and Pblap2/Pblap6, the phenotypes of which appeared 
indistinguishable from the single gene knockouts (Lavazec et al., 2009). Both individual 
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and double gene knockout studies thereby clearly indicate roles in sporogonic 
development. This is supported by proteomic studies in P. berghei, by which PbLAPs1-5 
have been detected in ookinetes, whilst PbLAP1 and PbLAP6 have also been detected in 
sporozoites (Hall et al., 2005).  
 
A main aim of the studies in this chapter was to investigate the cellular localisation of 
LAPs using P. berghei to study both the sexual and sporogonic stages of development. 
While the antibodies described in the previous chapter are useful for immunolocalisation 
studies, it is realised that their application may be limited due to problems associated with 
possible fixation artefacts, cross-reactivity and poor specificity. Furthermore, the 
antibodies generated do not permit the visualisation of live cells. An alternative approach 
for studying localisation is to ‘tag’ the gene product. This can be achieved through two 
approaches: an epitope tag, e.g. Myc, will render the tagged protein immunoreactive to an 
already existing, commercially available and well-characterised antibody (Jarvik, 1998), 
whilst the use of a fluorescent fluorophore, e.g. GFP, enables the direct visualisation of 
tagged proteins, without the addition of antibodies, providing the particular benefit of 
facilitating the visualisation of molecules within living cells (reviewed by Gubbels, 
2004). Transfection can be routinely performed in P. berghei and the feasibility of 
integrating gene targeting vectors into Pblap coding regions is demonstrated by the 
successful disruption of Pblap1,2,4,5 and 6 (Trueman et al., 2004; Raine et al., 2007; 
Ecker et al., 2008). With this in mind, chief aims of this chapter were to generate GFP 
and/or Myc-tagged versions of Pblaps and to perform cellular localisation studies on 
sexual and sporogonic stages of P. berghei, using both tagged transgenic parasites and 
antibodies generated in Chapter 3. It was intended that these results, and the outcome of 
further investigations based upon them, would provide a better understanding of the 
biological function of LAPs and help to decipher their suitability as TBV candidates.  
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4.2. Generation of PbLAP-GFP/Myc tagged parasites 
Plasmids encoding c-Myc or eGFP and a modified T. gondii dihydrofolate 
reductase/thymidylate synthase gene (Tgdhfr/ts) as a selectable marker were used for the 
generation of constructs aimed at tagging endogenous Pblap gene products at their C-
terminal end. GFP tagging provides the considerable advantage of fluorescence, which 
may facilitate a direct method to define localisation, but it is known that the bulky size of 
GFP can cause mislocalisation through steric hindrance or interruption of critical 
localisation or retention signals (Huh et al., 2003). Constructs aimed at the integration of 
c-Myc tagged transgenes were therefore generated in parallel, since the smaller size of c-
Myc increases the chance that a protein carrying the tag will retain normal structure and 
function (Jarvik et al., 1998).  
 
The adopted cloning strategy (see methods) was designed such that following 
transfection, the linearised vector integrates into the targeted locus by single homologous 
recombination, resulting in the replacement of the C-terminal gene portion of the 
endogenous gene with the GFP/myc recombinant. Successful integration thereby results 
in tagging of the endogenous gene copy, with the full-length gene being expressed with a 
3’ eGFP or c-Myc tag. The C-terminal regions of each Pblap were cloned into GFP/myc 
tagging vectors following KpnI/ApaI digests. Plasmid preparations were analysed by 
restriction digest and DNA sequencing to confirm the presence of a correct insert in 
frame with the GFP/myc tag: constructs encoding Pblap C-terminal fragments in frame 
with a GFP tag were successfully generated for Pblap4 and Pblap5 and constructs 
encoding Pblap C-terminal fragments in frame with a c-Myc tag were produced for 
Pblap1, Pblap3, Pblap4, Pblap5 and Pblap6. Plasmids are referred to as plap4-gfp, 
plap5-gfp, plap1-myc, plap3-myc, plap4-myc, plap5-myc and plap6-myc.  
 
A restriction site unique to the lap gene fragment (absent from the vector) was utilised to 
generate linearised plasmid DNA for transfections. Plasmids plap1-myc, plap4-gfp, 
plap4-myc and plap6-myc were digested with BsmI; plap3-myc with AarI; plap5-gfp and 
plap5-myc with SpeI. Linearised and purified vector constructs were transfected into 
wild-type P. berghei parasites by electroporation of P. berghei schizonts: the transfection 
of purified schizonts, cultured in vitro, has been demonstrated to be more successful than 
transfection of mixed blood stages (van Dijk et al., 1995). Following transfection, 
parasites were allowed to invade fresh red blood cells by incubation in naïve mouse blood 
for 20-30 minutes at 37°C, after which blood was injected into donor mice. Transgenic 
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parasites were selected by treatment of mice with the antimalarial drug pyremethamine. 
Expression of the T. gondii dihydrofolate reductase/thymidylate synthase gene (Tgdhfr/ts) 
renders transgenic parasites resistant to the drug. Parasitemias, which were monitored by 
Giemsa-staining of mouse tail blood smears, were observed in mice infected with plap4-
gfp, plap5-gfp, plap3-myc, plap4-myc and plap5-myc transfected parasites, but not for 
plap1-myc or pblap6-myc. Drug-resistant parasites were collected by removal of blood 
from mice, genomic DNA was extracted and integration of the construct DNA was 
analysed by PCR (Figure 4.1):  
- Wild-type (wt) gene fragments were amplified using primers specific for the 
target Pblap.  
- A combination of the 5’ primer used for amplification of the 5’ region of 
homology, and a GFP/Myc or Tgdhfr/ts reverse primer was used to amplify the 
plasmid DNA intended for integration (may be in the form of an episome, 
existing independently as a plasmid). 
- Integration was detected using a combination of a primer binding the upstream of 
the 5’ region of homology, and a GFP/Myc or Tgdhfr/ts reverse primer. 
 
The majority of transfections were unsuccessful as assessed by PCR. This could perhaps 
be related to the schizont preparations used for transfections, since parasitaemia of blood 
used at culture set-up, schizont viability, and the number of schizonts used per 
transfection have been identified as key factors correlated with the successful generation 
of transgenic parasites (A. Ecker PhD thesis, 2007). Transfection using the Amaxa 
Nucleofector system has increased the efficiency of transfection, but still several attempts 
are often required before a transgenic line can be generated.   
 
Integration appeared successful for Pblap4 and Pblap5, although in each case, DNA from 
the wild-type gene could be amplified more readily (Figure 4.1). PCRs also indicated that 
a large proportion of the construct DNA may have been present as episomal plasmids. 
Re-ligation of the linearised plasmid resulting in episomal contamination and generation 
of resistant parasites without integration is a frequent problem associated with 
transfections and is one that is not easily overcome. Indeed, it is suggested that the best 
strategy to deal with episomes is to repeat transfections until a clean population is 
obtained (A. Ecker PhD thesis, 2007).  
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Figure 4.1. Diagnostic PCR for the detection of Pblap-tagged transgenic parasites   
PCR products were amplified from genomic DNA extracted from parasites surviving pyremethamine –based 
drug-selection using primer sets represented in panel B. Diagnostic PCRs positive (+) and negative (-) for 
integration (indicating one successful and one unsuccessful transfection) are shown for both lap4-GFP and 
lap4-Myc. Fragments present in the wild-type gene were amplified using primers specific for Pblap4 (primer 
pair a+b). The presence of products from primer pair c+d indicated presence of the introduced vector, but not 
necessarily integrated into the wild-type gene locus. Integration was determined using primer pair a+d 
(forward primer binding upstream of the 5’ region of homology and a GFP or Myc reverse primer products 
(indicated with an asterisk) with which a product was only amplified if integration had been successful. 
Approximate DNA band size in base pairs is indicated. 
 
 
 
 
 
 
 
 137 
Populations of transgenic parasites, in which integrated construct DNA had been detected 
by PCR, were grown under drug selection in mice and immunoblotting and 
immunofluorescence analyses were performed on mixed blood stages/gametocytes and 
cultured ookinetes using commercial anti-GFP or anti-Myc antibodies to determine if the 
expression of LAP-GFP or LAP-Myc fusion proteins could be detected (Figure 4.2). To 
detect GFP fusion proteins, immunoblots were performed on lysates from PbLAP4-GFP, 
PbLAP5-GFP and PbConGFP parasites. ConGFP parasites, which constitutively express 
GFP throughout their entire life cycle (Franke-Fayard et al., 2004), were used as a positive 
control: a protein consistent with the expected size for GFP (30 kDa) was detected in 
immunoblots using anti-GFP antibodies. In contrast no bands were recognised in PbLAP4-
GFP and PbLAP5-GFP lysates (Figure 4.2A). Blood-stage parasites and parasites from 
ookinete cultures were also observed live under a fluorescent microscope to see if GFP 
fluorescence could be detected, and immunofluorescence analyses were performed on 
fixed cells using anti-GFP antibodies. Neither however revealed fluorescence above 
background level for any stages analysed (data not shown). Immunoanalyses were 
similarly performed using anti-Myc antibodies to see if PbLAP4-Myc and PbLAP5-Myc 
fusion proteins could be detected. A transgenic parasite line in which P. berghei gene 
number PB000814.03.0 (referred to here as Pb814) is tagged with a C-terminal Myc 
epitope (Dr. M. Delves, unpublished) was used as a positive control. Immunofluorescence 
assays on paraformaldehyde-fixed mixed blood stages, zygotes, ookinetes and sporozoites 
revealed that, whilst Pb814-Myc localisation could be observed in zygotes and ookinetes, 
no LAP-Myc fusion proteins could be detected in any life cycle stage examined. A 
representative result, in which Myc labelling is detected in Pb814-Myc zygotes, but is 
absent from LAP4-Myc and LAP5-Myc parasites, is shown in Figure 4.2. The cellular 
localisation of Pb814-Myc is described further in 4.5.2. 
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Figure 4.2. Analysis of lapGFP and lapMyc transgenic parasites by immunodetection  
A) lap4GFP, lap5GFP and conGFP gametocytes were extracted by Nycodenz separation of blood collected 
from infected mice. Parasites were lysed and proteins were separated by SDS-PAGE under reducing 
conditions. Proteins were transferred to a nitrocellulose membrane and probed with rabbit anti-GFP antibodies 
(dilution 1:1000). Binding was detected using HRP-conjugated anti-rabbit IgG (dilution 1:10000) and ECL 
chemiluminescence. Molecular weight marker is indicated in kilo Daltons. A band at approximately 30 kDa 
was detected in conGFP parasite lysates, whilst GFP was undetectable in lapGFP parasites. 
B) Immunofluorescence analyses were performed on lap4Myc, lap5Myc and 814-Myc parasites in 
paraformaldehyde-fixed blood smears. Cells were incubated with rabbit anti-Myc antibodies (1:200) and 
antibody binding to Myc epitopes was detected through use of AlexaFluor-488 anti-rabbit IgG secondary 
antibody (1:1500).  Fluorescence was noticeable in 814-Myc zygotes (bottom panel), but not in lap4Myc or 
lap5Myc gametocytes (upper panels).  
 
Table 4.1. Summary of attempts to generate GFP/Myc-tagged versions of PbLAPs 
 
 
 
 
 
 
 
 
 
 
 
 
Number of 
transfections 
Drug –
resistant 
parasites Integration Immunodetection 
 
lap1 MYC 2  - - 
 
lap3 MYC 2    
 
lap4 GFP 3    
 
lap4 MYC 3    
 
lap5 GFP 3    
 
lap5 MYC 3    
 
lap6 MYC 2  - - 
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Reasons for as to why GFP or Myc fusion proteins could not be detected are unknown. 
However, since the generation of Pblap knockout parasites demonstrated that it is possible 
to introduce recombinant DNA into the Pblap gene loci and select for transgenic parasites 
using pyremethamine, perhaps the most likely explanations are as follows: 
o Tagged proteins may be expressed at levels that are too low to enable their 
detection by immunoblot or immunofluorescence: perhaps due to misfolding of 
the fusion protein and its subsequent degradation. 
o Proteins may be incompletely expressed, and since tags were introduced at the    
C-terminal end, fusion proteins are not expressed. 
o The GFP or myc protein may be unstable in the cellular environment within which 
it is expressed. 
o Incorrect integration of the vector, for example, leading to frameshift mutations 
resulting in disruption of the protein. Phenotypic examination of transgenic 
parasites indeed suggested that DNA integration into lap4 resulted in gene 
disruption: the transgenic lap4 parasites failed to sporulate as is typical of ∆Pblap 
parasites. Other transgenic parasites however appeared phenotypically normal. 
 
 140 
4.3 Cross-reactivity/specificity of antibodies 
Since it was not possible to determine the subcellular localisation of LAPs from attempts 
to tag the proteins, cellular localisation studies focused on antibody detection utilising 
anti-LAP antibodies as described in Chapter 3. Results in Chapter 3 demonstrated that 
antisera generated against the SRCR domain of LAP1, the PA14 domain of LAP3 and the 
LCCL domains of LAPs 4 and 6 were all able to detect endogenous P. berghei 
gametocyte proteins in IFAs. To determine their suitability for use in cellular localisation 
studies, antibody cross-reactivity/specificity was examined using Pblap gene knockout 
parasites (available for all but Pblap3). Each gene was disrupted by integration of a gene 
targeting construct containing the Tgdhfr selectable marker by double homologous 
crossover at the 5’-UTR and 3’-UTR regions of the wild-type gene locus; ∆Pblap1 
(Trueman et al., 2004); ∆Pblap2, ∆Pblap4, and ∆Pblap6 (Raine et al., 2007); ∆Pblap5 
(Ecker et al., 2008). 
  
Immunoblots and immunofluorescence assays demonstrated that antibodies directed 
against LAP1SRSR were specific towards endogenous PbLAP1, whilst antisera that were 
raised against the LCCL domains of LAP4 and LAP6 cross-reacted with proteins other 
than the target antigens (Figure 4.3 and 4.4). In immunoblots anti-LAP1 antibodies were 
readily immunoreactive with wild-type P. berghei gametocyte lysates, whilst they did not 
detect protein in ∆Pblap1 gametocyte lysates, clearly indicating that the antibodies 
specifically react with LAP1 (Figure 4.3A). This specificity was robustly supported by 
immunofluorescence studies (Figure 4.3B). In contrast, anti-LAP4 and anti-LAP6 
antibodies appeared partly non-specific since antibody staining could also be detected on 
the respective ∆Pblap4 and ∆Pblap6 parasites (Figure 4.4 and 4.5). In wild-type 
gametocytes, staining appeared punctate suggesting cytoplasmic labelling. A similar 
labelling pattern was detected in knockout parasites, all-be-it at a lower intensity of 
fluorescence (Figure 4.4) in accordance with absence of the target antigen and a degree of 
cross-reactivity against another, similarly localised, gametocyte protein.  
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Figure 4.3. Specificity of anti-LAP1 antiserum  
For immunoblot analyses (A) wild-type (wt) and ∆lap1 P. berghei gametocyte lysates were prepared from 
gametocyte-enriched samples: infected mice were treated with sulphadiazine to kill asexual blood stages and 
parasites were subsequently purified by Nycodenz- density. Purified parasites were separated by SDS-PAGE 
(8% gel, reducing conditions). Proteins were transferred to nitrocellulose membrane and membranes were 
probed with αLAP1 (1:100 dilution) and then re-probed with an anti-tubulin antibody (1:10,000 dilution) as a 
loading control (lower panel). A band at approximately 150 kDa, present in wt and absent in ∆lap1, 
corresponds to the predicted size of PbLAP1 and indicates αLAP1 specificity. The specificity of αLAP1 was 
confirmed by immunofluorescence analysis (B). Blood smears from wild-type (wt) and ∆Pblap1 infected 
mice were fixed using 4% paraformaldehyde and cells were incubated with anti-LAP1 serum at a 1 in100 
dilution. Antibody labelling was detected with Alexa Fluor 448 anti-mouse IgG, at a dilution of 1 in 2,000 
and cells were co-stained with DAPI nuclear stain (blue). Scale bar represents 10 µm. 
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Figure 4.4. Immunofluorescence analyses indicating cross-reactivity of αLAP4 and αLAP6 antisera 
against gametocytes. Immunofluorescence analyses were performed on paraformaldehyde-fixed P. berghei 
blood stages of ∆lap1, ∆lap4, ∆lap6 and wild-type (wt) parasites. Cells were labelled using αLAP antibodies 
at a dilution of 1 in 100 and Alexa Fluor 448 anti-mouse IgG at a dilution of 1 in 2,000. DAPI (blue) was 
used to stain nuclei. Whilst antiserum against LAP1SRSR (αLAP1) was negative for immunoreactivity 
against the knockout ∆lap1, both αLAP4 and αLAP6 labelled gametocytes of the corresponding knockouts 
∆lap4 and ∆lap6, although at a lower intensity than labelling of wild-type (wt) gametocytes. Scale bar 
represents 2 µm. 
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Anti-LAP6 antibodies also cross-reacted with asexual blood stages in a non-specific 
manner (Figure 4.5). Co-labelling experiments in which parasites were labelled with anti-
formin antibodies (a gift from J. Baum; Baum et al., 2008b) revealed a localisation at the 
periphery of merozoites contained in schizonts and at the apical end tip of released 
merozoites (Figure 4.5). Formin plays an important role in actin polymerisation and 
localises to the parasite/erythrocyte moving junction during invasion (Baum et al., 
2008b). It is possible that the observed labelling with anti-LAP6 antisera at the apical end 
tip of merozoites could be indicative of cross-reactivity with proteins involved in 
invasion.    
Figure 4.5. Immunofluorescence analyses indicating cross-reactivity of αLAP6 antibodies against 
asexual blood stages. Immunofluorescence analyses were performed on paraformaldehyde-fixed P. berghei 
blood stages of ∆lap6 and wild-type (wt) parasites. Cells were labelled using αLAP antibodies at a dilution of 
1 in 100 and Alexa Fluor 448 anti-mouse IgG at a dilution of 1 in 2,000. DAPI (blue) was used to stain 
nuclei. A) Whilst antiserum against LAP1SRSR (αLAP1) was negative for immunoreactivity against asexual 
blood stages, αLAP6 antiserum was found to non-specifically bind asexual blood stages, labelling the tips of 
both wild-type (wt) and ∆lap6 merozoites. Scale bar represents 2 µm. B) Parasites were labelled at the 
periphery of the ring of developing merozoites and the apical tips of released merozoites, as demonstrated by 
co-localisation with αFormin. In co-labelling studies αFormin was used at a dilution of 1 in 50 with Alexa 
Fluor 546 anti-rabbit IgG at a dilution of 1 in 2,000. Scale bar represents 1 µm. 
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The cross-reactivity of anti-LAP4 and anti-LAP6 antisera could be attributed to antibody 
recognition of related antigens bearing common epitopes. Both anti-LAP4 and anti-LAP6 
antisera were raised against protein regions containing an LCCL domain. Since LCCL 
domains are characteristic features of all but one LAP, with four in PbLAP1, and a single 
LCCL domain in each of PbLAP2, 3, 4 and 6, the  Average sequence conservation 
between all PbLAP LCCL domains is 69% and may each maintain a common native 
structure though the presence of conserved cysteine residues (Figure 4.6).  It is also 
possible for antibodies to react against quite unrelated proteins. 
 
 
 
 
 
 
Figure 4.6 Amino acid conservation between PbLAP LCCL domains 
Multiple alignment of all predicted LCCL domains of P. berghei LAPs performed using T-COFFEE, version 
7.71: http://tcoffee.crg.cat/apps/tcoffee/index.html. Sequences are indicated in rows for each domain: LAP1 
LCCL1-4; LAP2 LCCL; LAP3 LCCL; LAP4 LCCL and LAP6 LCCL, with the final row representing the 
overall consensus (Cons). Columns are aligned with similarities between amino acids indicated by a coloured 
output, whereby red highlighted residues indicates a high identity, orange corresponds to average and green 
poor conservation. Asterisks indicate highly conserved residues. The multiple alignment highlights a 
conserved central core.   
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4.4. Studies on the expression and localisation of LAP1 during sexual and 
sporogonic development  
 
4.4.1. Expression in P. berghei gametocytes is female-specific and is not 
dependent on PbLAP2, PbLAP4, PbLAP5 or PbLAP6 
Previous studies provide clear indications that LAP expression is specific to female 
gametocytes. In a proteomic study of separated male and female P. berghei gametocytes, 
PbLAP1, PbLAP2 and PbLAP3 were detected in female but not male gametocytes (Khan 
et al., 2005). The expression of GFP under the control of Pblap1 and Pblap2 promoters 
confirmed female specificity (Khan et al., 2005). Furthermore, experiments with ∆Pblap 
parasites indicate by genetic crosses that PbLAP1, PbLAP2, PbLAP4 and PbLAP6 are 
female-inherited (Raine et al., 2007). In contrast, expression of the protein family in P. 
falciparum has been detected by immunofluorescence in both female and male 
gametocytes (Scholz et al., 2008), although PfCCp labelling has not been observed in 
exflagellating microgametes. Studies in P. falciparum have also demonstrated that in 
parasites in which Pfccp3(lap1) is knocked down, the expression of PfCCp1(LAP2) and 
PfCCp2(LAP4) is not detected by immunoblotting — indicating that expression of LAP2 
and LAP4 is dependent on LAP1 expression (Pradel et al., 2006) and suggesting that other 
members of the protein family could perhaps be similarly co-dependently expressed.   
 
In order to conclusively distinguish between male and female gametocytes, co-staining 
experiments were performed using an antibody against P. berghei male development 
gene-1 (MDV1) as a cellular marker (Lal et al., 2009a). MDV1 (also known as PEG3) is 
upregulated in developing gametocytes and is associated with the osmiophillic bodies and 
membranous structures of gametocytes (Silvestrini et al., 2005; Furuya et al., 2005). 
Recent immunolocalisation analyses demonstrate that antibody staining patterns appear 
markedly different in male versus female gametocytes. A punctate localisation is detected 
throughout the cytoplasm of the female gametocyte (Lal et al., 2009a) while staining is 
confined in one or a few large spots in male gametocytes. The identity of the subcellular 
structures responsible for the localised staining pattern of the MDV1 antibodies is 
unknown, but allows for confirmation of the distinction between male and female 
parasites. Co-staining experiments with rabbit MDV1 antibodies and mouse αLAP1 
indeed confirmed LAP1 to be female specific (Figure 4.7A). Further studies were 
performed to compare LAP1 expression in wild-type (wt), ∆Pblap1, ∆Pblap2, ∆Pblap4, 
∆Pblap5 and ∆Pblap6 female gametocytes (Figure 4.7B). Whilst previous studies in P. 
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falciparum (Pradel et al., 2006) have demonstrated that the expression of PfCCp1(LAP2) 
and PfCCp2(LAP4) is dependent on the presence of PfCCp3(LAP1), the converse does 
not occur in P. berghei: LAP1 expression was found to be expressed in ∆Pblap2, 
∆Pblap4, ∆Pblap5 and ∆Pblap6 gametocytes whilst absent from ∆Pblap1 gametocytes.  
 
 
 
 
Figure 4.7. Expression in gametocytes is female-specific and is not dependent  on PbLAP2, PbLAP4, 
PbLAP5 or PbLAP6. Immunofluorescence analyses were performed on paraformaldehyde-fixed blood 
smears containing wild-type P. berghei gametocytes. A) Antibody labelling using αLAP1 demonstrates 
female specific expression of LAP1 in P. berghei gametocytes.  Labelling using αLAP1 was detected using 
Alexa Fluor 448  anti-mouse IgG (green). Cells were co-labelled using antibodies against P. berghei MDV1: 
detected using Alexa Fluor 546 anti-rabbit IgG (red). B) Fixed IFA on wt, Pblap1, ∆Pblap2, ∆Pblap4, 
∆Pblap5 and ∆Pblap6 female gametocytes. Cells were stained as above with anti-LAP1 (green) and anti-
MDV (red) and counterstained with DAPI (blue). Scale bar represents 2 µm. 
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Interestingly, LAP1 antibody staining patterns frequently (but not exclusively) appeared 
distinct from the localisation of MDV1, with LAP1 often found predominantly at one side 
of the  gametocyte and MDV1 occupying the other (Figure 4.7B).  The apparently 
separate subcellular compartments/vesicles containing MDV1/LAP1 is consistent with 
the different functions. Gene disruption of Pbmdv1 indicates a role in the production of 
fertile female gametes and ookinete formation: Lal et al. (2009) calculated a 27% 
reduction in the proportion of female gametocytes activated and 83% reduction in the 
conversion of female gametes to ookinetes in ∆Pbmdv1 compared to wt P. berghei 
parasites. In contrast, the phenotypes of ∆Pblap parasites do not manifest until the late 
oocyst in which a deficiency in sporulation is observed (Ecker et al., 2008; Raine et al., 
2007; Trueman et al., 2004).  
 
4.4.2. Cross reactivity of anti-PbLAP1 antibodies with P. falciparum and antibody 
labelling patterns in during gametogenesis 
Considering the sequence similarities between PbLAP1 and its P. falciparum ortholog 
PfCCp3, immunofluorescence experiments were performed to assess the potential for 
cross-reactivity of anti-PbLAP1 antisera on P. falciparum parasites. Cultured P. 
falciparum gametocytes (provided by A. Blagborough, A. Talman or M. Delves), were 
smeared onto a slide, fixed in 4% formaldehyde and immunoreactivity of anti-PbLAP1 
antisera was tested. The antisera labelled cytoplasmic regions of P. falciparum female 
gametocytes, but not males (Figure 4.5A). Serum from an unimmunised mouse was used 
as a negative control and showed no labeling (data not shown). The demonstration of 
cross-reactivity enabled comparative analyses to be made. Firstly a comparison of anti-
PbLAP1 staining patterns on P. berghei versus P. falciparum, to assess if there a 
difference between P. falciparum and P. berghei LAP localisation. Secondly a 
comparison of anti-PbLAP1 versus anti-PfCCp staining patterns on P. falciparum, to 
assess if  anti-PfCCp antibodies label gametocytes differently. 
 
Antibody staining appeared markedly reduced in activated gametocytes compared to pre-
activation in both species (Figure 4.7B and 4.7C). Antisera against PfCCp3 (LAP1), 
PfCCp2 (LAP4) and PfCCp4 (LAP6), generated and provided by Pradel et al., were used 
in parallel IFA experiments. These demonstrated that antisera against PfCCp3 (LAP1) 
and PfCCp2 (LAP4) label parasites in a manner indistinguishable from that observed with 
anti-PbLAP1 antisera (Figure 4.7D and 4.7E). In contrast, antiserum against PfCCp4 
(LAP6) demonstrated an association with the parasite plasma membrane as previously 
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reported by Scholtz et al. (2008) and were the only to label activated male parasites 
(Figure 4.8F).  
 
Figure 4.8. Cross reactivity of anti-PbLAP1 antiserum with P. falciparum and antibody labelling 
patterns in gametocytes/gametes 
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Immunofluorescence analyses were performed on paraformaldehyde-fixed cells from a P. falciparum 
gametocyte culture (A, B, D, E and F) and on paraformaldehyde-fixed cells collected from the blood of a        
P. berghei-infected mouse (C). For each assay in A-C, αLAP1 antisera was used at a 1:100 dilution and 
labelling was detected with AlexaFluor-448 anti-mouse IgG secondary antibody at a dilution of 1:2,000.                             
In D-F, mouse antisera raised against the P. falciparum proteins PfCCp3, PfCCp2 and PfCCp4 (orthologs of 
PbLAP1, PbLAP4 and PbLAP6 respectively) were used to stain P. falciparum gametocytes and gametes. 
αPfCCp2 and αPfCCp3 antisera were used at a dilution of 1:100 and αPfCCp4 antiserum was used at a 
dilution of 1:50. In each case, antibody labelling was detected using AlexaFluor-448 anti-mouse IgG at a 
1:2,000 dilution. A) Immunofluorescence analysis using anti-PbLAP1 antisera on P. falciparum demonstrated 
immunoreactivity against female P. falciparum gametocytes. B) LAP1 labelling patterns in P. falciparum 
gametocytes undergoing gametogenesis were observed following gametocyte activation by suspension in 
ookinete medium. The top panel is representative of staining patterns on unactivated gametocytes and the 
three panels underneath this are of ‘rounding up’ gametes at various stages post-activation. C) LAP1 labelling 
patterns in unactivated P. berghei gametocytes and gametes, following activation by suspension in ookinete 
medium. D) Labelling of PfCCp3 (LAP1 ortholog) in unactivated P. falciparum gametocytes and gametes 
showing localisation at the poles of gametocytes and reduced levels of expression in gametes. E) Localisation 
of PfCCp2 (LAP4 ortholog) appears similar to that of anti-PfCCp3; labelling is detected at the poles of 
gametocytes whilst expression seems reduced in gametes. F) PfCCp4 localisation appears markedly different; 
labelling appears associated with the periphery of the parasite in both gametocytes and gametes, with 
expression also detected in activated male gametocytes. Scale bar represents 2 µm. 
 
Gametocytes of P. berghei and P. falciparum differ markedly in their morphology:         
P. falciparum gametocytes are crescentic shaped possess a subpellicular complex and 
reside in an extensive PV. In contrast, P. berghei gametocytes are round in shape, lack a 
subpellicular complex and fill almost the entirety of the iRBC. Considering these 
differences, the observed PbLAP1 staining patterns on both P. berghei gametocytes 
(punctuate across the entire cytoplasm) and P. falciparum gametocytes (towards the poles 
of the cell) appears consistent with an association with the ER or a vesicular network of 
the endomembrane system, in accordance with entry into the secretory pathway. In each 
species, antibody staining appeared markedly reduced in female gametes (Figure 4.8B 
and 4.8C), complying with the observation that expression of the proteins ceases after 
fertilisation and the suggestion that the proteins are secreted from the parasite (Pradel et 
al., 2004; Pradel et al., 2006).  
 
In parallel assays, immunofluorescent labelling of PfCCp3 (LAP1 ortholog), PfCCp2 
(LAP4 ortholog) and PfCCp4 (LAP6 ortholog) demonstrated that antisera against 
PfCCp3 (LAP1) and PfCCp2 (LAP4) label parasites in a manner indistinguishable from 
that observed with anti-PbLAP1 antisera (Figure 4.8D and 4.8E). In contrast, antiserum 
against PfCCp4 (LAP6) demonstrated an association with the parasite plasma membrane 
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as previously reported by Scholtz et al. (2008). Interestingly only anti-PfCCp4 serum was 
found to label activated male parasites (Figure 4.8F). The possible association of PfCCp4 
(LAP6) with the plasma membrane could have considerable implications for TBV 
development since based on antibody staining patterns it would appear to suggest that 
PfCCp4 (LAP6) as the most favourable target, although no transmission-blocking effects 
were detected when anti-PbLAP6 sera was tested in transmission-blocking assays 
(Chapter 3).   
 
4.4.3. Immunodetection of LAP1 in P. berghei zygotes 
Despite the observed reduction in PbLAP1 antibody staining of female gametes in both P. 
berghei and P. falciparum follows, further experiments revealed that LAP1 is expressed 
post-fertilisation in the developing zygote. P. berghei zygotes were cultured in vitro from 
gametocyte-infected blood and immunofluorescence assays were performed on samples 
containing zygotes (from 1 hour post activation). Co-staining with antibodies against 
MDV1 allowed developing zygotes to be distinguished from unfertilised gametocytes. 
Four hours after activation, the antibody staining pattern of MDV1 localisation changes 
dramatically from a punctuate distribution, to a ‘patch’ on the surface of the zygote (Lal 
et al., 2009). In parasites identified with this distinct anti-MDV1 antibody-labelling 
pattern, LAP1 antibody staining appeared punctuate across the parasite (Figure 4.9).  
 
Whilst it has been suggested that the apparent reduction in LAP/CCp represents secretion 
of the proteins from the cell, it could alternatively be explained by i) inhibition of 
expression or protein degradation, thereby reducing the amount of protein; or ii) a block 
in epitope access/conformational change in epitope(s), preventing antibody binding. The 
immunodetection of the protein again in the developing zygote could be explained by 
these effects being temporary in nature. Renewed levels of expression post-fertilisation 
could also represent the translation of a sub-population of previously translationally 
repressed lap mRNAs. In this way the female gametocyte may provide lap mRNA which 
is required for further zygote development, providing a possible explanation for the 
essential contribution of the female in lap function. Indeed there is evidence to suggest 
that Pblap4, Pblap5, and Pblap6 are regulated by DOZI (Development of Zygote 
Inhibited) RNA helicase, which is responsible for repression of translation of certain 
genes until after fertilisation. In ∆Pbdozi parasites, mRNAs that in wild-type parasites are 
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translationally repressed become degraded. The group of identified down-regulated genes 
includes Pblap4, Pblap5, and Pblap6, but not Pblap1 (Mair et al., 2006).  
 
 
Figure 4.9. Immunofluorescent labelling of PbLAP1 during zygote development  
Mice were infected with wild-type P. berghei parasites. Gametocyte-containing blood was removed and 
added to ookinete culture medium. Cultures were incubated at 19°C and samples removed between 4 and 6 
hours post activation and fixed using 4% paraformaldehyde. Immunofluorescence assays were performed 
using anti-PbLAP1 antisera (αLAP1, 1:100; Alexa 448, 1:2,000) and anti-PbMDV-1 antibodies (αMDV, 
1:1,000; Alexa 546, 1:2,000).  
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4.4.4. PbLAP1 is expressed in P. berghei ookinetes, localising to the crystalloids 
Intriguingly, imaging of LAP1 localisation within ookinetes revealed that fluorescence 
was concentrated intracellularly in one or two large circular spots, with overlay images of 
fluorescence and light microscopic images demonstrating that the antiserum stained 
pigmented areas (Figure 4.9A), corresponding to intracellular compartments known as the 
crystalloids. Immunoblot analysis confirmed the specificity of anti-LAP1 antisera on 
ookinete lysates and demonstrated the expression of LAP1 in ∆Pblap2, ∆Pblap4, 
∆Pblap5 and ∆Pblap6 ookinetes (Figure 4.10B). At the ultrastructural level, crystalloids 
appear as a cluster of electron-dense particles with no visible membrane (Figure 4.10C). 
Crystalloids have been observed by electron microscopy in the sporogonic stages of 
several species of Plasmodium and other haemosporidia (including Haemoproteus and 
Leucocytozoon species) since the 1960s. Among the first descriptions noted the 
resemblance to viral aggregation, comprising virus-like particles (Garnham et al., 1962; 
Das Gupta,1968; Terzakis, 1969; Terzakis et al., 1976). The possibility of a viral nature 
was doubted however due to the transient nature of the crystalloid, appearing only in 
certain life cycle stages, and was confirmed by the absence of DNA or RNA in the 
crystalloid inclusions of L. simondi (Desser et al., 1971). Various speculations have been 
made regarding their nature (discussed later in this thesis) but functions remain elusive. 
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Figure 4.10. PbLAP1expression and localisation in P. berghei ookinetes 
A) Immunofluorescence analyses were performed on paraformaldehyde fixed ookinetes, grown in culture 
from gametocyte-containing mouse blood: mice were infected with wild-type (wt) or lap1 P. berghei 
parasites, gametocyte-containing blood was removed, added to ookinete culture medium, and cultures were 
incubated at 19°C for 24 hours. Immunofluorescence assays were performed using anti-PbLAP1 antisera 
(αLAP1, 1:100; Alexa Fluor 448 anti-mouse IgG, 1:2,000). Scale bar represents 2 µm. B) Western blot 
analysis of wt and lap gametocyte lysates probed with αLAP1 (1:100). Antibody binding was detected by 
use of a secondary antibody anti-mouse IgG (1:10,000) and ECL chemiluminescence. C) Electron 
micrograph (x45,000) of P. gallinaceum ookinete crystalloid (CR) taken from Mehlhorn et al (1980).  
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4.4.5 Immunoreactivity of anti-LAP1 antibodies against P. berghei sporozoites 
Immunofluorescent staining of isolated salivary gland sporozoites with anti-LAP1 
antibodies indicated an apparent labelling of the surface of the parasite, with no 
substantial staining seen within the cell (Figure 4.11A). Immunoblot analysis of 
sporozoite lysates supported the detection of LAP1, demonstrating reactivity against a 
150 kDa protein band corresponding to the predicted size of LAP1. A protein of 
approximately 40 kDa was also detected alongside potential full-length protein (Figure 
4.11B).   
 
 
Figure 4.11. Immunoreactivity of anti-LAP1 antiserum against P. berghei sporozoites 
An stephensi mosquitoes were allowed to feed on anaesthetised mice infected with mature P. berghei 
gametocytes (day 3 post-infection). Salivary gland sporozoites (day 21 post mosquito feeding) were collected 
by dissection of salivary glands and immunoanalyses were performed to examine anti-LAP1 reactivity 
against sporozoite proteins.  
A) Immunofluorescence assays were performed on paraformaldehyde-fixed sporozoites. Antibody 
incubations (1:100) were performed with αLAP1, or as a control normal mouse serum (NMS) from an 
unimmunised mouse, using AlexaFluor-488 anti-mouse IgG (1:1500) for detection. αLAP1 appeared to label 
the periphery of the sporozoite; NMS showed no cross-reactivity with the parasites. 
 B) Immunoblots were performed on sporozoite proteins separated by SDS-PAGE in 8% polyacrylamide 
under reducing conditions. Proteins were transferred to a nitrocellulose membrane and antibody binding was 
detected by incubation with anti-mouse IgG secondary antibody (1:10,000) and ECL chemiluminescence. 
αLAP1 bound proteins migrating at approximately 150 kDa and 40 kDa; No protein bands were detected 
following incubation with normal mouse serum (NMS) from an unimmunised mouse. 
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Immunoreactivity against sporozoites is in agreement with previous studies: the 
expression of LAP1 in P. berghei sporozoites has been detected by both proteomic 
analysis (Hall et al., 2005) and by immunodetection (Claudianos et al., 2002; Trueman et 
al., 2004). In immunofluorescence assays, Claudianos et al. (2002) showed that an anti-
peptide antibody against two peptides specific to the SR domains of LAP1 stained the 
apical portion of sporozoites, whilst immunoblots demonstrated reactivity against two 
sporozoite proteins of approximately 40 and 60 kDa (Claudianos et al., 2002). Using 
antibodies against P. falciparum LAPs (Delrieu et al., 2002), which were found to cross-
react against P. berghei, Trueman et al. (2004) observed surface labelling of P. berghei 
sporozoites by immunofluorescence and detected a 60 kDa band by immunoblotting.  The 
consistent demonstration of immunoreactivity against proteins with molecular weights 
considerably lower than the predicted size of the full-length protein (Claudianos et al., 
2002; Trueman et al., 2004; and this study) is indicative of a proteolytic processing, as 
previously suggested by Claudianos et al. (2002).  
 
Although the possibility of cross-reactivity with other parasite proteins was not excluded, 
the indication of anti-PbLAP1 immunoreactivity against the sporozoite surface raised the 
question: is anti-LAP antiserum able to prevent sporozoite invasion of salivary glands? In 
the mosquito, sporozoites emerge from oocysts into the haemocoel within which they 
migrate to and invade salivary glands. The ability to deliver set volumes of a solution into 
the haemocoel of P. berghei-infected mosquitoes by microinjection enabled in vivo 
assays to be performed to determine if anti-LAP1 antiserum could inhibit sporozoite 
invasion of salivary glands. For each experiment, six pots of 70-80 mosquitoes were 
allowed to feed on three anaesthetised mice infected with P. berghei (gametocytemia 
approximately 5%). Mice/mosquitoes were rotated every 5 minutes to compensate for 
variation in host parasitemia and immune factors. All unfed mosquitoes were removed the 
following day and those remaining were maintained in new pots at 19°C. From day 14 
post-infection, mosquitoes were taken as samples for dissection to assess for the presence 
of sporulating oocysts (usually) and haemocoel injections were performed once the first 
ruptured oocysts had been observed. For each experiment, two pots of approximately 30 
mosquitoes were injected with anti-LAP1 antiserum and the same number with normal 
mouse serum (NMS) from an unimmunised mouse. Antiserum was injected into the 
haemocoel of mosquitoes using a microinjector and glass needle to deliver a volume of 
138 nl by double injection of 69 nl. Mosquitoes were subsequently maintained at 19°C. 
Mosquito post-injection mortality appeared similar for each group: ranging from 
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approximately 43-67% over a period of three days. Surviving mosquitoes were dissected 
and salivary gland sporozoites counted on day 3 post-injection. Mean values for the 
number of sporozoites per mosquito were attained by analysis of the infection of groups 
of between 5 and 10 mosquitoes. The glands were homogenised together in a 1 ml glass 
homogeniser to release sporozoites and sporozoites were counted using a 
haemocytometer to calculate the number of sporozoites per ml. Sporozoite numbers per 
mosquito were estimated by dividing the total number of sporozoites divided by the 
number of infected mosquitoes.  Overall data revealed that sporozoite salivary gland 
invasion appeared reduced by approximately 50% in mosquitoes injected with anti-
PbLAP1 sera in comparison to mosquitoes injected with normal mouse serum from an 
unimmunised mouse (Table 4.2).  
 
Table 4.2. Antiserum raised against LAP1 appears to partially block sporozoite invasion of 
mosquito salivary glands   
 
Serum Mortality Mosquitoes dissected 
Prevalence 
of infection 
Mean 
number of 
sporozoites 
Sporozoite 
invasion 
(% of control) P 
         
i NMS  67% 20 (two groups of 10) 65% (13/20) 4233 100%  
 αLAP1  53% 28 (two groups of 10 
and one group of 8) 
71% (20/28) 1791 42.3% * 
         
         
ii NMS  50% 30 (three groups of 10) 67% (20/30) 4717 100%  
 αLAP1  53% 28 (two groups of 10 
and one group of 8) 
79% (22/28) 1823 38.7% *** 
         
         
iii NMS  53% 28 (four groups of 5 
and one group of 8) 
86% (24/28) 3005 100%  
 αLAP1  43% 37 (two groups of 5, 
2x6, 1x7 and 1x8) 
84% (31/37) 2056 68.4% * 
         
         
 NMS  56.7%   72.7% 3985 100%  
 αLAP1  49.7%   78.0% 1890 49.8%  
         
 
138 ng of anti-LAP1 antiserum or normal mouse serum (NMS) was injected into the thorax of P. berghei-
infected mosquitoes harbouring sporolating oocysts. Groups i and ii represent results obtained from the same 
initial feed, with serum injections performed on day 16 (i) and day 17(ii) post-feed. In iii, serum injections 
were performed on day 15 post-feed. Mortality indicates the proportion of mosquitoes that died in the 3-day 
period post-injections; an approximate value based on the injection of 60 mosquitoes per group. Mosquitoes 
were dissected three days post-injection; the glands from between 5 and 10 mosquitoes (as indicated) were 
homogenised together in a 1 ml glass homogeniser to release sporozoites and sporozoites were counted using 
a haemocytometer to calculate the number of sporozoites per ml. Prevalence of infection was determined 
following examination of mosquito midguts. Mean numbers of sporozoites (per infected mosquito) were 
estimated by dividing the total number of sporozoites divided by the number of infected mosquitoes; this is 
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represented as a percentage compared to NMS. P indicates the significance in differences between anti-LAP1 
and NMS injection based on P-values determined by Mann-Whitney tests on estimated means; i)*(P=0.0375), 
ii)***(P<0.0001), iii)*(P=0.0201). Overall mean values of the three experiments are shown in bold. 
 
The possibility that natural variation in parasite loads could account for the differences 
observed is not ruled out, therefore results are considered with caution. Given that values 
for the mean number of sporozoites per mosquito represent an estimate based on total 
number of sporozoites for a group of up to ten mosquitoes, taking into account 
prevalence, it is noteworthy that a few very heavily infected mosquitoes and/or levels of 
prevalence could have a considerable impact. Nevertheless, the apparent reductions in 
sporozoite salivary gland infection following the injection of anti-LAP1 antiserum into 
haemocoel indicate that the serum antibodies may bind to sporozoites in the haemolymph 
and inhibit invasion of salivary glands. Possible mechanisms for antibody-mediated 
blockade in sporozoite invasion may be by stearic interference or by inducing lysis of 
sporozoites. It is also possible that the antibodies may initiate an inhibitory effect by 
binding mosquito molecules. As a starting point for further investigations, it would be 
interesting to establish whether or not the antibodies are capable of neutralising 
sporozoites in vitro. In P. berghei, this could be performed by incubation of sporozoites 
obtained from An. stephensi followed by in vitro incubation in culture media containing 
antisera. The effect on infectivity can be assessed by following liver-stage development in 
cultured mouse hepatocytes: after inoculation of a known number of sporozoites, the 
number of sporozoites capable of invasion and transformation into trophozoites can be 
determined.  
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4.4.6. Summary of PbLAP1 localisation 
o PbLAP1 expression was shown to be specific to female gametocytes, as revealed 
by double-labelling experiments with anti-MDV1 serum, which is known to 
differentially label male and female gametocytes.  
o The absence of PbLAP2, PbLAP4, PbLAP5, or PbLAP6, does not affect the 
expression of PbLAP1, as determined by the immunodetection of LAP1 in 
∆Pblap2, ∆Pblap4, ∆Pblap5, and ∆Pblap6 parasites.   
o Labelling of PbLAP1 appears in distinct areas of the cytoplasm of female 
gametocytes.  
o Antisera against the SR domains of P. berghei LAP1 cross-react with female     
P. falciparum gametocytes, with antibody staining patterns in each species 
appearing similar.  
o Antibody labeling of LAP1 appears reduced following gametogenesis, yet despite 
this, LAP1 expression is detected by immunofluorescence in developing zygotes. 
o In P. berghei ookinetes, LAP1 was found to localise to the crystalloids. 
o Labelling of LAP1 was undetectable in oocysts, but antibodies were found to 
label the periphery of salivary gland sporozoites. 
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4.5. PbLAPs localise in ookinete crystalloids and appear necessary for 
crystalloid formation   
IFAs using anti-LAP3, anti-LAP4 and anti-LAP6 antisera on P. berghei ookinetes 
revealed that all antibodies labelled the ookinete crystalloids (Figure 4.12). 
Immunofluorescent labelling with anti-LAP4 revealed an antibody staining pattern 
indistinguishable from that observed with anti-LAP1 antisera (Figure 4.12B) whilst anti-
LAP3 and anti-LAP6 antisera distinctly labelled both the crystalloids and also a small 
apical component at the tip of the ookinetes (Figure 4.12A and C). Interestingly, despite 
the cross-reactivity of anti-LAP4 and anti-LAP6 in gametocytes (as demonstrated in 
Figure 4.4), neither antibody labelled the ookinete crystalloid in corresponding knockout 
parasites. Using anti-LAP6 antisera, both crystalloids and apical tips were labelled in 
wild-type ookinetes, whilst in ∆Pblap6 ookinetes labelling of crystalloids was abolished 
but the apical tip staining remained present. Through these observations it became 
noticeable that the Pblap mutants were somewhat deficient in crystalloid formation. 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Antisera against PbLAP3, 4 and 6 label ookinete crystalloids   
Immunofluorescence analyses were performed on paraformaldehyde fixed cells collected from a 24 h P. 
berghei ookinete culture. Wild-type (wt) or lap P. berghei parasites were stained using αLAP1, 1:100 
(secondary Alexa 448, 1:2,000) and αFormin 1:50 (secondary Alexa 546, 1:2,000) and counterstained with 
DAPI nuclear stain (blue). Scale bar represents 2 µm. 
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Given that crystalloids have previously been demonstrated to be positive for lipids 
(Desser et al., 1971), the lipophilic dye Nile Red was chosen as a stain in order to 
facilitate their visualisation and quantification. Nile Red fluoresces in lipid-rich or highly 
hydrophobic environments and indeed was found to label ookinete crystalloids (Figure 
4.13B).  The seeming impermeability of a large proportion of ookinetes to the stain and 
the high amount of background florescence however made analysis problematic. 
Nevertheless, crystalloids could be clearly distinguished by Giemsa-staining — in wild-
type ookinetes, appearing as a vacuole surrounded by pigment (Figure 4.13A). In 
contrast, in ∆Pblap ookinetes, pigment often appeared more dispersed and mutant 
ookinetes appeared to lack an obvious pigmented surrounded vacuole, suggesting a lack 
of cellular organisation. Assessment of the number of crystalloids in cultured wt and 
∆Pblap ookinetes revealed that the proportion of ookinetes with crystalloids was 
constantly lower in ∆Pblap ookinetes compared to wild-type ookinetes (Figure 4.13C).  
 
 
Figure 4.13. Pblap ookinetes appear deficient in crystalloid formation 
A) Giemsa stained ookinetes; wt and ∆Pblap ookinetes were grown in culture from gametocyte-infected 
mice. Parasites were collected by centrifugation from 24 h cultures, smeared onto a slide and stained with 
Giemsa solution. Crystalloids were clearly visible as vacuoles surrounded by pigment in wild-type ookinetes 
(upper panel) whereas ∆Pblap ookinetes lacked an obvious pigment surrounded vacuole. Images shown are 
representative of at least three independent ookinete cultures. B) Ookinete stained with Nile Red; cultured 
ookinetes were suspended in PBS containing Nile Red and after a five minute incubation were observed by 
light and fluorescent microscopy.  
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Although During the course of this study, transgenic parasite lines of PbSR (LAP1) 
tagged at C-terminal by GFP or the N-terminal by mCherry were successfully generated 
by Carter et al. (2008) and GFP-tagged versions of PbLAP2 and PbLAP3 were 
subsequently generated by Saeed et al. (2010). Reassuringly, examination of the tagged 
parasites revealed cellular localisation very similar to the results presented in this thesis. 
Labelling was detected throughout the cytoplasm of female gametocytes, macrogametes, 
zygotes and early retorts and in mature ookinetes and young oocysts, fluorescence was 
confined to the crystalloids (Carter et al., 2008). Furthermore, the disruption of PbLAP1 
was shown to be associated with a deficiency in crystalloid formation by both fluorescent 
microscopy and electron microscopy (Carter et al., 2008). 
 
Several studies based on electron microscopy indicate that crystalloids derive from 
electron-dense particles interspersed in the female gametocyte (Desser et al., 1971; 
Canning and Sinden, 1973; Davies et al., 1974; Gallucci et al., 1974; Trefiak et al., 1973; 
Mehlhorn et al., 1980), an observation which is consistent with the involvement of LAPs 
in their formation given that PbLAPs have been shown to be inherited from the female 
gametocyte: it has been demonstrated through genetic crossover experiments with Pblap 
gene knockout parasites that LAPs are inherited from the female gametocyte (Raine et al., 
2007). It may thereby be envisaged that LAPs may be among the molecules derived from 
the female gametocytes that are required for crystalloid formation, perhaps playing 
important roles in binding, sorting or packaging components to the crystalloid, their 
knockout therefore leading to disruption of cellular organisation.  
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4.6. Features and predicted roles of Plasmodium crystalloids 
4.6.1. Crystalloids have hypothesised roles as cellular storage compartments 
which may be essential for oocyst development 
Through electron microscopy, crystalloids have been recognised in several species of 
Plasmodium over the past 50 years. Although their functional significance remains 
unknown, a number of suggestions have been proposed regarding possible roles. Principal 
hypotheses include an involvement as a metabolic resource, as initially proposed by 
Garnham (1969) and Desser et al. (1970). It is considered that the crystalloid may act as a 
cellular storage compartment which is essential for oocyst development; for example by 
aiding in the proliferation of ER, Golgi apparatus, secretory vesicles and mitochondria 
(Sinden et al., 1984) or by providing a source of oocyst wall components (Garnham, 
1969; Terzakis et al., 1976).   
 
Plasmodium is assumed to depend on its host for the acquisition of amino acids. During 
blood stages, the parasite acquires nutrients from both the RBC cytoplasm and the 
surrounding plasma. Proteins are converted to amino acids in the parasite’s digestive 
vacuole and amino acids are transported to the rest of the cell. In contrast, no known 
nutrient uptake occurs once the parasite is in the mosquito blood meal. It is thereby 
speculated that the crystalloid may act as a protein store, containing surplus protein 
generated from nutrient acquisition in blood stages to be released as amino acids for 
oocyst development. Cell storage bodies can take a variety of different forms. For 
example, protein storage organelles can release amino acids used for further synthesis; 
lipid bodies comprise an energy reserve of fatty acids; polyphosphate bodies/volutin 
granules comprise polymers of phosphates joined by pyrophosphate bonds which may be 
broken down to supply inorganic phosphate (e.g. for ATP); glycogen or amylopectin 
granules form a carbohydrate reserve in many cell types, providing a source of glucose.  
 
It is understood that crystalloid bodies may be analogous to refractile bodies (RBs), 
which among apicomplexan parasites are particularly prominent in Eimeria sporozoites 
(Roberts et al., 1970). Yet rather than a homogeneous electron dense cellular structure, as 
is typical of Eimeria RBs, crystalloids appear as electron-dense particles, which may be 
arranged either in a random orientation or in an ordered honeycomb-like pattern, (Figure 
4.15). Also termed paranuclear bodies, usually two RBs are present, one either side of the 
nucleus — with an anterior RB localised between the nucleus and the apical complex 
often smaller than a large posterior RB. Associations with glycogen/amylopectin granules 
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have been detected in several Eimeria species (Roberts and Hammond, 1970). The RB 
has proposed roles as a reservoir for proteins involved in invasion, perhaps eliciting the 
relocalisation of proteins such as the aspartyl protease Eimepsin to the apical end of 
sporozoites just before invasion (Jean et al., 2000). This is supported by the detection of a 
number of invasive proteins in an Eimeria RB-enriched proteome (Venevelles et al., 
2006) and is consistent with the disappearance of the RB after sporozoite invasion: the 
anterior Eimeria RB has been described to break up and disappear within 10 hours post-
invasion, although in a few species, RBs may be found in merozoites (Roberts et al., 
1970). Proteomic analysis of Eimeria RB-enriched preparations also detected several 
proteins implicated with energetic and metabolic functions (Venevelles et al., 2006). 
Proteins detected included a lactate dehydrogenase, involved in metabolism, and a group 
of proteins involved in redox mechanisms, namely a carbonyl reductase, a haloacid 
dehalogenase type hydrolase (implicated in detoxification in bacteria) and a 2-cys 
peroxiredoxin. A protein of the ubiquitin family was also detected (Venevelles et al., 
2006). Potential for involvement in a form of energy metabolism has also been indicated 
in Cryptosporidium by the finding that a unique fusion protein pyruvate:NADP+ 
oxidoreductase (CpPNO) has been shown though immunofluorescent and transmission 
electron microscopy to localise to the C. parvum crystalloid bodies (Ctrnacta et al., 2006). 
Therefore, although literature on the nature of crystalloids and potentially similar 
organelles in apicomplexan parasites is limited, there are indications to support roles as a 
store for the distribution of proteins, and/or an involvement in energy metabolism.   
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Figure 4.14. Examples of crystalloid and refractile bodies of apicomplexan parasites 
A) Drawing of a P. gallinaceum ookinete showing five crystalloids (CR). Also shown: MN, micronemes; PG, 
protein granules; S, spindle apparatus; PE, pellicle; Taken from Mehlhorn et al. (1980).  B) Electron 
micrographs of haemosporidian crystalloids from: i) Leukocytozoan simondi ookinete (x47,600); ii) L. 
simondi early oocyst (x17,000); iii) L. simondi sporozoite (x42,500); iv) P. gallinaceum ookinete (x40,000); 
v) Parahaemoproteus fringillae ookinete (x40,000); vi) P. velans ookinete (x40,000); vii) Haemoproteus 
columbiae; viii) Isospora ohioensis day 7 (x23,800);     ix) I. ohioensis day 14 (x23,800). Taken from Trefiak 
and Desser (1973); Gallucci (1974); Lindsay et al. (1997). C) Drawing of an Eimeria sporozoite showing two 
prominent refractile bodies (RB), one on either side of the nucleus. Also shown: C, conoid; MN, micronemes; 
RH, rhoptries; MP, micropore; MI, mitochondria; ER, endoplasmic reticulum; DB, dark bodies; L, lysosome; 
N, nucleus; NU, nucleolus; V, vacuole; IM, inner membrane; OM, outer membrane; Taken from Scholtyseck 
(1979). D) Drawing of an Isospora sporozoite showing a large central refractile body (RB). Also shown: P, 
polar ring; C, conoid; RH, rhoptries; N, nucleus; MI, mitochondrion; PE, pellicle; A, amylopectin granules; 
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MN, micronemes; PV, parasitophorous vacuole; MPV, membrane of PV; GO, golgi; ER, endoplasmic 
reticulum; HC, host cell; Taken from Scholtyseck (1979). E) Representation of a Cryptosporidium sporozoite 
showing a large posterior crystalloid body (CB). Also shown: RH, rhoptries; MN, micronemes; DG, dense 
granules; N, nucleus; Taken from Tetley et al. (1998). 
 
4.6.2. The crystalloid is a transient cellular compartment of P.berghei ookinetes 
and early oocysts to which Pb814, a potentially micronemal protein, localises 
Recent efforts to characterise putative ookinete micronemal proteins (identified by Lal et 
al., 2009b) have led to the identification of a further crystalloid protein — the first to be 
identified outside of the LAP family. PB000814.03.0 (referred to here as Pb814) is a 
small (30 kDa) hypothetical protein shares no sequence homologies to other known 
proteins with no known putative protein domains. In an initial attempt to characterise the 
protein, a transgenic parasite line expressing a c-Myc-tagged version of Pb814 has been 
generated (Dr. M. Delves, unpublished). These parasites (a gift from Dr. M. Delves) 
provided a positive control for attempts to tag PbLAPs (section 4.2). Interestingly, 
cellular localisation studies using an anti-Myc antibody revealed the protein to be 
localised to P. berghei crystalloids and thereby provided a means of tracing the 
progression of crystalloid development.  
 
Unlike LAPs, Pb814 expression was absent from gametocytes, with the tagged protein 
first detectable in zygotes, approximately 4 hours post-activation (Figure 4.14), consistent 
with the indication that mRNA transcripts of Pb814 may be held under translational 
repression in the female gametocyte (Mair et al., 2006). Fluorescent staining of Pb814-
Myc depicts a cytoplasmic localisation during the early stages of ookinete development 
and as ookinete development proceeds via protrusion from the apical end, becomes 
noticeably associated with pigmented areas of the parasite, clearly concentrating in a 
single focal spot in ookinetes 12 hours post-activation. Over the following 12 hours, the 
nucleus migrates from the posterior end to the middle of the cell and mature ookinetes are 
characterised by an enlarged anterior end, a central nucleus, and pigment representing the 
crystalloid at one or both sides of the nucleus. In mature ookinetes, Pb814 appears 
localised in the crystalloids, and interestingly, a putative association with ookinete 
micronemes is apparent — indicating a potential link between the crystalloid and the 
apical organelles.  
 
In An. stephensi midguts with early stage infections with transgenic Pb814-Myc parasites 
(24-48 hours post-blood-feed) labelling of Pb814 is observed in the crystalloid of 
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transforming ookinetes (tooks), representing recently invaded ookinetes. Labelling of the 
crystalloid remains prominent in young oocysts (day 2 post-blood-feed) and appears 
diminished in 4-day old oocysts. The described pattern of Pb814-Myc labelling of 
crystalloids is shown in Figure 4.14. Labelling was absent in mature oocysts and 
sporozoites (data not shown).  
 
 
 
 
 
Figure 4.14. Subcellular localisation of Pb814 during zygote/ookinete development and in early oocysts 
Upper panel shows representative images of ookinete development on parasites cultured in vitro. The 
ookinete develops by protrusion of the apical end into a mature 24 h ookinete with dense pigment 
representing crystalloids at one or both sides of the nucleus. Lower panel shows representative images 
during the first five days of development in the mosquito. The crystalloid is present in young oocysts, but is 
lost during oocyst development and is absent in mature oocysts.  
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Concentration of Pb814 in the early stages of development in the oocyst and its apparent 
dispersion and later disappearance by day 5 oocysts is consistent with previous electron 
microscopic observations of Plasmodium crystalloids, which describe their presence only 
during the early stages of oocyst development and not in mature oocysts or sporozoites 
(Mehlhorn et al., 1980). Regression of the crystalloid appears to follow one of two 
patterns, relating to oocyst growth:  
– In Plasmodium and Haemoproteus, oocysts undergo dramatic cell growth and 
produce thousands of sporozoites from multiple sporoblasts. Crystalloids 
typically disperse in young oocysts, prior to the formation of sporoblasts 
(Mehlhorn et al., 1980).  
– In Leucocytozoon species, oocysts remain small and a relatively small number of 
sporozoites (less than 100) are formed from a single sporoblast. The crystalloid 
fragments and a portion of the crystalloid progresses into budding sporozoites 
(Valkiunas, 2005).  
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4.7. Can bypassing the midgut restore ∆Pblap sporulation? 
A comparison of the albeit limited protein expression and localisation data available for 
the LAP family in apicomplexan parasites reveals an interesting association with life 
cycle stages involved in infection of the host gut;  
– In Plasmodium, the proteins are expressed in stages within the mosquito midgut. 
– In Babesia divergens are expressed in phases of parasite development in the 
mosquito midgut (Becker et al., 2010).  
– In Cryptosporidium, The immunolocalisation of C. parvum CCp1 (an ortholog of 
LAP2) shows possible associations with the micronemes.   
– In Toxoplasma, members of the protein family have been shown to be localised 
in sporozoites, immunolocalisation studies on T. gondii CCps (TgSR1, TgSR2, 
TgCCp5A and TgCCp5B) indicate their localisation in dense granules of 
sporozoites (Tosini et al., COST Action Conference, May 2008).  
 
This raises the interesting possibility that the proteins may play essential roles in the 
environment of the gut.  
 
Interestingly, Carter et al. (2008) demonstrated that when ∆Pblap1 oocysts were cultured 
in vitro, sporulation appeared to occur normally. The ability of ∆Pblap1 to form 
sporozoites in vitro but not in the environment of the midgut indicates that Pblap1 may 
not be essential for sporulation per se, and raises the possibility that functions might 
involve mosquito factors (Carter et al., 2008). It is possible to bypass midgut invasion and 
study the development of Plasmodium in the absence of midgut interactions by the 
microinjection of ookinetes into the haemocoel of mosquitoes. This technique can be used 
to investigate if the phenotype of ∆Pblap parasites alters if ookinetes are allowed to 
develop in the absence of mosquito factors and the midgut epithelial barrier bypassed. A 
rescue of phenotype would indicate an essential role during ookinete invasion of the 
midgut epithelium, as is demonstrated for example for the ookinete micronemal protein 
PbCTRP; injection of ∆Pbctrp ookinetes into the haemocoel restores infectivity (Nacer et 
al., 2008).  
 
To assess if interaction with the midgut plays a role in ∆Pblap phenotypes, haemocoel 
injections were performed and subsequent sporozoite development was assessed by 
enumeration of salivary gland sporozoites. For each experiment, ookinete haemocoel 
injections were performed in parallel to ookinete membrane feeds. Wild-type ookinetes 
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were able to establish an infection in the mosquito independent of the mode of 
administration and ∆Pblap phenotypes appeared indistinguishable whether ookinetes 
were fed or injected (Table 5.2). Although some salivary gland sporozoites were detected 
in ∆Pblap1-5, numbers were extremely low compared to wild-type. No sporozoites were 
detected in ∆Pblap6 infections.  
 
The inability to rescue phenotypes when the midgut epithelium barrier is bypassed by 
ookinete haemocoel injections indicates that LAPs function independently from 
interactions with the mosquito epithelia and lends support to the theory that the 
crystalloid may act as a storage compartment during ookinete development, with 
subsequent functions in the oocyst. In seeking possible reasons for the observed Pblap1 
redundancy in vitro, it is perhaps possible that growth factors present within the in vitro 
oocyst culture medium could provide signals for proliferation that are otherwise absent 
during development in the mosquito. This would imply that ∆Pblap oocysts may be able 
to respond to growth signals if provided, resulting in sporulation, but in the absence of 
such additional cues in the mosquito oocysts remain defective. Alternatively, the 
observed in vitro ∆Pblap1 phenotype may be similar to that of ∆Pfccp3 parasites, which 
are capable of forming sporozoites, but that these are defective and unable to invade 
salivary glands. 
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Table 4.3. Injection of ∆Pblap ookinetes into the haemocoel of mosquitoes does not restore 
sporulation.  
 
 Ookinete membrane feed  Ookinete haemocoel injection 
 N 
 
Number of  
sporozoites % of wt  N 
Number of 
sporozoites % of wt 
        
wt 7 7,967 100%  19 9,167 100% 
∆Pblap1 10 20 0.25%  19 98 1.1% 
        
wt 9 10,173 100%  18 24,440 100% 
∆Pblap1 15 73  0.72%  17 393 1.6% 
        
        
wt 20 2,678  100%  20 8,049 100% 
∆Pblap2 18 0 0%  20 0 0% 
∆Pblap4 19 0 0%  20 58 0.72% 
        
wt 20 3,981 100%  20 9,240 100% 
∆Pblap2 15 0 0%  20 0 0% 
∆Pblap4 20 11  0.28%  20 60 0.65% 
        
        
wt 20 10,243 100%  15 2,871 100% 
∆Pblap5 20 0 0%  20 35  1.2% 
        
wt 13 5,077 100%  18 5,200 100% 
∆Pblap5 20 0 0%  20 38  0.73% 
        
        
wt 20 6,866  100%  15 6,839  100% 
∆Pblap6 20 0 0%  20 0 0% 
        
wt 20 10,944  100%  20 13,241 100% 
∆Pblap6 20 0 0%  20 0 0% 
        
 
Ookinetes were cultured in vitro and the same culture was delivered to An.  stephensi mosquitoes either by 
membrane feeding or by haemocoel injection. Salivary gland sporozoites were counted 21 days post-
feed/injection. N refers to the number of mosquitoes dissected. Salivary glands were dissected, homogenised 
in groups of 5-10, and sporozoites were counted using a haemocytometer. Sporozoite numbers are shown as 
the mean number of salivary gland sporozoites per mosquito. 
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4.8. Differential gene expression profiles of wild-type and ∆Pblap1 parasites 
LAP expression appears to cease prior to sporulation, yet essential effects of Pblap are 
not apparent until sporozoite formation, as revealed by gene knockout studies. Given the 
new finding that ∆Pblap parasites appear deficient in crystalloid formation in 
zygotes/ookinetes, it is hypothesised that the loss of LAP may have molecular effects in 
the ookinete, leading to a defect in sporulation through widespread knock-on effects. To 
investigate this, microarray-based transcriptional profiling was performed to analyse how 
the loss of Pblap and consequent absence of crystalloid formation impacts gene 
expression.  
 
Microarray-based transcriptional profiling provides an effective means of examining 
patterns of gene expression in a cell population on a genome-wide scale. Based on the 
hybridisation between immobilised DNA probes and labelled cDNA / RNA targets 
derived from RNA samples, DNA microarrays can simultaneously measure mRNA 
activity for each gene within a particular mRNA sample. Therefore through the 
application of microarray experiments, it can be distinguished how Plasmodium responds 
to the disruption of lap in terms of gene expression across the entire genome. In doing so 
there exists the possibility of identifying how defects in sporulation are related to the loss 
of lap and the signalling pathways required for sporozoite formation. 
 
Since phenotypic differences between wild-type and ∆Pblap parasites first appear 
noticeable in the ookinete, it was predicted that at this stage of development, differences 
in gene expression may be detectable. Therefore an analysis of the transcriptional activity 
of in vitro cultured ∆Pblap1 ookinetes was made as a comparison to wt ookinetes 
cultured in parallel, with the aim of measuring the transcriptional profile of Pblap1 
ookinetes relative to wt. mRNA was reversed-transcribed into cDNA, labelled with a 
fluorescent dye (∆lap1 derived cRNA with Cy3 labelled CTP and wt derived cRNA with 
Cy5 labelled CTP) and hybridised on the array. Expression levels at each spot of the array 
(corresponding to a specific gene) were quantified by fluorescent imaging. Intensity of 
fluorescence correlates to the amount of mRNA in a sample complementary to each gene, 
providing a means of comparing expression levels among wild-type and knockout 
samples. Four independent samples were analysed in a single microarray experiment, 
identifying 274 genes showing at least fold average change >1.5 (log2 normalised ratios 
>0.6) in regulation in the absence of LAP1.  
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4.8.1. Genes downregulated in ∆Pblap ookinetes   
Genes most strongly downregulated (Table 4.4) included two members of the PyST-B-
2TM family. This is a gene family found in the rodent malaria parasites P.yoelii, 
P.chabaudi and P.berghei with no direct orthologs in P. falciparum, but have a structure 
similar to that of the P.falciparum PfMC-2TM and PfST-2TM family (Carlton et al., 
2002). These gene families are among those located in the variable subtelomeric regions 
of the chromosomes. The gene products are predicted exported transmembrane proteins 
of the asexual blood stage parasites involved in protein transport and trafficking (Sam-
Yellowe et al., 2008). Despite this, PB103795.00.0 was found to be significantly (3.7 
fold) down-regulated in ∆Pbdozi parasites compared to wild-type (Mair et al., 2006).  
 
Table 4.3 lists the 34 most down-regulated genes. Of these approximately a third are 
specific to Plasmodium, and encode hypothetical proteins with no predicted homologies 
to known protein domains. Around half however are widely found across eukaryotic 
phyla, representing genes that encode proteins essential to key signalling pathways, many 
of which could be potentially be important for Plasmodium sporogony. Those with a 
potential involvement in cell cycle regulation most notably included cyclin 4 and a 
HORMA domain-containing protein, both of which are known in other eukaryotes to be 
key regulators of mitosis (Aravind and Koonin, 1998). A number of translational 
machinery components were also down-regulated including a tRNA synthetase, a tRNA 
ligase and an RNA polymerase. Furthermore, proteins with potential biosynthetic, 
metabolic and trafficking activities were also down-regulated. These included a putative 
patatin-like phosphatase, with predicted roles in lysophospholipid lipolytic activity. 
Known patatin domain containing proteins include the yeast  ER integral membrane 
protein is lysophospholipase neuropathy target esterase-1 (NTE1), which has an identified 
role in lipid membrane homeostasis and is regulated by components of the yeast secretory 
machinery which are involved in lipid metabolism and vesicular trafficking (Fernandez-
Murray and McMaster, 2007). In addition, a putative member of the mitochondrial carrier 
protein family, with associated roles in the transfer of molecules across the membranes of 
organelles for energy transfer (Walker, 1992). 
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Table 4.4. Genes most strongly downregulated in Pblap1 ookinetes 
 
Gene ID Gene annotation Log2 ratio 
   
PB103795.00.0 Pb-fam-3 protein, PyST-B-2TM family -2.6 
PB103567.00.0 Pb-fam-3 protein, PyST-B-2TM family -1.8 
PB000504.00.0 cyclin 4, putative -1.5 
PB000682.02.0 HORMA domain containing protein -1.5 
PB000811.03.0 Polynucleotide kinase, putative -1.4 
PB100551.00.0 Hypothetical protein -1.4 
PB000457.02.0 Conserved hypothetical protein -1.3 
PB001040.03.0 Chloroquine resistance marker protein -1.3 
PB001122.02.0 TPR domain containing protein, putative -1.3 
PB000074.02.0 Conserved hypothetical protein -1.2 
PB000102.02.0 Conserved hypothetical protein -1.2 
PB000402.00.0 Step II splicing factor, putative -1.2 
PB000570.02.0 tryptophanyl-tRNA synthetase, putative -1.2 
PB000578.03.0 Adenosine deaminase, putative -1.2 
PB000696.01.0 Conserved hypothetical protein -1.2 
PB001161.01.0 Conserved hypothetical protein -1.2 
PB001212.00.0 Glycoprotease family, putative -1.2 
PB001303.00.0 Hypoxanthine phosphoribosyltransferase, putative -1.2 
PB300245.00.0 ribosome biogenesis protein tsr1, putative -1.2 
PB300528.00.0 Hypothetical protein -1.2 
PB000026.02.0 microfibril-associated protein homologue, putative -1.1 
PB000280.03.0 Tryptophan—tRNA ligase, putative -1.1 
PB000932.01.0 Patatin-like phospholipase, putative -1.1 
PB102910.00.0 Hypothetical protein -1.1 
PB104007.00.0 NLI interacting factor, putative -1.1 
PB000108.01.0 DNA-directed RNA polymerase -1.0 
PB000308.02.0 Conserved hypothetical protein -1.0 
PB001049.02.0 ATPase, AAA family, putative -1.0 
PB001070.01.0 Conserved hypothetical protein -1.0 
PB001232.00.0 Cyclophilin, putative -1.0 
PB001243.02.0 Isomerise, putative -1.0 
PB001371.02.0 Mitochondrial carrier protein, putative -1.0 
PB401649_00_0 Conserved hypothetical protein -1.0 
PB000436_03_0 PBS lyase HEAT-like repeat domain protein, putative -1.0 
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4.8.2. Genes upregulated in ∆Pblap1 ookinetes 
Genes upregulated in ∆Pblap1 ookinetes (Table 4.5) included a number of cytoskeletal 
associated proteins. These included MTIP, an essential component of the apicomplexan 
invasion machinery and a second putatively inner membrane complex (IMC) related 
skeletal protein. MTIP localises to the IMC and interacts with MyoA tail domain, which 
is essential for gliding (Meissner et al., 2002; Bergman et al., 2003), whilst the putatively 
IMC related membrane skeletal protein may have important roles in cell development, 
shape, and structural integrity (Tremp et al., 2008). The IMC for example forms a 
scaffold for the assembly of daughter parasites therefore is essential for cytokinesis and is 
likely to be required to maintain the shape of invasive stages. In addition, a 2-fold 
upregulation in circumsporozoite protein (CSP), which plays essential roles in organising 
the formation of the cytoskeleton of budding sporozoites (Thathy et al., 2002) was also 
upregulated. It is possible that the upregulation of genes may represent a compensatory 
mechanism for the absence of Pblap1. Both CSP and PbLAPs are implicated with roles in 
sporozoite development, as indicated by gene disruption studies, lending support to the 
idea that csp transcripts may be upregulated to compensate for the loss of lap1. 
Alternatively, mis-regulation of events in the ookinete as a result of lap1 gene disruption 
could perhaps trigger premature csp expression. A number of conserved enzymes 
including kinases, ribonucleotide reductase, phosphatidylserine decarboxylase, which 
may initiate various interactions and reactions involved in cellular development were also 
detected as being upregulated. 
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 Table 4.5. Genes most strongly upregulated in Pblap1 ookinetes 
 
Gene ID Gene annotation Log2 ratio 
PB001102_00_0 Conserved hypothetical protein 1.2 
PB000238_03_0 Conserved hypothetical protein 1.1 
PB000653_03_0 Conserved hypothetical protein 1.1 
PB000193_03_0 myosin A tail domain interacting protein MTIP, putative 1 
PB000408_03_0 Conserved hypothetical protein 1 
PB000102_00_0 Conserved hypothetical protein 0.9 
PB000602_02_0 Conserved hypothetical protein 0.9 
PB000863_02_0 Serine/threonine protein kinase, putative 0.9 
PB001043_02_0 Conserved hypothetical protein 0.9 
PB000058_02_0 ribonucleotide reductase small subunit, putative 0.8 
PB000090_02_0 Conserved hypothetical protein 0.8 
PB000202_00_0 3-methyl-2-oxobutanoate dehydrogenase (lipoamide) 0.8 
PB000282_03_0 Conserved hypothetical protein 0.8 
PB000288_03_0 Conserved hypothetical protein 0.8 
PB000344_00_0 Membrane skeletal protein, putative 0.8 
PB000442_00_0 ubiquitin conjugating enzyme E2, putative 0.8 
PB000737_02_0 Conserved hypothetical protein 0.8 
PB000934_02_0 Conserved hypothetical protein 0.8 
PB001135_02_0 Conserved hypothetical protein 0.8 
PB001578_02_0 phosphatidylserine decarboxylase, putative 0.8 
PB300785_00_0 Conserved hypothetical protein 0.8 
PB000051_02_0 Conserved hypothetical protein 0.7 
PB000105_00_0 sodium/hydrogen exchanger, putative 0.7 
PB000346_00_0 Conserved hypothetical protein 0.7 
PB000495_00_0 protein kinase, putative 0.7 
PB000613_03_0 Conserved hypothetical protein 0.7 
PB000711_02_0 thioredoxin-like protein, putative 0.7 
PB000725_01_0 aminopeptidase, putative 0.7 
PB000877_01_0 ATP-dependent DNA helicase, putative 0.7 
PB001026_00_0 circumsporozoite (CS) protein, putative 0.7 
PB001069_02_0 Conserved hypothetical protein 0.7 
PB001131_01_0 Conserved hypothetical protein 0.7 
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4.8.3. Interpretation of transcriptional profiles  
Transcriptional analysis demonstrated that the absence of Pblap1 in ookinetes is 
associated with differential expression of a number of genes that could potentially 
account for defects in cytokinesis. A total of 274 genes were identified showing at least 
>1.5 fold average change in regulation in the absence of LAP1. This included the 
upregulation of genes involved in cell growth and the downregulation of genes required 
for cellular division, which could potentially lead to the characteristically large 
unsporulated ∆Pblap1 oocysts, typified by growth despite the absence of division.  
 
The microarray analysis of was designed to be an initial single-point analysis, comparing 
gene expression in ∆Pblap1 ookinetes with wt P. berghei ookinetes. Clearly it would be 
of interest to extend this to a time-series analysis, incorporating comparisons through 
from gametocytes to oocysts. However, although microarrays have great potential in 
offering insights through transcriptional profiling, they also have a number of imitations. 
Most notably, they are expensive, require a large amount of high-quality mRNA, which 
can be difficult to acquire, and artefacts are common. It is predicted that a proportion of 
the genes in an array may be found to be differentially expressed in different by chance 
alone. In order to verify results it is desirable to confirm differentially regulated genes by 
RT-PCR: it would be wise to test the genes that appear to be most strongly up-/down-
regulated in ∆Pblap1 ookinetes by RT-PCR analysis. Furthermore, the transcription of a 
gene does not necessarily indicate its translation. Considerable changes in protein levels 
may act at the level of protein expression rather than the level of transcript, perhaps 
through alterations in protein stability or targeting. This is clearly demonstrated by the 
finding that the disruption of Pfccp3 (Pblap1) causes loss of LAP2 and LAP4 protein, but 
not of the transcript (Pradel et al., 2006).  
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4.9. Conclusions and discussion 
4.9.1. Summary of findings 
Studies presented in this chapter aimed to provide a better understanding of the biological 
roles of LAPs and their suitability as TBV candidates. Main findings were as follows:  
 
o The absence of surface labelling of gametes, zygotes and ookinetes with anti-
LAP sera correlates with the lack of transmission-blocking immunity conferred 
by the antibodies. 
o Anti-LAP1 sera labelled the periphery of P. berghei salivary gland sporozoites 
and may act to inhibit sporozoite migration/invasion of salivary glands. 
o Antisera raised against the SR domains of LAP1, the PA14 domain of LAP3 and 
the LCCL domains of LAPs 4 and 6 were all found to label the crystalloids of P. 
berghei ookinetes. ∆Pblap1, ∆Pblap2, ∆Pblap4, ∆Pblap5, and ∆Pblap6 parasites 
were observed to be defective in crystalloid formation by light microscopy, 
indicating that LAPs are in some way involved in crystalloid formation and/or its 
maintenance. The association of PbLAPs with the crystalloids provides an 
immediate indication of a potential link to the observed phenotypes of the ∆Pblap 
parasites, on the basis that the crystalloid may be associated with cellular events 
in the oocyst. 
o Immunofluorescent labelling of Myc-tagged Pb814 protein identified Pb814 as a 
protein localised to crystalloids demonstrated that crystalloids appear as transient 
compartments of P. berghei ookinetes and early oocysts, fragmenting thereafter, 
consistent with observations through electron microscopy. 
o The injection of ∆Pblap parasites into the haemocoel of mosquitoes (thereby 
bypassing the midgut) did not rescue sporulation, indicating that LAPs function 
independently from interactions with the mosquito epithelia. 
o The outcome of the microarray analysis comparing the transcriptional profiles of  
∆Pblap1 and wild-type P. berghei ookinetes highlights the potential ‘knock-on’ 
effects of lap gene disruption and provides insight into how the loss of LAP1 and 
associated defect in crystalloid formation may result in disrupted development.  
 
4.9.2. PbLAP cellular localisation studies 
Main aims were to study the cellular localisation of PbLAPs through a parallel 
assessment of localisation by antibody detection methods and of GFP and/or Myc-tagged 
versions of the PbLAPs. However, transfection attempts were unsuccessful in generating 
 178 
transgenic parasites in which GFP fluorophores or Myc epitope tags could be detected. 
The inability to detect GFP or Myc fusion proteins may be related to low expression 
levels of tagged proteins, incomplete expression of the fusion proteins, mis-folding and/or 
degradation of the GFP fluorophore or Myc epitope, or loss of protein function caused by 
integration of the tagging construct (as described in 4.2). During the course of this study, 
transgenic parasite lines of PbSR (LAP1) tagged at C-terminal by GFP or the N-terminal 
by mCherry were successfully generated by Carter et al. (2008) and GFP-tagged versions 
of PbLAP2 and PbLAP3 were subsequently generated by Saeed et al. (2010). These 
studies confirmed that LAPs can be tagged to study cellular localisation and comparing 
methods/results reveals possible reasons as to why attempts described as part of this 
thesis may have failed to yield parasites expressing LAPs where the tag could be 
detected. Carter et al. (2008) interestingly indicated by immunoblot analysis that whilst 
the N-terminal tagged PbSR/mCherry remained intact (detecting full-length PbSR 
product), the C-terminal GFP was cleaved (giving rise to a band of 27 kDa corresponding 
to monomeric GFP). Although the GFP appeared to remain associated with the target 
protein, cleavage of the tag represented a problem in tagging at the C-terminal end. A 
similar scenario could potentially explain why C-terminal GFP/Myc tagging attempts as 
part of this thesis were unsuccessful. Indeed the subsequent successful generation of 
GFP-tagged PbLAP2 (Saeed et al., 2010) was produced by single crossover homologous 
recombination at the 3’end. Meanwhile, a double crossover homologous recombination 
strategy targeting the entire gene was used in the generation of GFP-tagged PbLAP3 
(Saeed et al., 2010).  
 
Although for this thesis the localisation of LAPs could not be traced by tagging the 
proteins, antisera generated against the SR domains of LAP1, the PA14 domain of LAP3 
and the LCCL domains of LAPs 4 and 6 as described in Chapter 3 proved to be effective 
tools for the study of LAP localisation in fixed cells. Studies focused on the localisation 
of LAP1 given that only anti-LAP1 sera, raised against the two unique SR domains, was 
confirmed to react specifically against the endogenous target protein. The outcome of 
studies (summarised in 4.4.6) revealed interesting insights into LAP expression and 
localisation. The protein was notably expressed specifically in cytoplasmic regions of 
female gametocytes, with no labelling of male gametocytes. Detection of the protein 
appeared markedly reduced in female gametes, yet — whilst previous studies in P. 
falciparum (Pradel et al., 2004; Pradel et al., 2006; Scholtz et al., 2008) suggested that 
expression ceases following fertilisation— anti-LAP labelling in this study indicated the 
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continuation of expression beyond fertilisation. Intriguingly, anti-LAP sera were found to 
label the crystalloids of P. berghei ookinetes, becoming the first antibodies known to do 
so. Reassuringly, examination of PbSR-GFP and mCherry-PbSR parasites (Carter et al., 
2008) and PbLAP2-GFP and PbLAP3-GFP (Saeed et al., 2010) revealed cellular 
localisation very similar to the antibody based detection methods. Localisation was 
detected throughout the cytoplasm of female gametocytes, macrogametes, zygotes and 
early retorts; whilst in mature ookinetes and young oocysts, labelling was confined to the 
crystalloids (Carter et al., 2008; Saeed et al., 2010).  
  
4.9.2. How does the observed cellular localisation compare to bioinformatic 
predictions and proteomic data? 
Bioinformatic predictions, analysing LAP sequences from each Plasmodium species for 
which genome sequence data is available, indicate that LAPs contain an N-terminal  
signal peptide (as predicted using SignalP: http://www.cbs.dtu.dk/services/SignalP/) and 
implies that LAPs are extracellular proteins (as predicted using WoLF PSORT: 
http://wolfpsort.org/). The presence of an N-terminal signal sequence, composed of 5-10 
hydrophobic amino acids followed by a peptidase cleavage site, mediates transfer to the 
ER. It is predicted that the proteins are not retained in the ER or any other subcellular 
compartments, since further typical eukaryotic sorting signals (which may denote 
retention in the ER or specify transport to another organelle) appear absent. It is therefore 
predicted that the proteins progress through the parasite’s secretory pathway and are 
distributed to the plasma membrane. The proteins lack transmembrane regions or GPI 
anchors, but may it is thought that they may be retained on the parasite’s surface by 
protein-protein interactions through their multitude of putative adhesive domains.  
 
The absence of sorting signals however does not necessarily preclude transport to 
intracellular compartments. Apicomplexan parasites have intricate cellular organisations, 
containing several specialised cytoplasmic structures and organelles, and mechanisms for 
intracellular segregation are poorly understood. For example, no protein sorting 
sequences are known for directing transport to the micronemes, rhoptries or dense 
granules. Proteins can be transported without sorting signals, most commonly through the 
bulk flow pathway, according to which proteins remain in a donor compartment until 
reaching a bulk concentration, at which point they are trafficked to an acceptor 
compartment. It is thought that proteins may be delivered to the dense granules by the 
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bulk flow pathway (Coppens et al., 1999). Apicomplexan parasites also have sorting 
signals that are not found in typical eukaryotic cells, for example, proteins targeted to the 
apicoplast possess a two-part N-terminal signal comprising a signal peptide to enter the 
ER and a transit peptide to cross the two inner membranes of the plastid (Waller et al., 
2000). It is interesting that, using software to predict apicoplast-targeted sequences 
(PATS: http://gecco.org.chemie.uni-frankfurt.de/pats/pats-index.php; Zuegge et al., 
2001), certain LAP sequences are predicted to be targeted to the apicoplast. These include 
P. berghei LAP 2, 5 and 6; P. falciparum LAP 2, 3 and 6; and P. yoelii LAP 1, 2, 4, 5 and 
6. Cellular localisation studies do not confirm apicoplast targeting, nevertheless, the 
predicted presence of a transit peptide following the signal peptide may be important in 
directing LAP cellular transport. To investigate this further, tagged versions of mutant 
parasites could be generated in which the putative transit peptide is disrupted and the 
signal peptide retained.    
  
The finding that LAPs localise intracellularly within P. berghei ookinetes contrasts with 
subcellular proteomic studies, which have detected PbLAP1-6 in an ookinete surface 
protein preparation (Stanway, 2007) and PbLAP1-4 in a putative ookinete micronemal 
preparation (Lal et al., 2009). It could be reasoned that LAPs represent contaminating 
proteins of the preparations rather than true surface or micronemal proteins. During 
preparation of the putative ookinete surface proteome, which was generated by biotin-
labelling of surface proteins followed by affinity purification, it is possible that parasites 
may rupture or become permeabilised during or prior to biotinylation. As such, the 
biotinylation reagent may be able to enter the cell and label intracellular proteins, and/or 
proteins that are released from the ookinete may adhere to the biotin-labelled ookinete 
surface. A number of intracellular proteins such as histone h2A, RNA helicase and 
components of the cytoskeleton, including myosin and tubulin appear enriched in the 
surface proteome (Stanway, 2007). Given the high protein-binding capabilities of LAPs, 
it is plausible that they may have associated with the ookinete surface and thereby be 
among the contaminating proteins detected as being ookinete surface-enriched. The 
presence of contaminants is similarly recognised in the ookinete microneme preparation, 
which was generated by separation of the supernatant of lysed nycodenz-purified 
ookinetes on a sucrose gradient (Lal et al., 2009b). The 1.1 M sucrose fraction was 
identified as being enriched in known microneme proteins such as CTRP and SOAP and 
was shown by electron microscopy to be predominantly comprised of dense granules 
characteristic of micronemes (~85% of total structures in the fraction were assessed to be 
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micronemes). However, 68 ribosomal proteins were detected in the preparation (Lal et al., 
2009b) and is quite possible that LAPs may be similarly detected as contaminants, 
particularly since they are found associated with the electron dense regions of the 
crystalloids, which could conceivably co-segregate with the dense granules of the 
micronemes. It is possible of course that the crystalloids represent secretory granules, 
within which LAPs are stored prior to their secretion and that the antibodies generated, 
whilst able to bind the intracellular proteins, may fail to recognise secreted forms.     
 
4.9.3. Possibilities for LAP1 roles in sporozoites 
Although LAPs have not been localised in sporozoites by tagging approaches (Carter et 
al., 2008; Saeed et al., 2010), the detected antibody labelling at the periphery of salivary 
gland sporozoites with anti-LAP1 antisera (4.4.5) alludes to putative roles of the protein 
beyond sporulation, with possibilities for involvements in functions relating to sporozoite 
survival, development and infectivity. Several surface/secreted proteins of Plasmodium 
sporozoites are for example known to mediate roles in invasion. The sporozoite is the 
only developmental stage of the parasite’s life cycle to invade multiple cell types: 
sporozoites must first invade the salivary glands of the mosquito (described in 1.5.8), and 
once in the vertebrate host, actively migrate through skin cells (Mota et al., 2001; 
Vanderberg and Frevert, 2004) before entering the bloodstream and subsequently 
invading hepatocytes. Those sporozoites that travel through the portal venule or hepatic 
arteriole stop their migration by abruptly adhering to extracellular matrix proteoglycans 
protruding through endothelial fenestrations on the sinusoidal cell layer (Coppi et al., 
2007). They glide across the sinusoid until encountering and entering a Kupffer cell 
(macrophage of the liver), in which the sporozoite becomes enclosed in PV, and safely 
passes through to traverse the sinusoidal cell layer and reach hepatocytes (Baer et al., 
2007; Prudencio et al., 2006). Sporozoite surface proteins (e.g. CSP and TRAP) are 
known to interact with carbohydrate receptors on both the salivary glands and the 
extracellular matrix of the sinusoidal layer to initiate invasion. Given their adhesive 
properties, it is certainly plausible that any of the LAPs may be involved in mediating 
invasion by binding to host receptors. Such a role would be consistent with the 
phenotypes of ∆Pfccp parasites — individual gene knockouts of all but PfCCp6 resulted 
in parasites that were capable of   forming sporozoites, but these were unable to invade 
the salivary glands, leading to the suggestion that the proteins may be involved in 
sporozoite binding and invasion of the salivary glands (Pradel et al., 2004). 
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Less well characterised potential roles of proteins secreted from the sporozoite include 
roles in mediating immune protection/modulation of the parasite’s surrounding 
environment Among the possible functions that may be attributed to LAP1 may be a role 
in mediating protection against such responses for example by interfering with immune 
signalling cascades. Immunomodulatory roles have indeed been suggested as putative 
functions of the protein in light of the indication that predicted domains of the protein are 
found in many immune-related proteins. For example, SRCR domains are found in  
macrophage SR1 (Freeman et al., 1990) and complement factor 1 (Goldberger et al., 
1987). This has led to the suggestion that LAP1 may serve a role in protecting the parasite 
from complement in the blood meal (Claudianos et al., 2002; Delrieu et al., 2002; 
Lasonder et al., 2002), although it could equally act in the haemocoel where parasites are 
exposed to mosquito immune response mechanisms such as phagocytosis and 
melanisation (described in 1.5.6), or indeed perhaps in the vertebrate host. Among the 
speculated mechanisms through which the protein may be involved in immune evasion is 
by competitive binding. For example, it has been suggested by Trueman et al. (2004) that   
LAP1 may compete for ligand binding with An. gambiae serine protease Sp22D, which 
like LAP1, contains two SRCR domains (Gorman et al., 2000). The protein could also 
play roles in modulation whilst parasite’s residing in salivary glands or hepatocytes. An 
example of parasite-mediated modulation of mosquito physiology and manipulation of 
feeding behaviour is the reduction of mosquito apyrase activity, resulting in difficulties in 
obtaining a full blood meal and therefore increased feeding attempts (Smartt et al., 1995). 
Meanwhile, in infected hepatocytes, it has been revealed that CSP is exported across the 
PV mediated by a pexel/VTS motif and is detected in the cytoplasm of the host cell and 
been found to localise around and within the hepatocyte nucleus where it is implicated 
with binding to importins and thereby inhibits nuclear translocation of NFκB to promote 
parasite growth by influencing the expression of host genes (Singh et al, 2007). As with 
CSP — for which roles in sporozoite formation, sporozoite invasion, and host-cell 
modification have been determined — it is speculated that LAP1 and other LAP family 
members may have multiple roles in parasite development.  
 
4.9.4. Are LAPs proteolytically processed? 
Throughout this study, immunoblotting analysis frequently detected proteins of molecular 
masses lower than that expected for the full-length LAPs, possibly indicating the 
detection of proteolytic processed products of the protein. Indeed, the possibility of LAP 
proteolytic processing has been previously suggested by Claudianos et al. (2002) 
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following the finding that antibodies raised against LAP1 appeared to be immunoreactive 
against two sporozoite proteins of approximately 40 and 60 kDa (Claudianos et al., 2002). 
A sporozoite protein of 60 kDa was similarly detected by Trueman et al. (2004).  
Furthermore, antibodies against PfCCp2 and PfNPA were found to recognise 
differentially sized proteins in gametocytes: in immunoblots, αPfCCp2 detected bands of 
180 kDa and 60 kDa, whilst αPfNPA detected proteins migrating at molecular weights 
corresponding to 100 kDa and 60 kDa (Scholz et al., 2008). 
 
Proteins are often expressed in the form of a precursor, which is then cleaved by specific 
proteolytic enzymes to yield mature protein. A well-characterised example of proteolytic 
processing of Plasmodium proteins is the cleavage of MSP1. Synthesised as a high 
molecular weight precursor of around 200 kDa during early schizogony (Holder, 1988), 
MSP1 undergoes proteolytic processing at the end of schizogony to form a complex 
consisting of four fragments of approximately 83, 30, 38 and 42 kDa, which is bound to 
the merozoites surface by the C-terminal GPI-anchor of the 42 kDa fragment (MSP142) 
(Blackman et al., 1991; Blackman and Holder, 1992; Gerold et al., 1996; Kauth et al., 
2006). During invasion, MSP142 is cleaved by proteolysis mediated by a subtilisin-like 
serine protease (SUB2) (Blackman et al., 1990; Blackman and Holder, 1992; Barale et al., 
1999).  A 33 kDa fragment is shed with the rest of the complex, whilst a 19kDa C-
terminal fragment (MSP119) remains attached to the merozoite surface via the GPI-
anchor and is carried into the erythrocyte upon invasion (Blackman et al., 1990; 
Blackman et al., 1991; Blackman and Holder 1992). The micronemal merozoite protein 
AMA1 is also processed (Howell et al., 2003; Howell et al., 2005; Narum and Thomas, 
1994) as is Pfs230: mature Pfs230 (310 kDa) is present on the surface of gametes 
following processing during gametogenesis of a 360 kDa precursor protein (Pfs260) 
which exists on the gametocyte surface (Vermeulen et al., 1985).  
 
It is predicted that LAPs are expressed with an N-terminal signal peptide, the synthesis of 
which mediates entry into the ER via interaction with a signal recognition particle, 
enabling the ribosomal complex to enter the ER by binding to a SRP receptor on the ER 
membrane. The N-terminal signal peptide may be cleaved from the rest of the protein by 
a specific signal peptidase of the ER membrane. Disulphide bonds — each linking two 
cysteine residues — are known to form between various conserved cysteines in several of 
the LAP domains. These form as newly synthesized proteins enter the ER, after which the 
proteins may undergo any number of additional enzymatically catalysed post-translational 
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modifications, including cleavage by proteases. Processed forms may then be transferred 
to a final destination — for example, secreted into the extracellular environment or 
transported to a specific organelle.  
 
To study potential proteolytic processing, antibodies against various regions of the 
protein would be raised. For such purposes, peptide antibodies would be suitable, since 
antibodies generated against short, unique amino acid sequences are likely to be highly 
specific. The occurrence of proteolytic cleavage can be examined by immunoblot 
analyses, in which changes in molecular mass detected by different antibodies would be 
indicative of proteolytic cleavage. It would be possible to identify protein fragments by 
excision of a gel slice containing the protein of interest followed by proteolytic digestion 
and mass spectrometric analysis of the resulting peptides, based on the output of which 
the identity of the protein can be determined by software to match peptide sequences 
to a protein in the sequence database. For the purpose of vaccine development, it would 
be important to determine the subcellular localisation of the processed products. 
Subcellular fractionation experiments followed by further immunoblot analyses could be 
performed to decipher if differently processed protein forms are detected in different 
cellular compartments. More informative would be immunolocalisation studies through 
which the antibody staining patterns of specific anti-peptide antibodies corresponding to 
different regions of the protein (e.g. C-terminal or N-terminal) can be compared.  
 
Regarding the nature of proteolytic processing, the use bioinformatic prediction software 
(for example PeptideCutter; http://expasy.org/tools/peptidecutter/) can be used to reveal 
potential protease cleavage sites based on protein amino acid sequences. Based on this, 
the effects of specific protease inhibitors can be examined to see if they interfere with 
processing. It is interesting to note that gene knockout of a P. berghei aspartyl protease, 
Pbasp, results in mutant parasites with phenotypes similar to those of ∆Pblaps: high 
numbers of large unsporulated oocysts and substantial reductions in number of salivary 
gland sporozoites observed (Ecker, 2007; Ecker et al., 2008). Since a common mutant 
phenotype is often indicative of involvement in the same molecular pathway, this raises 
the question as to whether LAPs and ASP may interact during the parasite development 
— as such it could be envisaged that ASP could potentially be involved in processing of 
LAPs. The mRNA transcript of PbASP appears under translational repression in the 
female gametocyte (Mair et al., 2006) and the protein is identified in the P. berghei 
ookinete proteome (Hall et al., 2005). Attempts to study the cellular localisation of the 
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protein in P. berghei by c-Myc epitope tagging were not successful (Ecker, 2007), yet 
interestingly, a homolog in Eimeria, Eimepsin, has been localised to the RB of 
sporozoites (Jean et al., 2000).  Given the similarities between the phenotypes of ∆Pbasp 
and ∆Pblap oocysts, ∆Pbasp ookinetes were examined for the presence of crystalloids 
during this PhD study; revealing that indeed ∆Pbasp ookinetes may indeed have possible 
defects in crystalloid formation: in experiments described in section 4.5, only 14% of 
∆Pbasp ookinetes were deemed to contain a compartment resembling a crystalloid as 
assessed by light microscopy of Giemsa-stained ookinetes (data not shown). Further 
studies investigating the immunodetection of LAPs in ∆Pbasp ookinetes were attempted 
but unfortunately were inconclusive since in these studies the antibodies tested failed to 
recognise wild-type LAP. It would be interesting to investigate this with a new set of 
antibodies. 
 
4.9.5. Thoughts on crystalloid formation and the involvement of LAPs  
Plasmodium crystalloids have been identified as transient cellular compartments, forming 
in the developing zygote/ookinete, and fragmenting during early stages of oocyst 
development. Previous observations by electron microscopy indicate that the crystalloids 
derive from electron-dense particles interspersed in the female gametocyte (Desser et al., 
1971; Canning and Sinden, 1973; Davies et al., 1974; Gallucci et al., 1974; Trefiak et al., 
1973; Mehlhorn et al., 1980), providing a notable parallel to the manner by which 
PbLAPs have been shown to be female inherited (Raine et al., 2007). It is thereby 
hypothesised that LAPs are among the molecules derived from the female gametocytes 
that are required for crystalloid formation. Two main possibilities are considered 
regarding crystalloid formation: i) it may be derived directly from the female-inherited 
ER; or ii) it may be formed from molecules inherited independently from the ER. 
 
As is typical of metazoan species, the Plasmodium zygote acquires membrane-bound 
organelles such as the ER from the female cell through cytoplasmic inheritance. There 
exists the potential that the crystalloid may correspond to a compartment of the 
endomembrane system. The possibility that the crystalloid represents an ER-derived 
organelle is supported by electron microscopy observations, which in P. gallinaceum 
ookinetes have revealed a close association between the crystalloid and budding sheets of 
smooth ER and Golgi-like vesicles (Mehlhorn et al., 1980). The ER is classically divided 
into three subcompartments — the rough ER, smooth ER, and nuclear envelope — but is 
a highly complex and dynamic structure, capable of undergoing dramatic morphological 
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changes (reviewed by Federovitch et al., 2005).  Among the most widely found forms of 
differentiation is proliferation of the smooth ER to form a regularly arranged crystalloid 
structure (reviewed by Federovitch et al., 2005). Meanwhile, plant cells display the 
capacity to assemble large protein bodies, which may be either retained in the ER or 
transported via release into the cytoplasm to protein storage vacuoles (reviewed by 
Chrispeels, 1991; Okita and Rogers, 1996; Galili, 2004). The protein bodies/protein 
storage vacuoles provide the cell with a store of proteins that are degraded by proteases 
during germination known to provide plant cells with resources for rapid growth upon 
germination or after periods of dormancy (reviewed by Hermin and Larkins, 1999). 
Plasmodium crystalloids could perhaps represent similar forms of differentiated ER 
compartments. Although typical ER retention signals are absent from LAPs, they may 
perhaps be retained in the ER by other protein-protein interactions, as is suggested for 
several protein body components of plant cells (reviewed by Okita and Rogers, 1996).  
 
Another possible hypothesis regarding the nature of crystalloids is that they may be 
analogous to transient Golgi complexes. The Golgi apparatus is known to undergo 
reorganisation at various stages of the cell cycle in many eukaryotic cells and parallels 
can be made between crystalloid formation and Golgi inheritance. Notably, in 
mammalian cells, the Golgi disassembles during mitosis by fragmentation and 
redistribution of its components, and subsequently reassembles (possible processes 
involved in generation and regulation of the Golgi are discussed by Jesch et al., 2001 and 
reviewed by Jesch, 2002). Patterns of Golgi biogenesis are generally poorly understood in 
protozoan parasites and the extent to which the Golgi is reorganised is uncertain. 
However, there are studies to support the existence of transient Golgi-like structures in 
the simple protozoa Giardia (Stefanic et al., 2009). Giardia lamblia lacks a distinct Golgi 
complex, but compartments termed encystation specific vesicles are known to occur in 
encysting trophozoites. The vesicles appear important for cyst wall formation and 
evidence for a Golgi-like nature is provided by dependence of their assembly on the 
GTPases Sar1 and Rab1 (Stefanic et al., 2009). Similar studies in Plasmodium, for 
example using specific inhibitors blocking trafficking out of ER and examining the 
effects of select gene knockouts on crystalloid formation, would help to determine the 
degree to which crystalloid formation is dependent on the ER.    
 
It is hypothesised LAPs are in some way required for incorporating molecules to form the 
crystalloid and/or for retaining the structure of the crystalloid. In this regard, it could be 
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envisaged that LAPs may be involved in trafficking processes — for example, by acting 
as chaperones to direct molecules to the crystalloid; and/or act as a type of scaffolding 
matrix involved in guiding crystalloid formation and maintaining its structure. Given that 
LAPs are predicted to form a complex, it is considered that interactions between one or 
more LAP partners may be required for crystalloid formation. Complex formation is 
known to be essential in the transport of a number of proteins. For example, families of 
chaperones are known to act as complexes (Pavithra et al., 2007), whilst formation of 
nuclear pore complexes is generally required to direct the selective transport of specific 
molecules between the cytosol and nucleus. A specific example in Plasmodium includes 
the formation of a complex between the rhoptry proteins PfRhopH1/H2/H3 and the 
rhoptry-associated proteins PfRAP1/2/3 (Topalska et al., 2004).  
 
Further studies examining the nature of crystalloid formation would be of interest not 
only regarding the biology of LAPs, crystalloids and Plasmodium sporogony, but also 
because there may be the possibility of inhibiting crystalloid formation by 
chemotherapeutic attack of vertebrate blood stages (as suggested by Dessens 2011): 
according to the understanding that crystalloid formation appears to depend on 
inheritance of molecules from gametocytes. 
 
4.9.6. Concluding remarks 
Cellular localisation studies were unable to confirm a surface labelling of gametocyte, 
gametes, zygotes and ookinetes, correlating with the lack of transmission-blocking 
immunity conferred by the antibodies. However, a possible surface localisation on 
sporozoites was identified using anti-LAP antiserum and in vivo assays indicated that the 
antibodies may be capable of inhibiting sporozoite invasion of salivary glands — 
suggesting that perhaps the lack of transmission-blocking activity at earlier stages of 
development in the mosquito may be associated with absence of surface localisation or 
inaccessibility of epitopes in these stages.  
 
Based on the results of immunolocalisation studies, it was intriguingly revealed that 
LAPs may be key intracellular regulatory proteins involved in formation of crystalloid 
compartments in ookinetes. It is hypothesised that the crystalloids may be required for 
sporulation and that LAPs are among the components inherited from the female 
gametocyte required for crystalloid formation. The functional significance of the 
crystalloids remains unestablished; however, it is hypothesised that it may represent a 
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cellular compartment within which molecules are captured and stored/inhibited — the 
predicted tight packaging of proteins inhibiting their degradation, activation, or 
involvement in further signalling by preventing accessibility to enzymes and binding 
partners. The cellular events that lead to the formation of sporozoites in the oocyst are 
poorly understood, but it could be envisaged that it depends of the timely release of 
crystalloid contents early in oocyst development. In accordance, the defects in sporulation 
observed in Pblap gene knockouts could be attributed to indirect effects of the loss of 
LAP —  the defect in sporulation being linked to a defect in crystalloid formation — 
rather than a more direct involvement of the proteins in sporulation. Microarray-based 
transcriptional analysis of ∆Pblap1 ookinetes compared to wild-type ookinetes has 
provided an initial indication of differential expression of a number of genes in ∆Pblap1 
parasites that could potentially account for defects in cytokinesis: identifying for example 
upregulation of genes involved in cell growth and the downregulation of genes required 
for cellular division. Future studies into the role of the crystalloid, for example its 
association with the endomembrane system, cytoskeletal components and events during 
cytokinesis could reveal new insights into the processes of Plasmodium sporogony and 
potentially reveal new targets for malaria transmission blockade.  
 
.  
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5  GENERAL DISCUSSION 
 
Genome sequencing has revolutionised biological research, providing masses of genetic 
information, and the potential of identifying new therapeutic targets. With the availability 
of a wealth of data stemming from the sequencing of Plasmodium genomes it is necessary 
to characterise targets of interest and determine which should be pursued for the 
development of control strategies. Incentivised by the requirement for new targets to 
block transmission, this thesis aimed to examine whether a group of mosquito-stage 
malaria parasite proteins referred to as LCCL/lectin adhesive–like proteins (LAPs) could 
be feasible candidates for the development of antimalarial transmission-blocking vaccines 
(TBVs).  
 
5.1. Viability of LAPs as TBV candidates  
The idea that LAPs could represent potential TBV candidates followed the proteomic and 
bioinformatic analyses, whereby six LAPs have been identified as putatively secreted 
mosquito-stage proteins with predicted extracellular adhesive domains — properties 
which are desirable for TBV candidates. Having been identified as prospective TBV 
candidates, this study aimed to use P. berghei to evaluate the potential of LAPs as 
transmission-blocking antigens. 
 
Codon-enriched E.coli strains were utilised for expression of LAP recombinant proteins 
as means of reducing protein expression problems associated with extreme AT codon bias 
of Plasmodium (Mehlin et al., 2006; Flick et al., 2004). Due to the large size of the 
proteins (up to 200 kDa) Pblap gene fragments predicted to encode protein of size 25-40 
kDa were selected for expression rather than attempting to express whole proteins; since 
low molecular weight proteins are more likely to be expressed successfully (Mehlin et al. 
2006; Vedadi et al., 2008). Proteins corresponding to specific regions of the LAPs 
(LAP1SRSR, LAP2RG, LAP3PA14, LAP3LCCL, LAP4LCCL, LAP5AB, LAP6AB, and 
LAP6LCCL) were successfully expressed in E. coli, although expression was almost 
exclusively in an insoluble form. Antibodies were effectively raised against the SR 
domains of LAP1, the PA14 domain of LAP3 and the LCCL domains of LAPs 3, 4 and 6, 
of which αLAP1SRSR, αLAP3PA14, αLAP3LCCL, αLAP4LCCL, and αLAP6LCCL 
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were reactive against endogenous proteins. Antibodies however, did not elicit 
transmission-blocking activity, as determined by a combination of in vitro and in vivo 
parasite development assays, and did not show an obvious localisation with the surface of 
early sexual and sporogonic stages of the parasite, as assessed by immunofluorescence 
assays. Therefore although feasible to generate in a heterologous expression system and 
immunogenic in mice, antibodies generated were perhaps reactive against epitopes not 
exposed on the surface of the parasite or were only weakly active against antigens in their 
native forms. 
 
Difficulties in expressing recombinant antigens in a form that allow the generation of 
high titres of biologically active antibodies is a frequently encountered problem, posing 
renowned barriers to malaria vaccine development (Saul, 2007; Williamson, 2003). 
Antibody activity generally depends on the recognition of antigens in their native 
conformation, yet the generation of recombinant antigens with tertiary structures 
mirroring that of the native antigen is often difficult to achieve, particularly when 
antigens are expressed in E. coli. Consequently, recombinant proteins produced in E. coli 
often fail to induce antibodies with anti-parasitic activity generally due to the low 
concentration of properly folded epitopes within the recombinant protein preparation 
(Milek et al., 1998; Anders et al., 1998; Hodder et al., 2001). Antibody properties can 
alter considerably depending on antigen expression system, host species for antibody 
production, and adjuvant. For example, expression of Pb25 in a baculovirus system 
(Margos et al., 1995), Pf25 expression in yeast (Barr et al., 1991) and Pfs48/45 in a 
modified E. coli expression system (Outchkourou et al., 2008) considerably improved the 
production of properly folded proteins.  
 
It remains uncertain whether anti-LAP antibodies generated in a different manner may 
yield antibodies that might disrupt parasite development. Further investment in the 
generation of anti-LAP antibodies was not pursued due to the uncertainty over whether 
LAPs are accessible to antibodies on the surface of the parasite. In their native, 
endogenous states, the proteins, or at least critical residues, may be inaccessible to 
antibody. They may, for example, be absent from the parasite surface, or perhaps hidden 
within protein complexes. Absence of an obvious surface localisation of PbLAP1, 
PbLAP2 and PbLAP3 has been reaffirmed by tagging the proteins. It is possible that 
LAPs may be secreted from the parasite in a soluble form and are not retained on the 
surface of the parasite, or are perhaps retained in intracellular compartments of the cell.  
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Immunofluorescence studies using anti-PfCCp4 (LAP6) sera indicate that the localisation 
of LAP6 may be distinct from that of the other family members (noticeably associated 
with the plasma membrane rather than cytoplasmic). This should perhaps distinguish 
LAP6 as the focus of any LAP-based TBV studies and it would be interesting to examine 
the cellular localisation of a tagged version of LAP6. 
 
There are indications that LAPs may undergo both processing and complex formation: 
the detection of differentially sized protein bands by immunoblotting may be an indicator 
of processing, whilst co-immunoprecipitation studies indicate possible complex formation 
with other sexual stage proteins. This complicates antibody design since both proteolytic 
processing and complex formation affect which portions of a protein are accessible to 
antibody. For example, Pfs230, exists as a 360 kDa precursor protein (Pfs260) on the 
gametocyte surface (Vermeulen et al., 1985) and during gametogenesis is processed to a 
mature 310 kDa protein (Pfs230), therefore antibodies must be raised against the mature 
processed protein to elicit transmission-blocking activity. The merozoite micronemal 
protein AMA1 is among the antimalarial vaccine candidates known to be involved in 
complex formation. AMA1 is transported to the parasite surface where it forms a 
complex with rhoptry neck proteins (RONs) as has been demonstrated in T. gondii 
(Alexander et al., 2006; Cao et al., 2009). Initial studies of LAP complex formation have 
been performed by affinity binding studies with PfCCp recombinant proteins and by co-
immunoprecipitation assays on P. falciparum gametocyte lysates. Studies could be 
extended to investigate molecular interactions in P. berghei gametocytes and ookinetes.  
 
5.2. Insights into LAP biology  
Prior to this study it had been demonstrated that LAP expression appears to begin in 
gametocytes, where it has been suggested that the proteins may play critical roles in 
extracellular interactions during gametogenesis and fertilisation, possibly acting to 
enhance fertilisation by aiding adherence or perhaps by forming a protective barrier 
against factors in the blood meal (Pradel et al., 2004; Pradel et al., 2006). This work has 
since been extended by studies utilising recombinant proteins to investigate the molecular 
interactions between the PfCCp proteins in affinity binding studies (Simon et al., 2009). 
Immunoblot analysis of eluted protein complexes revealed interactions between 
numerous domain combinations (Simon et al., 2009). Furthermore, interactions between 
PfCCps and sexual stage TBV candidates Pfs48/45 and Pfs230 have been detected by co-
immunoprecipitation assays on gametocyte lysates, and with Pfs25 on activated 
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gametocytes, leading to the suggestion that the PfCCps form a large multiprotein complex 
on the surface of gametes with other sexual stage adhesive proteins (reviewed by Kuehn 
et al., 2010). Nevertheless, the outcome of gene knockout studies in both P. falciparum 
and P. berghei indicate that the proteins may be involved in further roles later in parasite 
development, namely in oocyst maturation and sporozoite production or sporozoites 
infectivity: gene disruption of Pblap1, Pblap2, Pblap4, Pblap5 and Pblap6 results in 
oocysts defective in sporulation (Claudianos et al., 2002; Raine et al., 2007; Ecker et al., 
2008), whilst in ∆Pfccp1-3, ∆Pfccp6 and ∆Pffnpa parasites, sporozoites are produced but 
are incapable of invading salivary glands (Pradel et al., 2004; Scholz et al., 2008).  
 
Using P. berghei as an amenable system to study Plasmodium development beyond 
fertilisation, studies presented in this thesis were able to use antibody detection methods 
to examine the cellular localisation of LAPs and potential functions in later stages of 
sporogony. Antisera against the SR domains of LAP1, the PA14 domain of LAP3 and the 
LCCL domains of LAPs 4 and 6 were all found to label the crystalloids of P. berghei 
ookinetes. Despite being identified by electron microscopy in the 1960s, the functional 
significance of Plasmodium crystalloids remains unknown, although among one of its 
most early suggested roles is that of a storage organelle, perhaps supplying molecules 
required for oocyst development (Garnham (1969) and Desser et al. (1970). ∆Pblap1, 
∆Pblap2, ∆Pblap4, ∆Pblap5, and ∆Pblap6 parasites were observed to be at least partially 
defective in crystalloid formation by light microscopy, supporting the localisation of 
LAPs in crystalloids and indicating that LAPs may play important roles in intracellular 
regulation to maintain the cellular organisation of P. berghei ookinetes (possibilities are 
described in 4.9.5) 
 
LAPs are predicted to be extracellular proteins in light of their identification as 
potentially secreted multidomain lectin-like proteins, with similarities to many known 
extracellular adhesive proteins (outlined in 1.6.1). Lectins however are an extremely 
diverse protein family — with many playing central roles in intracellular regulation 
(reviewed by Dodd and Drickamer, 2001). The specificity of lectin binding is for example 
commonly utilised to direct protein entry into a certain cellular pathway, (e.g. secretory or 
lysosomal) and promote the correct folding of proteins: 
– L-type lectins recognise correctly folded proteins and assist their exit from the 
ER and progression along the secretory pathway;  
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– Calnexin and homologues are ER-resident lectins that bind incompletely 
processed glycoproteins bearing terminal glucose residues prevent misfolded 
glycoproteins from exiting the ER and mediate their presentation to proteins 
which assist in folding.  
– Members of the glycoside hydrolase protein family (M-type lectins) recognise 
permanently misfolded proteins and assist their exit from the ER into the 
cytoplasm for degradation. 
– F-box lectins recognise misfolded proteins that have been removed from the ER 
and promote their proteasomal degradation.  
– P-type lectins recognise mannose 6-phosphate residues, for example on 
hydrolases, and direct proteins to lysosomal compartments 
– R-type lectins play roles in directing enzyme targeting and glycoprotein turnover. 
(reviewed by Dodd and Drickamer, 2001). 
 
There are a number of notable similarities between LAPs and lectins which may be 
involved in intracellular regulation. For example, pentraxin/ConA-like domains are found 
in calnexins and L–type lectins; levanase-type lectin domains and PA14 domains are 
widely found in enzymes involved in processing of N-linked glycoproteins; and R-type 
lectins contain a ricin B domain. Therefore, whilst LAPs were distinguished as being 
putative extracellular proteins in light of their lectin-like properties, analogies can equally 
be made to intracellular lectins. The need for lectins in directing protein trafficking and 
protein quality control processes in Plasmodium is debatable due to evidence suggesting 
that N-glycosylation of proteins is absent in the parasite (Dieckmann et al., 1992; Gowda 
et al., 1997; Gowda et al., 1999). In agreement with the predicted lack of N-glycosylation, 
calnexin family proteins, conserved members of which are involved in glycoprotein 
processing across eukaryotes, including plants, fungi, and animals, are not identified in 
the Plasmodium genome (Pavithra et al., 2007). Thereby, studies into the possible 
intracellular roles of LAPs in Plasmodium have the potential to reveal novel insights into 
the parasite’s biology. 
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5.3. Future directions 
The possibility of generating transmission-blocking antibodies against LAPs is not 
excluded and different approaches to produce antibodies with improved biological 
activities (as described in 3.5.3) could prove fruitful. The major aim would be to produce 
recombinant proteins closely resembling the native structure of the corresponding 
endogenous proteins. This would not only be important for antibody production but also 
for any structural analyses. Perhaps as an alternative strategy to expressing the entire full-
length proteins, it may be possible to effectively generate antibodies against epitopes 
along the full length of the proteins by the expression of protein fragments and 
subsequent immunisation of hosts for antibody production with a mixture of fragments 
constituting the full protein. This method could be useful as a more conclusive screen to 
establish whether a protein may be a viable TBV target. However, the inclusion of certain 
epitopes may have a counterproductive effect, masking potential transmission-blocking 
activity induced by other epitopes.  
  
Aside from the further generation of antigens and antibodies for testing in transmission-
blocking assays, there are countless further experiments that could be performed 
regarding the biology of the proteins. Of particular interest would be elucidating possible 
roles in intracellular trafficking. The use of small molecule inhibitors would be an 
interesting start to study the effects of specific trafficking steps and to determine the 
possible contribution of components of the endomembrane and cytoskeletal systems on 
LAP function and crystalloid formation. For example, the fungal toxin Brefeldin A or 
acyl-CoA:cholesterol acyltransferase inhibitors can effect multiple membrane trafficking 
pathways in eukaryotic cells including inhibition of vesicle budding from the ER and 
inhibition of trafficking of material to the ER (Brown and Schimidt, 2005). The ability to 
culture P. berghei ookinetes, oocysts and sporozoites provides a system for the 
application of such studies.  
 
Expression in heterologous systems could be used to infer the functional attributes of 
Plasmodium proteins (reviewed by Birkholtz et al., 2008), for example by studying their 
interactions with endogenous proteins or by studying the adhesive properties of proteins 
by expression of the proteins via endogenous signal sequences and GPI-anchoring motifs 
to elicit expression on the plasma membrane. The single-celled amoeba Dictyostelium 
discoideum, which can be readily cultured and genetically manipulated, has become an 
important model organism for studying numerous aspects of eukaryotic cell biology, 
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including cell division, cell motility, intracellular signalling and trafficking pathways. It 
offers considerable advantages for the heterologous expression of Plasmodium proteins 
since it shares an AT codon bias (77.4%) (Szafranski et al., 2005). The system has been 
used to reveal insights into a number of Plasmodium proteins. For example, expression of 
P. falciparum chloroquine resistance transporter (PfCRT) demonstrated targeting to the 
digestive compartments of D. discoideum and provided evidence that mutations in PfCRT 
mediate resistance to chloroquine by reducing chloroquine accumulation (Naudé et al., 
2005). Expression in Xenopus oocytes has become a valuable tool for the functional 
characterisation of Plasmodium transporters, for example P. falciparum hexose 
transporter PfHT1 (Woodrow et al., 1999) and the aquaglyceroporins PfAQP and PbAQP 
(Hansen et al., 2002; Promeneur et al., 2007). The Xenopus oocyte system has been used 
to study how PfCRT affects CQ susceptibility by modulation of food vacuole transporters 
(Nessler et al., 2004) and to identify a SERCA-type Ca2+ ATPase PfATP6 as a target of 
artemisinins (Eckstein-Ludwig et al., 2003). Furthermore, roles of a P. falciparum 
leucine-rich repeat antigen (PfLRR1) in regulating protein phosphatase activity and cell 
cycle progression were implied from expression in oocytes, where the protein was found 
to regulate the G2/M cell cycle transition by binding Xenopus protein phosphatase PP1  
(Daher et al., 2006).  
 
As potentially multifunctional proteins, it is certainly possible that LAPs may have both 
intracellular and extracellular functions. For example, it is recognised that the proteins 
may be secreted from the parasite as soluble molecules that impact mosquito physiology 
or innate immune responses. Investigation of the potential roles of LAPs in interactions 
with the mosquito host was beyond the scope of this thesis, but the predicted structural 
properties, of LAP1 in particular, have initiated the hypothesis of immunomodulatory 
roles. For example, it is suggested that PbLAP1 could scavenge or compete with the 
ligands of its molecular homologues such as Anopheles Sp22D. Sp22D is the ortholog of 
Drosophila GRAAL and appears to be involved in immune recognition in a manner 
analogous to that of the horseshoe crab clotting factor C (Danielli et al., 2000; Gorman 
and Paskewitz, 2001). In order to investigate possible interactions between PbLAPs and 
mosquito immune factors, it may be possible to study potential co-localisation of PbLAPs 
and known mosquito immunity proteins, provided reliable markers can be generated. It is 
also possible to study the effects of the presence and/or absence of PbLAPs on the 
expression of mosquito genes, at a genome-wide level by microarray analysis, or on 
select genes by RT-PCR. Differences in gene expression could be examined following the 
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administration of recombinant LAPs compared to control protein in membrane feeds, or 
by comparing the expression of mosquito genes in following feeds with ∆Pblap 
compared to wild-type parasites.   
 
The intriguing finding that gene disruption of Pblap can lead to an increase in ookinete 
and oocyst numbers when compared to wild-type infections (Raine et al., 2007; A. Ecker 
PhD thesis, 2007) could possibly be explained by affects on mosquito physiology (for 
example, higher oocyst loads could be related to slower digestion of the mosquito blood 
meal, as is the case in younger mosquitoes) or by a deficiency in regulatory mechanisms, 
such as inefficient clearance of cells in the absence of LAPs. Regarding the latter, it could 
be hypothesised that LAPs may act as signal molecules for phagocytosis or apoptosis, 
perhaps via a mechanism similar to the mode of action of mannose-binding lectin. 
Mannose-binding lectin does not bind viable cells since sialic acid moieties present on the 
cell surface inhibits binding of the protein, but the absence of sialic acid residues on 
apoptotic cells facilitates the binding of mannose-binding lectin, resulting in activation of 
complement-mediated lysis to promote the clearance of apoptotic cells (Tsutsumi et al., 
2005). A number of apoptotic markers could be utilised, such as acridine orange or 
annexin (see Ali et al., 2010), to observe apoptosis: for example the compare the number 
of apoptotic cells in Pblap knockout parasites with wild-type and to perform co-
localisation studies with markers of apoptosis to determine if LAPs are present on cells 
undergoing apoptosis.  
 
Future studies such as these mentioned would not only help to decipher more conclusive 
roles of the proteins, but could also yield insights into processes Plasmodium 
development in the mosquito perhaps aid in the further development of transmission-
blocking strategies.  
 
5.4. Value of the P. berghei experimental system  
Studies presented in this thesis utilised the rodent malaria parasite species P. berghei, 
which provides an amenable system for the study of Plasmodium transmission stages, 
offering exceptional opportunities for understanding molecular mechanisms underlying 
the developmental processes of Plasmodium in the mosquito, for identifying and 
characterising putative targets for transmission blockade, and for performing 
transmission-blocking assays. Genomes of P. berghei and human malaria parasites 
contain a core of conserved genes (Hall et al., 2005), reflecting conserved biological 
features (reviewed by Kooij et al., 2006) and the high level of sequence similarities 
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between P. berghei LAPs and orthologs in P. falciparum strongly implies that the 
proteins may perform analogous roles in each species. There are however notable 
differences between human and rodent malaria parasites, in particular at the level of 
gametocyte biology. Gametocytes of P. falciparum are unusual in morphology (crescent-
shaped rather than round) and have a prolonged development (9-12 days compared to 26-
30 hours). These discrepancies are associated with marked differences in biological 
processes such as sequestration and nutrient acquisition, and even conserved proteins may 
be observed to elicit different functions in the two species. Indeed differences in gene 
knockout phenotypes of highly conserved members of the 6-cys protein family are 
apparent. For example, P. berghei Pbs47 is essential for female fertility (Mair et al., 
2006), whereas although P. falciparum Pfs47 is similarly expressed on the surface of 
female gametes, but does not appear crucial for fertilisation (van Schaijk et al., 2006).  
 
Differences are apparent between the gene disruption of phenotypes of Pblaps and their 
orthologs in P. falciparum, Pfccps: ∆Pblap1, ∆Pblap2, ∆Pblap4, ∆Pblap5 and ∆Pblap6 
are defective in sporulation, whilst ∆Pfccp1(Pblap2) ∆Pfccp2(Pblap4) and 
∆Pfccp3(Pblap1) results in a defect in the transition from midgut to salivary gland 
sporozoites (Pradel et al., 2004) and interestingly ∆Pfccp4(Pblap6) shows no essential 
function (Scholtz et al., 2008). It is difficult to distinguish whether these discrepancies 
relate to true differences in the biological functions of the genes in each species, or 
whether distinct phenotypes are observed as a consequence of variation in experimental 
procedures. For example, P. falciparum is grown in culture and P. berghei in mice, and 
different mosquito species were utilised to examine phenotypes in the mosquito. In a 
similar manner, variable results due to species and experimental differences between P. 
berghei and P. falciparum transmission-blocking assays cannot be excluded. Nevertheless 
the technical advantages of studying Plasmodium transmission in P. berghei 
overwhelmingly justify the examination of transmission-blocking candidates using P. 
berghei. Furthermore, investigating LAPs in P. berghei has highlighted their nature as 
potentially multifunctional proteins with possible roles throughout sexual and sporogonic 
development of the parasite in the mosquito — revealing possible functions that have not 
yet been identified through studies in P. falciparum. 
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5.5. Perspectives 
Efforts to control and eliminate malaria have to date been largely limited to the 
application of drugs and insecticides, with only limited success in areas of high 
endemicity. Therefore, although understanding the molecular mechanisms underlying a 
pathogens development is not essential to control a disease, attempts to understand the 
molecular basis of Plasmodium infection have been initiated to improve the chances of 
successful long-term control, in particular by identifying new targets for intervention. The 
development and distribution of drugs, vaccines, or novel vector control interventions 
intended to interrupt the transmission of malaria are expected to be key to the success of 
future malaria control and elimination programmes. A transmission-blocking vaccine 
(TBV) is particularly appealing, especially given the recent advances in vaccine 
development against pre-erythrocytic stages of the parasite. Knowledge of the biology of 
malaria has been transformed by molecular biology and post-genomic technologies and 
continued research on parasite development at a molecular level is certain to yield further 
targets for intervention and reveal insights into the intriguing biology of the malaria 
parasite. Meanwhile, re-consideration of the feasibility of antimalarial vaccines based on 
whole parasites could offer an alternative approach to sub-unit vaccines. 
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